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Outline  
This doctoral thesis evaluates physical function (related) assessments in older adults and their 
predictive value for health risks and mortality. In addition, it reports on changes in physical 
function occurring over time. 
This first chapter starts with several facts and figures on the ageing and aged population. 
Thereafter, physical function assessments are introduced. This introduction includes conceptual 
and operational definitions of physical frailty, sarcopenia, and low levels of physical function. It 
also consists of the latter’s underpinning mechanisms, purposes, and epidemiology. Thereafter, the 
research objectives are expressed and motivated. This is followed by a summary of the two cohort 
studies in which these questions were investigated. Finally, the chapter ends with a description of 
the used methodology. 
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1.1 THE AGEING AND AGED POPULATION 
1.1.1 (HEALTHY) LIFE EXPECTANCY 
Increasing life expectancy 
Globally, the average life expectancy at birth has increased from approximately 28.5 years in 1800 
to approximately 70 years now (1,2) (Figure 1). The continuous increase in life expectancy at birth 
across Europe during the last century is driven by reductions in infant mortality, rising living 
standards, improved lifestyles and better education, as well as advances in healthcare and medicine 
(2–4). 
 
 
 
 
 
 
Figure 1. Life expectancy from birth by world region over time. 
While the earliest health transitions already began in the 1770s in Europe, a steep increase in life expectancy 
estimates occurred from about 1920 to about 1973 (after World War I and the global influenza pandemic). 
Afterwards the pace of advancing life expectancy slowed down again (1). 
Visualization adapted from Roser (2); data up to 2001 are from Riley (1); data for 2000, 2012, and 2013 are from the 
World Health Organization (5); data for Asia in 2009 are from the Organization for Economic Co-operation and 
Development (6). 
In 1800, the region of Belgium had the highest life expectancy at birth of all regions with just 40 
years (2). In 2013, Belgium’s average life expectancy at birth was 80.4 years (7), just below the 28-
membered European Union’s average of 80.6 years in 2013 (4). Over the past 20 years annual 
progress in life expectancy in Belgium was a mean 0.2 years (72 days). However, there has been a 
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significant increase of 0.6 years (218 days) in life expectancy in 2014, with average life expectancy at 
birth for women being 83.5 years and for men 78.6 years (8). Based on mortality data between 1991 
and 2012, it has been hypothesized that life expectancy at birth in 2060 will be 88.4 years for 
women and 86.1 years for men (9). These further gains are expected to be achieved mostly from the 
reduction in mortality at older age. Figure 2 displays the increasing life expectancy at age 65. In 
1996, life expectancy at age 70 was 11.7 years for men and 15.3 years for women. This has 
increased to 14.6 years and 17.4 years respectively in 2014 (7).  
Figure 2. Life expectancy and healthy life years from age 65 since 1995. 
Results on healthy life years should be interpreted with caution, because sample sizes vary remarkably and because 
the underlying health measure was not always truly comparable to make valid comparisons. 
Health expectancy until 2001 was based on the disability question of the ‘European Community Household Panel’ 
survey, which paid less attention to the translation aspect for true harmonisation across countries.  
Health expectancy from 2004 onwards was based on the ‘Statistics on Income and Living Conditions’ question on 
long-term health related disability (Global Activity Limitation Indicator). The wording of the question slightly 
changed in 2005 for Belgium to better reflect the European Union standard. In addition, the wording of the question 
has been revised in 2008 for most countries including Belgium and in 2007 for Italy. 
Data for 1996 – 2001 are from EurOhex – the European Community Household Panel (10); data for 2004 – 2013 are 
from EurOhex – Statistics on Income and Living Conditions (11).  
THE AGEING AND AGED POPULATION 
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Ageing of the population 
The increasing life expectancy together with the reduction in fertility are the main reasons for the 
ageing of the European population (4,8). In 2015 in Belgium, 1 152 835 women and 857 424 men 
were aged 65 years or more, they represent 20% and 16% of female and male population (12) 
(Figure 3). 
Figure 3. Structure of the Belgian population in 2015 according to age and gender. 
Data are from Statistics Belgium (12). 
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Healthy life expectancy 
Unfortunately, the mean number of years expected to live does not fully represent the mean 
number of years expected to live in good health, which has a less favorable evolution. Life 
expectancy can be divided into life spent in different states of health. The most common health 
expectancies are those based on activity limitation or chronic morbidity. Figure 4 depicts the 
increasing prevalence of activity limitation and chronic morbidity with age in Belgium (based on 
cross-sectional data from 2013). Across age categories, women were more frequently than men 
experiencing morbidity (51% vs. 41% at 70 years of age) and activity limitation (54% vs. 44% at 70 
years of age).  
Hereafter, life expectancy without long-term activity limitation is referred to as healthy life years (13). 
Figure 2 shows that in 2012 the number of healthy life years at age 65 has increased to 11.1 years 
and 10.7 years for women and men respectively (not taking into account the institutional 
population)(13). This means that women and men at age 65 can expect to spend 52% and 60% 
respectively of their life without self-reported long-term activity limitations. While life expectancy 
in 2012 in Belgium was below the European average, the healthy life years surpassed the European 
average. Prevalence rates of activity limitation were lower compared to the mean trajectory in the 
European Union after the age of 45 years for women and 50 years for men (13). 
In general, life expectancy has always been longer for women. However, the difference between 
genders keeps on decreasing. In addition, the difference in healthy life years is much smaller, which 
leads to women spending a larger proportion of their life in poor health (13) (Figure 2). 
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Figure 4. Prevalence of activity limitation and chronic morbidity in Belgium according to 
gender and age group (2013).  
Data are from EurOhex – Statistics on Income and Living Conditions (11).  
Data were collected through personal interview (proxy as an exception) or registers. 
These results should be interpreted cautiously given the sample size comprised 6025 women and 5686 men excluding 
the institutional population, such as people living in nursing homes (14). 
The question on chronic morbidity was implemented as “Do you have any longstanding illness or health problem? 
By longstanding I mean illnesses or health problems which have lasted, or are expected to last, for 6 months or 
more”. Prevalence of chronic morbidity ranges from 24% to 45% in men, and 29% to 56% in women. The relatively 
high prevalence in younger persons may partially be explained by the fact that interviewers were instructed to be as 
inclusive as possible. This means problems that are seasonal or intermittent, problems not seem by the respondent as 
very serious (hay fever), problems that have not been diagnosed by a doctor, etc. are also included. 
The question on activity limitations was implemented as “For at least the past 6 months, to what extent have you 
been limited because of a health problem in activities people usually do?” Response categories made a distinction in 
three levels of severity (yes strongly limited, yes limited, no not limited at all). Prevalence of activity limitations 
(regardless of severity) range from 18% to 62% in men, and 23% to 70% in women. 
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1.1.2 HEALTH RISKS IN THE AGED POPULATION 
In addition to the above mentioned age-associated increases in activity limitation and morbidity, the 
aged population (65 years or more) is also more exposed to various health risks compared to other 
age categories (Figure 5). Mortality events in 2012 occurred in over 90 000 older Belgian citizens 
aged 65 years or more. The most common causes of death in these older persons were 
cardiovascular diseases (32%), cancer (24%), and respiratory diseases (12%) (15). Hospital 
admissions with an overnight stay happened in more than 715 000 patients aged 65 years or more. 
Of all in-patients who stayed in hospital up to 90 days, older persons had the longest mean length 
of hospital stay (LoS) with 10.3 days. Stays in day hospital happened in more than 826 000 older 
persons (data for 2012 (16)). In-hospital death occurred in over 44 000 older persons in 2012, which 
corresponded to 6% of all older inpatient stays of type H or L (these include the standard 
hospitalizations with overnight stay and the prolonged stays of over six months with discharge 
during the first semester of the registration period, respectively) (17). Long-term care in Belgian 
institutions was received by over 124 000 persons aged 65 years or more. These older long-term 
care recipients represented 1% of the total population and 7% of the population aged 65 years or 
more (data for 2010 (18)). 
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Figure 5. Health risks in the aged population. 
Data for all-cause mortality (2012) are from the FOD Volksgezondheid veiligheid van de voedselketen en leefmilieu 
(15), data for hospital stays ≤ or > 90 days (2012) are from the FOD Volksgezondheid veiligheid van de voedselketen 
en leefmilieu (16), data for hospital stays type H or L and in-hospital mortality (2012) are from the FOD 
Volksgezondheid veiligheid van de voedselketen en leefmilieu (17), data for long-term care in institution (2010) are 
from the Organization for Economic Co-operation and Development (18).  
Dotted lines represent the percentage of women (20%) and men (16%) aged 65 years or more in the female and male 
Belgian population, respectively (2015) (12).  
* within persons with hospital stay type H or L. 
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1.2 PHYSICAL FRAILTY, SARCOPENIA, AND LOW LEVELS OF PHYSICAL FUNCTION 
1.2.1 CONCEPTUAL AND OPERATIONAL DEFINITIONS 
Physical frailty: Towards a conceptual definition, yet still in search of a consented 
operational definition 
The age-related loss of physiologic reserve and hence loss of resistance to stressors is characteristic 
for the condition called frailty, in which minimal stress can lead to functional impairment. 
Following a minor stressful event (for example a urinary tract infection), robust older persons 
experience a relatively small decline in function and afterwards return to homeostasis. Whereas frail 
older persons, who already have lower function, experience a larger decline, making them 
dependent. They require more time to recover and do not return to baseline homeostasis (Figure 
6) (19). 
Figure 6. Resilience to stressors.  
A frail older person has an increased vulnerability to stressors, with reduced ability to maintain or regain homeostasis 
after a destabilizing event (20). Adapted from Clegg et al. (19). 
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There are many different conceptual definitions of frailty, some of them are reported in Table 1. 
Those before 2008 are reviewed by Gobbens et al. (21,22). The unsuccessful attempts to arrive at a 
consensus around frailty, may be due to the unresolved distinctions between broad definitions of 
frailty and more specific subsets. Therefore, a frailty consensus group (consisting of participants 
from six major international, European and US societies) recognized and separated physical frailty 
from the broader definition of frailty, with the former being a more specific medical syndrome and 
the latter being a general state or condition of an individual (23). Another frailty consensus group 
(the Frailty Operative Definition-Consensus Conference Group) failed to arrive at a consensus 
definition, however > 80% agreement was reached on several statements regarding the concept and 
framework of frailty (24). One of these strongly agreed statements concerns that frailty is a dynamic 
nonlinear process, different from multimorbidity and disability. 
Table 1. Some conceptual definitions of frailty. 
Rockwood et al. 1999 (25) Frailty is a combination of aging, disease, and other factors that make some 
people vulnerable 
Fried et al. 2001 (26) Frailty is a biologic syndrome of decreased reserve and resistance to stressors, 
resulting from cumulative declines across multiple physiologic systems, and 
causing vulnerability to adverse outcomes 
Gobbens et al. 2010 (22) 
(On behalf of an expert 
group) 
Frailty is a dynamic state affecting an individual who experiences losses in 
one or more domains of human functioning (physical, psychological, social) 
which is caused by the influence of a range of variables and which increases 
the risk of adverse outcomes 
Morley et al. 2013 (23) 
(On behalf of a frailty 
consensus group) 
Physical frailty is a medical syndrome with multiple causes and contributors 
that is characterized by diminished strength, endurance, and reduced 
physiologic function that increases an individual’s vulnerability for developing 
increased dependency and/or death 
Boers et al. 2015 (27) Frailty is the weakening of the resilience or capacity to cope, and to maintain 
and restore one’s integrity, equilibrium, and sense of wellbeing in three 
domains: physical, mental, and social 
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Indeed, frailty should be distinguished from multimorbidity (which refers to the concurrent 
presence of multiple chronic diseases or conditions) and from disability (which can refer to the 
presence of one or more difficulties or dependencies in basic activities of daily living (ADL)(22,28), or 
to mobility limitations as indicated by physical domains of health-related quality of life 
questionnaires). These are three distinct yet partially overlapping entities (28). Multimorbidity is more 
prevalent in older adults than frailty (23), Fried et al. reported that 68% of frail subjects also have 
multimorbidity, while only 10% of subjects with multimorbidity simultaneously have frailty. 
Prevalence of ADL disability and frailty was similar, with about 27% overlap (26). Some authors 
have postulated that frailty can be considered as a form of pre-disability (29). Indeed, frailty is a risk 
factor for disability (26), but disability can exist without previous frailty. Therefore, disability should 
not be included in a definition of frailty (21,24).  
Two widely accepted frameworks, where most operational definitions of physical frailty rely upon, 
are the phenotype model and the cumulative deficit model.  
The phenotype model was developed by Fried et al., who consider frailty as a clinical syndrome. It 
includes characteristics of shrinking (weight loss, sarcopenia), weakness, exhaustion (poor 
endurance), slowness, and low activity (26). Their physical phenotype, consisting of unintentional 
weight loss, weak Grip strength, self-reported exhaustion, slow Gait speed, and low energy 
expenditure, was validated in the Cardiovascular Health Study (CHS). Many others have developed 
a slightly altered or simplified frailty phenotype. Ensrud et al. validated the parsimonious Study of 
Osteoporotic Fractures (SOF) index (which consists only of weight loss, weakness, and poor 
endurance) for prediction of adverse outcomes and found no difference in validity with the original 
Fried frailty phenotype (30,31). 
The cumulative deficit model underpins the Frailty index score, which was developed by Rockwood et 
al. and validated in the Canadian Study of Health and Aging (32). A higher frailty index score, which 
reflects the proportion of potential deficits (symptoms, signs, disease states, disabilities, and 
abnormal laboratory values) present, indicates a higher likelihood that frailty is present. Subsequent 
studies have demonstrated that the checklist with deficits can be reduced without loss of predictive 
validity (33).  
A third approach, where some operational definitions of frailty are based upon, relies on clinical 
judgment. For example with the Clinical Frailty Scale, also developed by Rockwood et al. (34) and 
validated in the Canadian Study of Health and Aging, the physician assigns the patient a score of 1 
PHYSICAL FRAILTY, SARCOPENIA, AND LOW LEVELS OF PHYSICAL FUNCTION 
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(being very fit) to 7 (being severely frail). The Clinical Global Impression of Change in Physical 
Frailty (35) has the clinician determine change in intrinsic and global frailty compared to notes from 
a prior baseline assessment, which considered 13 domains. Amount of change is scored from 1 
(marked worsening) to 7 (marked improvement). Also the Gérontopôle Frailty Screening Tool (36) 
contains a part in which the view of the general practitioner about the frailty status of an individual 
is expressed. 
Finally, a fourth model, on which operational definitions are increasingly being built, is the 
multidimensional one. As there is consensus that global frailty is multidimensional and may involve 
psychological, social, emotional, and spiritual aspects in addition to physical components (24). There 
are several instruments which try to capture this multidimensional nature. The Tilburg Frailty 
Indicator (37) considers ten determinants of frailty (including gender and age) and eight physical, 
four psychological, and three social components of frailty (cutoff point ≥ 5 components). The 
Groningen Frailty Indicator (38) considers nine physical, one cognitive, three social, and two 
psychological domains (cutoff point ≥ 4). The Edmonton Frail Scale (39) samples ten domains 
among which cognition, health attitudes, quality of life, social support, and mood. 
Both Rockwood et al. (40) and Gobbens et al. (22) have proposed criteria that should be reflected in a 
successful definition of frailty. They believe that this frailty definition should be multidimensional, 
make clear its dynamic state, and predict adverse outcomes. Many definitions apply cutoff points to 
classify subjects as robust, pre-frail, or frail. However, this approach impedes looking at the 
dynamic nature of frailty. While Rockwood et al. propose including frailty’s relation to disability and 
comorbidity, Gobbens et al., reinforced by consensus groups mentioned above, advocate the 
exclusion of disease, comorbidity and disability from any frailty definition. Unfortunately, to date 
no operational definition of frailty meets all these criteria. 
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Sarcopenia: Similar story 
The term sarcopenia was derived from the Greek ‘sarx’ for flesh and ‘penia’ for loss or poverty. It 
was introduced by Rosenberg in 1989. He wanted to bring more attention to the age-related decline 
in muscle mass by giving it a name, as it is “the most functionally significant decline with age” (41). 
While originally sarcopenia was considered to be the age-related loss of muscle mass, currently its 
definitions also incorporate elements such as strength or function. However, there is still no widely 
accepted operational definition for sarcopenia at the moment. 
In 1998, Baumgartner et al. (42) were first to assess sarcopenia, which back then was defined solely 
by muscle mass. They obtained an index of relative skeletal muscle mass via estimating 
appendicular skeletal muscle mass through an anthropometric prediction equation and dividing it 
by height squared. Since 2009 several meetings were convened to arrive at a consensus definition of 
sarcopenia. Table 2 displays the consensus diagnostic criteria for sarcopenia according to the 
European Working Group on Sarcopenia in Older People (EWGSOP), the European Society for 
Clinical Nutrition and Metabolism Special Interest Group (ESPEN SIG), the International 
Working Group on Sarcopenia (IWGS), the Society of Sarcopenia, Cachexia and Wasting 
Disorders (SCWD), and the Foundation for the National Institutes of Health Sarcopenia Project 
(FNIH) Biomarkers Consortium. Both EWGSOP, ESPEN SIG, as well as SCWD defined their 
cutoff point for low muscle mass based on the distribution of values for healthy young adults. In 
contrast, the FNIH cutoff points for Grip strength and muscle mass were derived from a large, 
diverse sample of older adults to best identify mobility impairment and weakness, respectively. 
Other indices of low muscle mass are summarized nicely by Fielding et al (43). 
Sarcopenia is primarily age-related, however its development can also accompany conditions that 
are not exclusively seen in older persons, like malnutrition and cachexia. Similar to frailty, 
sarcopenia needs to be distinguished from overlapping entities, in particular cachexia, which may 
be defined as a “multifactorial syndrome characterized by severe body weight, fat and muscle loss 
and increased protein catabolism due to underlying disease(s)” (44). 
While muscle mass is lost with ageing, visceral abdominal fat mass may be preserved or even 
increased. The term ‘sarcopenic obesity’ is used to describe the combination of excess weight and 
reduced muscle mass or strength (45). 
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Table 2. Diagnostic criteria for sarcopenia according to several consensus definitions. 
 PARAMETERS VARIABLES MEASUREMENT TOOLS CUTOFF POINTS 
EWGSOP 2010 (46) Low muscle mass 
 
AND EITHER 
Low muscle strength 
 
OR 
Low physical performance 
* ALM/height² 
Skeletal muscle mass/height²  
or absolute muscle mass/height² 
* Grip strength 
 
 
SPPB 
* Usual Gait speed 
Timed Up and Go 
DXA 
BIA 
 
 > 2 SD below young healthy mean 
 
 
Gender (and BMI) adjusted, based on 
statistical analyses or quartiles of study 
group 
≤ 8/12 
≤ 0.8 m/s 
ESPEN SIG 2010 (44) Low muscle mass 
 
AND 
 
Low muscle strength 
Undefined 
 
 
 
Gait speed (4 m) 
  ≥ 2 SD below young mean (gender and 
ethnicity adjusted) 
 
 
 < 0.8 m/s 
IWGS 2011 (43) Low muscle mass 
AND 
Poor functional capacity 
* ALM/height² 
 
Bedridden or 
Non-ambulatory or 
Cannot rise from a chair or Gait speed 
DXA 
 
♂ ≤ 7.23 kg/m² ♀ ≤ 5.67 kg/m² 
Sex-specific lowest 20% of the distribution 
in well-functioning older persons (47) 
 
 < 1 m/s 
SCWD 2011 (48) Low muscle mass 
AND 
Limited mobility 
ALM/height² 
 
Gait speed (4 – 6 m) 
6-minute walk 
 ≥ 2 SD below young mean (gender and 
ethnicity adjusted) 
< 1 m/s 
< 400 m 
FNIH 2014 (49–53) Low lean mass 
 
Weakness 
ALM 
* ALMBMI 
* Grip strength 
Grip strength / BMI 
DXA 
 
Jamar® dynamometry 
 
♂ < 19.75 kg 
♂ < 0.789 
♂ < 26 kg 
♂ < 1.00 
♀ < 15.02 kg 
♀ < 0.512 
♀ < 16 kg 
♀ < 0.56 
Most groups allow for parameters to be measured by a variety of variables, however their most favored assessment is indicated with an asterisk *. EWGSOP = 
European Working Group on Sarcopenia in Older People, ESPEN SIG = European Society for Clinical Nutrition and Metabolism Special Interest Group, IWGS 
= International Working Group on Sarcopenia, SCWD = Society of Sarcopenia, Cachexia and Wasting Disorders, FNIH = Foundation for the National Institutes 
of Health, ALM = Appendicular lean mass, SPPB = Short Physical Performance Battery, ALMBMI = Appendicular lean mass to Body mass index - ratio, BMI = 
Body mass index, DXA = Dual-energy X-ray absorptiometry, BIA = Bioelectrical impedance analysis, SD = Standard deviation. 
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Physical function: The core feature of physical frailty and sarcopenia 
Frailty and sarcopenia are closely related and have therefore been called ‘twin’ conditions (54). 
Cooper et al. (55) even suggested the term ‘sarcopenic frailty’ referring to “the inability of active, 
autonomous, community-dwelling older people without current disabilities (but with low muscle 
mass) to cope with stressors, leading to increased risk of adverse outcomes”. However, there is 
some controversy about the causal relation between frailty and sarcopenia. On the one hand, 
sarcopenia might be considered the pathophysiological pathway through which the negative health-
related outcomes of physical frailty arise (a clinical manifestation). On the other, however, 
sarcopenia might precede frailty and act as a biological substrate for its development (54,56). 
Although sarcopenia might be a component of frailty, there is agreement that frailty is more 
multifaceted than sarcopenia alone (23) (Figure 7). 
Cesari et al. (54) advocate diverting the focus towards the shared feature of physical frailty and 
sarcopenia, instead of determining the causality of their relationship. Indeed, their unique core 
feature is low physical function, which is usually measured by objective tests of Gait speed and 
muscle strength (Figure 8). This shift in focus has also been picked up by others. For instance, 
physical performance measurements have been tested as simple instruments for identifying physical 
frailty (phenotype) in community-dwelling older people. While Gait speed (< 0.8 m/s) and Timed 
Up and Go (> 10.0 seconds) both had high sensitivity (> 90%), their specificity was only moderate 
indicating that around 40% of cases would be falsely classified as frail (57). In addition, the FNIH 
Biomarkers Consortium avoids using the term sarcopenia, but consistently discriminates the 
contributions of muscle mass and function (49).  
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1.2 Indeed, by focusing on this shared feature of low physical function, the opportunity arises to define 
a novel target for interventions against disability (54). Currently the treatment of frailty and 
sarcopenia overlaps (58) and there is agreement that interventions against sarcopenia could be 
clinically beneficial in cases of frailty (23). Possible interventions are described in Chapter 4.3.3. 
When an intervention is capable of positively influencing both conditions at the same time, the 
direction of the relationship between frailty and sarcopenia will no longer be clinically relevant (54). 
Figure 7. The conceptual idea that sarcopenia is a key component of frailty. Adapted from 
Rizzoli et al. (59). 
Figure 8. The relationship between sarcopenia, frailty, and low levels of physical function. 
Adapted from Cesari et al. (54). 
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Physical function: Levels and assessments 
Low levels of physical function include impairments, functional limitations, and disabilities. 
According to the classification of Liu et al. (60), which was used in their Cochrane review and based 
upon the Nagi model of health states, impairments may be detected through measurements of 
muscle strength (amongst others). Functional limitations may be assessed through simple physical 
activities, such as Balance, Gait speed, Timed Up and Go, Chair rising, etc. Finally, assessment of 
physical disabilities may include evaluations of reported measures of ADL and of physical domains 
of health-related quality of life. 
In this doctoral thesis ‘physical function’ encompasses both muscle strength, physical performance, 
as well as functional status. With regard to the above mentioned levels of physical function, ‘muscle 
strength’ can relate to Grip strength; ‘physical performance’ can relate to functional limitations and 
thereby includes performance-based tests of Balance, Gait speed, Timed Up and Go, and Chair 
rising; ‘functional status’ can relate to physical disabilities and comprises reported measures of both 
ADL and mobility limitations. More details concerning the physical function measurements 
assessed in this thesis and their psychometric properties are provided in Chapter 1.5.1. A common 
performance-based test, which was not assessed in this thesis, is the Short Physical Performance 
Battery (SPPB). It includes an assessment of Standing balance (holding three positions for ten 
seconds each), a timed Gait at normal pace, and a Five Times Sit To Stand test. Subtest scores all 
range between 0 – 4 points and the total summary score ranges between 0 – 12 points, with higher 
scores indicating higher performance (61). 
Physical function assessments most often apply continuous scoring systems and hence physical 
function may be easier to approach as a dynamic process compared to frailty and sarcopenia, 
whose operational definitions often apply ordinal scoring systems. Change in physical function can 
be estimated in different ways. Two approaches are most found in literature. The first is to take the 
absolute difference between two measuring points (follow-up - baseline) and classify persons 
according to cutoff points for meaningful change, which can be established by a consensus panel 
(62,63) or can be based on distribution (64). When more than two measuring points are available, 
change from baseline can further be considered as intermittent or persistent (62,63). The second is to 
calculate the rate or slope of change from linear models using two or more measuring points. This 
latter approach also takes into account the time between measurements (64–66). 
In this thesis ‘physical function (related) assessments’ is used to refer to instruments of physical 
frailty and sarcopenia, and assessments of physical function.   
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1.2 1.2.2 UNDERPINNING MECHANISMS  
Multisystem physiological changes underlie the development of frailty and sarcopenia, including 
dysregulations in the interrelated neuromuscular, endocrine and immune systems. 
Neuromuscular changes 
The loss of skeletal muscle mass is an integral component in the development of both sarcopenia 
and frailty. However, loss of muscle strength can only be partially explained by loss in skeletal 
muscle mass. Other age-induced neuromuscular alterations may also be implicated, including motor 
cortex and spinal reflex lower excitability, decline in number of alpha motor neurons, decline in 
number and size of type II fibers, loss in tendon stiffness, increased myocellular lipid content, and 
maladaptations in excitation-contraction coupling (67,68). 
Inflammation & coagulation 
With sarcopenia and frailty, both inflammatory and coagulation pathways are increasingly active (69). 
Serum levels of interleukin-6 and C-reactive protein, as well as numbers of white blood cells and 
monocytes have shown to be elevated in frail older adults (70–74), suggesting a chronic low-grade 
inflammatory status. Likewise, higher levels of coagulation markers, such as D-dimer, factor VIII 
and tissue plasminogen activator, have been associated with prevalent and incident frailty (71,73,75). 
Although the inflammatory and coagulation pathways interact with each other, their increased 
activity might predominantly be explained by the relative increase in adiposity with ageing and 
frailty (76), since adipose tissue highly expresses both pro-thrombotic factors and pro-inflammatory 
cytokines. 
Hormonal dysregulation 
Endocrine factors influence synthesis and degradation of skeletal muscle proteins. Declines in 
levels of testosterone, dehydroepiandrosterone-sulfate and insulin-like growth factor-1, insulin 
resistance, alterations in levels of sex-hormone binding globulin and estrogens, increases in cortisol 
levels, and vitamin D deficiency might play a role in the development of sarcopenia and frailty.  
Most (but not all (77)) cross-sectional studies found a linear inverse relation between testosterone 
levels and prevalent frailty in men (78,79) and one study found a U-shaped relation in women (78). 
Prospective studies in men found change in testosterone to be associated with frailty progression 
(80), but also found baseline testosterone not to be independently significantly associated with 
incident physical frailty (79). Testosterone levels have been associated with concurrent Grip strength 
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(77,81), although this might have been mediated through appendicular lean mass (ALM) (81). The 
association of baseline testosterone levels with decrease in muscle mass has been inconsistent (82,83). 
Increasing levels of estradiol have been associated with prevalent frailty in older women (84) and 
with greater decrease in ALM in older men (83). However, the association between increasing levels 
of estradiol and frailty is controversial, as another study in men did not find an association between 
(bioavailable) estradiol and prevalent and incident physical frailty (79).  
Lower serum levels of the adrenal androgen dehydroepiandrosterone-sulfate have been associated 
with prevalent physical frailty (85), concurrent number of frailty deficits (86), and incident frailty in 
both older women and men (87).  
Insulin-like growth factor-1 promotes protein synthesis in skeletal muscle by activating anabolic 
and anti-catabolic pathways (68). Indeed, low levels of insulin-like growth factor-1 have been 
associated with poor lower limb muscle strength, slow Gait speed, and sometimes (88) frailty in 
cross-sectional studies (85,89) and with higher decrease in Gait speed and greater decrease in ALM in 
a longitudinal study including older Belgian men (83).  
Insulin is an important anabolic hormone and insulin resistance has been associated with lower 
Grip strength (90), lower skeletal muscle mass index (91), and incident frailty (73). Likewise, diabetes 
has been associated with lower muscle strength (92) and with greater declines in muscle mass and 
strength (82,93). The multifactorial elements in the development of sarcopenia and frailty are 
interlinked with those of diabetes, and hence it remains unclear which condition precedes the other 
(94). 
Associations with sex-hormone binding globulin have been inconsistent. While higher levels were 
observed in physically frail older persons (77,86) and were predictive of decreasing ALM and incident 
IWGS sarcopenia (in unadjusted models) (83), non-significant associations have also been found 
with prevalent and incident physical frailty (79,80), incident EWGSOP sarcopenia and decreasing 
Gait speed and Grip strength (83). Increased evening cortisol levels have been observed in older 
women with physical frailty (95). In addition, high cortisol to dehydroepiandrosterone-sulfate - ratio 
could predict the risk of developing frailty (87).  
Lastly, vitamin D also has an effect on muscle metabolism. Although inconsistent associations have 
been found of low serum 25(OH)-vitamin D levels with concurrent (96,97) and prospective (83,96) 
physical performance (96–98), prevalent (99) and incident (83,100) sarcopenia, and prevalent (88,99,101–103) 
and incident (88,101,103) frailty. 
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1.2 Biological & genetic underpinnings  
Several age-associated molecular mechanisms and genetic variations may underlie these multisystem 
physiological dysregulations and hence have potential relevance to the development of sarcopenia 
and frailty. However, these remain largely unexplored in human frailty research (20,58).  
Mitochondrial dysfunction with increased production of reactive oxygen species might play a role 
in the development of frailty. In fact, markers of increased oxidative stress such as elevated levels 
of 8-epi-FGFα isoprostanes and lipoprotein phospholipase A2 mass, have been associated with 
increased odds of prevalent physical frailty and slower Gait speed (104). Telomere attrition has also 
been proposed as a biomarker of ageing. While shorter telomeres in peripheral blood mononuclear 
cells have been observed in sarcopenic older persons (105), most studies found no association with 
prevalent and incident physical frailty (105,106). With ageing, there is also a decreased clearance of 
senescent and apoptotic cells. In this respect, CD8+CD28−CD27+, which is a specific T-cell subset 
and marker of immuno-senescence, has been associated with physical frailty (107).  
Finally, polymorphisms across genes related to apoptotic and transcription regulation pathways 
might also be involved in the development of frailty (108). 
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1.2.3 PURPOSES 
Physical function (related) assessments can be used for different purposes. Frailty instruments have 
been used *to predict adverse health outcomes, *to find risk factors for frailty and understand its 
etiology, *to compare with other instruments and evaluate clinimetric properties, *to find 
biomarkers of frailty, *to screen subjects for inclusion/exclusion into a study, *to estimate the 
prevalence of frailty, *to guide clinical decision making, and *to evaluate the impact of an 
intervention (109,110). 
The most common purpose (31%) of frailty instruments (for which the CHS phenotype has most 
often been used) is to predict adverse health outcomes. In community-dwelling older persons, 
operational definitions of physical frailty, especially the CHS phenotype, have been associated with 
incident disability (26,31) and mortality (31,111). Likewise, operational definitions of sarcopenia, 
especially EWGSOP sarcopenia, have been associated with incident disability (112) and mortality 
(113,114). Nevertheless, inconsistent results were found for the association of FNIH sarcopenia with 
mortality, while this is the only well-established instrument with data-driven criteria (52,115,116). 
Finally, objective physical function measurements have also been associated with incident disability 
(61,117–119) and mortality (120) in community-dwelling older persons. However, follow-up in mortality 
studies has usually been less than ten years (except for Grip strength) (120), while meta-regression 
analyses of Grip strength studies with various follow-up have indicated a weaker association with 
mortality in studies with longer follow-up (120). In hospitalized older patients, operational definitions 
of frailty (121,122) and sarcopenia (114,123) have also been associated with hospital outcomes. Albeit 
reported measurements of physical function are most often used in this setting. Disability 
instruments related to ADL have consistently been associated with mortality and 
institutionalization, but less consistently with LoS (more details are provided in Chapter 4.2.1). 
To date, much less commonly reported is the clinical use of frailty instruments (only 2% of all 
purposes) (109), for example to manage a particular disease differently in frail vs. robust older 
persons or to evaluate an older person’s capability to undergo a surgical procedure (109,124). An 
international survey among clinicians belonging to professional societies (with 12% respondents 
from Belgium) on the use of certain tools in clinical practice found around 60% of geriatricians, 
endocrinologists and rheumatologists assess muscle mass in their daily practice. Muscle strength 
was assessed in 53% to 61% of all medical specialties. Assessment of physical performance 
depended on the field of interest of respondents: most geriatricians (84%) assessed physical 
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performance in their clinical practice whilst 53% to 54% of endocrinologists and rheumatologists 
assessed it (125).  
There is likewise a paucity on the interventional use of frailty instruments as outcome measure (also 
only 2% of all purposes) (109). In a systematic review on interventions targeting frailty, only 11 
studies (published before November 2011) were found which used the entire construct of frailty as 
an outcome (126).  
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1.2.4 EPIDEMIOLOGY 
Frailty 
The prevalence of frailty depends to a great extent on its operational definition and the setting in 
which it is used.  
In community-based studies, frailty has been detected in 23 to 59% of older adults according to 
more broad, multidimensional definitions such as the Groningen Frailty Indicator, Tilburg Frailty 
Indicator, and Sherbrooke Postal Questionnaire (127,128). However, only 4 to 17% of community-
dwelling older adults have been identified as frail according to definitions of physical frailty (127). 
Within the concept of physical frailty, prevalence varies less along with its operationalization. For 
instance, the Fried phenotype (CHS) identifies 4 to 17% as frail (127), and 38 to 53% as pre-frail, 
whilst the SOF index identifies 4 to 17% as frail, and 19 to 50% as pre-frail (30,31,129–131). 
Nevertheless there is only moderate agreement between the indexes, in other words the various 
physical frailty phenotypes lead to different selections of patients, albeit of similar size (30,31,129,131). 
Agreement between the CHS phenotype and global frailty instruments was poor in the Survey of 
Health, Ageing, and Retirement in Europe (128). Prevalence of frailty in the community is higher in 
women (127), older age (127), and certain ethnic origins. In the US, African American persons are 
more likely to have physical frailty compared with white persons (132–134). Across Europe, frailty is 
more prevalent in southern countries such as Spain and Italy, although the difference with northern 
countries is attenuated when education is accounted for (135).  
In acute care, frailty has been detected in 49 to 91% of hospitalized older patients according to 
more broad, multidimensional definitions such as the Clinical Frailty Scale (136), the Edmonton Frail 
Scale (137), and the Groningen Frailty Indicator (138), and in 27 to 66% of older in-patients according 
to definitions of physical frailty (139–142). Frailty, as defined by SOF, was present in 33% of Belgian 
(142) and in 27% of Italian (140) patients admitted to a geriatric ward. In hospitalized older patients, 
prevalence of frailty varies across clinical wards, with the highest prevalence rates found in the 
geriatric ward (up to 91% according to the Groningen Frailty Indicator) (138).  
In long-term care, frailty has been detected in 64 to 85% of residents (143), although the actual 
prevalence might even be higher since non-ambulatory and cognitively impaired subjects were not 
taken into account. 
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Frailty, however, has a dynamic nature. Transitions from a robust state to a more frail state have 
been reported in 27 – 36% of robust older community-dwelling adults, while transitions to a lesser 
frail state have been observed in 13 – 30% of (pre-)frail older adults, according to physical frailty 
phenotypes (133,144,145). 
Sarcopenia 
Likewise, the prevalence of sarcopenia depends on its diagnostic parameters, resultant variables and 
measurements tools, and the setting in which it is used.  
In community, sarcopenia has been detected in 9 to 40% of older persons when it is defined solely 
by low ALM measured with dual-energy X-ray absorptiometry (DXA) (43,83,115,133,146), in 0.9 to 29% 
when defined by the EWGSOP (83,115,146–148), in 0.0 to 3% when defined by the IWGS (83), and in 0.6 
to 8% when defined by the FNIH (52,115,116,146,149).  
In acute care, EWGSOP sarcopenia has been detected in 10% of hospitalized older patients.  
In older long-term care residents prevalence reports vary from 14 to 33% (147).  
Prevalence of sarcopenia increases with age. Between genders, there is inconsistency as to which 
sex has the highest prevalence, although higher rates are mostly found in women (147). Reported 
prevalence rates of low ALM measured with DXA vary more widely in women than men (43), 
furthermore prevalence of EWGSOP sarcopenia varies greatly in women according to the cutoff 
points applied (148). 
The Health, Aging, and Body Composition study has followed older persons over nine years and 
found few (1%) participants with normal ALM, Grip strength and Gait speed at baseline to 
develop low muscle mass (without low physical function) and no participants to become 
sarcopenic. Of participants with low ALM at baseline, 7% transitioned to sarcopenia, while 4% 
transitioned to more normal states. Of sarcopenic participants only 1 – 2% transitioned to more 
normal states and 8 – 12% died (150). 
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1.3 RESEARCH OBJECTIVES 
1.3.1 GENERAL AIMS 
The aged population is more exposed to various health risks compared to other age categories. 
Identifying which older subjects are at increased risk of adverse health events is of pivotal 
importance for prevention and targeted interventions. The general aim of this doctoral thesis is 
twofold. First, we aim to evaluate the predictive value of assessments of frailty, sarcopenia and 
physical function for health risks in older adults. Second, we want to assess changes in physical 
function occurring over time and during hospital stay.  
1.3.2 SPECIFIC AIMS IN COMMUNITY-DWELLING OLDER MEN 
Chapter 2 focuses on apparently healthy community-dwelling older Belgian men. The population-
based European cohort with long-term follow-up of this chapter enables contributions to the 
validation of physical function (related) assessments. First, the association of physical frailty, 
sarcopenia, and physical function with long-term all-cause mortality is explored. Second, change in 
physical function over 3-year time and its effect on mortality hazard are examined.  
SOF Frailty & mortality 
In Chapter 2.1 we aim to evaluate the SOF frailty index for prediction of mortality. The 3-item 
SOF index has been found just as accurate for discriminating death as the 5-item CHS index in US 
studies. Moreover, the SOF index is considered to be more practical in the clinical setting, because 
of its limited number of items and its non-distribution based cutoff points. However, with 
inconsistent results found in hospitalized and non-US populations, we found it necessary to 
investigate the validity of the SOF index towards mortality, which has to date not been explored in 
a population-based European community-dwelling sample. 
FNIH sarcopenia & mortality 
In Chapter 2.1 we also aim to evaluate the FNIH cutoff points for weakness and low muscle mass 
for prediction of mortality. The FNIH criteria are data-driven and based on discriminative and 
predictive ability towards mobility impairment and weakness. This is unlike criteria from other 
sarcopenia consensus groups that are founded on medical literature and their distribution in 
reference populations. While previous related studies have been performed outside of Europe and 
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showed inconsistent results, we are able investigate the validity of the FNIH criteria towards 
mortality in European community-dwelling men. 
Physical function & mortality 
In Chapter 2.2 we aim to evaluate six physical function measurements assessed at a single time 
point for prediction of all-cause mortality. While most previous studies have had relatively short 
follow-up, we are able to investigate associations with subsequent 15-year mortality. By expressing 
hazard ratios (HRs) per increase of 1 standard deviation (SD), we also compare the predictive value 
of Rapid Disability Rating Scale-2 (RDRS-2) ADL, Short Form-36 (SF-36) Physical Function 
Index, Grip strength, Standing balance, Chair rising, and Timed Up and Go. 
Changes in physical function & mortality 
In Chapter 2.3 we aim to evaluate the association between (rate of) change in physical function 
and all-cause mortality (independent from baseline physical function). Most studies have examined 
physical function at a single time point. We investigate whether assessing physical function 
repeatedly over time adds prognostic information independent from that available with single 
assessment. 
1.3.3 SPECIFIC AIMS IN OLDER IN-PATIENTS 
Chapter 3 focuses on hospitalized older Italian men and women admitted to acute care. The 
assessment of Grip strength and Gait speed in these in-patients may contribute to the applicability 
of objective measurements of physical function in hospital setting, where reported measurements 
of physical function are most common. Firstly, the association of physical function with adverse 
hospital outcomes is explored. Secondly, change in physical function during hospital stay and its 
predictors are examined. 
Physical function & hospital outcomes 
In Chapter 3.1 we aim to identify which factors on admission can predict hospital outcomes, i.e. 
LoS, in-hospital mortality, and institutionalization. We analyze prospectively collected data, 
including both socio-demographic factors and multifaceted aspects of ageing e.g. nutritional status, 
functional status, and physical performance measurements. We investigate whether physical 
function measurements add prognostic information independently from that available with 
routinely collected parameters. 
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Functional changes during hospital stay 
In Chapter 3.2 we aim to examine functional changes during hospital stay through measurements 
of both functional status and objective physical function. In addition we investigate which 
characteristics of older in-patients are associated with meaningful in-hospital improvement in 
physical performance. 
STUDY POPULATIONS 
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1.4 STUDY POPULATIONS 
1.4.1 COMMUNITY-DWELLING OLDER MEN 
All analyses presented in Chapter 2 were performed on a sample of community-dwelling older 
men participating in the Merelbeke study. This observational community-based cohort study was 
designed to investigate the process of aging, mainly focusing on hormonal changes and bone 
metabolism. Previous findings have been the subject of several publications (151–169). Participants 
were recruited from the population register of Merelbeke, a semi-rural community of 22 000 
inhabitants near Ghent University Hospital (Belgium). Age between 70 and 85 years and 
willingness to participate were the only selection criteria at recruitment. All participants gave 
written informed consent for participation in this study, which the ethics committee of Ghent 
University Hospital has approved (Project 96/22). As displayed in Figure 9, the study started in 
1996 with follow-up visits annually until 2000, one visit in 2003, and thereafter annual follow-up by 
postal questionnaires and telephone contacts (still ongoing). 
Figure 9. Overview of the Merelbeke study.  
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1.4.2 OLDER IN-PATIENTS 
All analyses presented in Chapter 3 were performed on a sample of hospitalized older patients 
participating in the CRIteria to assess appropriate Medication use among Elderly complex patients 
(CRIME) study. This multicentre, observational study was designed to assess prescribing patterns 
in older adults hospitalized in Italy and to produce recommendations for pharmacological 
prescribing in older complex patients. Previous findings have been the subject of several 
publications (123,170–178). Participants were recruited from the internal and geriatric medicine acute 
care wards of three academic hospitals in Italy (Università Cattolica in Rome, University of Perugia, 
and University of Ferrara) and four centres of the Italian National Institute of Health and Science 
on Aging (INRCA)(situated in Ancona, Cosenza, Fermo, and Rome). Age of at least 65 years and 
willingness to participate were the only selection criteria at inclusion. All participants gave written 
informed consent for participation in this study, which the ethics committees of all participating 
centres have approved. The study recruited patients between June 2010 and May 2011. Participants 
were assessed within 24 hours of hospital admission and followed until the day of discharge, 
transfer to another ward, or in-hospital death (Figure 10). 
Figure 10. Overview of the CRIteria to assess appropriate Medication use among Elderly 
complex patients study. 
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1.5 METHODOLOGY 
1.5.1 PHYSICAL FUNCTION (RELATED) ASSESSMENTS 
Frailty 
The SOF index (30,31) was used to define (pre-)frailty in Chapter 2.1. It was the only validated frailty 
instrument that could be applied retrospectively to the Merelbeke study without any modifications. 
According to the SOF index, frailty is defined as the presence of at least two of the following 
components, pre-frailty as the presence of only one component, and robustness as the absence of 
all components. 
1) Weight loss (irrespective of intent to lose weight) of 5% or more between the second and 
fifth visit (mean time between visits 3.0 ± 0.1 years). For subjects with missing data on 
weight at the second visit (N = 11), weight at the first visit was used. 
2) Inability to rise from a chair five consecutive times without using the arms. 
3) Poor energy as identified by a negative answer to the question "do you feel full of 
energy?" on the 30-item Geriatric Depression Scale (GDS) (179). 
Sarcopenia 
The FNIH criteria (49–53) were used to define sarcopenia in Chapter 2.1. Due to the lack of data on 
Gait speed in the Merelbeke study, other operational definitions, such as those suggested by 
ESPEN SIG and SCWD, could not be applied retrospectively without any modifications. 
According to the FNIH criteria, weakness and low muscle mass in men are defined respectively as: 
1) Maximum Grip strength < 26 kg or Grip strength to Body mass index (BMI) - ratio  
< 1.00. 
2) ALM < 19.75 kg or ALM to BMI - ratio (ALMBMI) < 0.789. 
ALM was assessed using DXA, a bone density measurement technology that can also be used to 
estimate total body composition. While computed tomography and magnetic resonance imaging are 
gold standards to measure muscle mass, DXA is the preferred alternative method due to its 
relatively higher accessibility, low cost, rapid scan time, and low ionizing radiation dose (< 5 µSv) 
(46).  
DXA-calculated ALM closely approximates limb skeletal muscle mass as it includes mainly skeletal 
muscle and only a small amount of skin and connective tissue. 
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DXA cannot differentiate between water and bone-free lean tissue. It relies on the constant 0.73 
ratio of total body water/fat-free mass for estimation of fat-free mass. Extracellular fluid 
accumulation in older persons may cause fluctuation in fat-free mass hydration and overestimation 
of lean body mass (180,181). 
Functional status 
SF-36 Physical Function Index 
The SF-36 (182) is a health-related quality-of-life questionnaire, developed for persons aged 14 years 
and more. It assesses eight health domains: vitality, physical function, bodily pain, general health 
perceptions, role limitations due to physical health problems, role limitations due to emotional 
problems, limitations in social activities because of physical or emotional problems, and mental 
health. The Physical Function Index consists of ten items asking about mobility limitations at the 
present time. Responses are self-reported on a three-point scale (yes, limited a lot / yes, limited a 
little / no, not limited at all). All points are summed and transformed to total scores ranging 
between 0 and 100 with higher values indicating better health status.  
In older community-dwelling subjects, the Physical Function Index has shown to be feasible with 
item completion rates exceeding 90% (183,184). Floor effects increase from 4% in subjects aged 70 – 
74 years to 20% in subjects aged 85 years or more, while ceiling effects decrease from 4 to 0.5%, 
respectively (183). Previous studies in older adults all report good to excellent internal consistency 
(Cronbach’s alpha > 0.80) (183–188), and good inter-rater and intra-rater reliability (intra-class 
correlation coefficient (ICC) > 0.75) (185,187,189). 
In the Merelbeke study, the SF-36 questionnaire was administered at each visit. During all of these 
visits, hardly 1% of participants scored the minimum value. Ceiling effects were highest at the 
second visit in 1997 with 11% of men scoring the maximum value. Internal consistency was always 
excellent with Cronbach’s alpha ranging between 0.90 and 0.92.  
RDRS-2 ADL 
The RDRS-2 (190) is a disability questionnaire, developed specifically for older patients. It consists of 
two parts. The first part assesses assistance required in eight activities, mostly ADL (feeding, 
transferring, mobility, bathing, dressing, toilet use, grooming, and practical tasks). The second part 
assesses the level of disability in ten activities. Responses are reported by a proxy, who knows the 
subject and has observed him in ADL. Ratings are on four-point scales and should be based on 
actual status, not on ability. The total sum of points ranges between 8 and 32 for the first part, with 
higher values indicating more assistance needed. The original study reports good inter-rater 
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reliability of the eight items with ICCs between two raters ranging between 0.73 and 0.98 (190). Total 
scores on the full RDRS-2 range from 18 to 72 points. 
In the Merelbeke study, the RDRS-2 was administered to a proxy at each visit. Very high ceiling 
effects could be detected for the first part of the RDRS-2, with 74 to 87% of subjects scoring the 
best (lowest) possible value.  
Katz index ADL 
The Katz index of ADL (191) was developed for older and chronically ill persons as a measure of 
biological and psychosocial function. It assesses six functions: bathing, dressing, toilet use, 
transferring, continence, and feeding. Dependence in any of these functions is reported by an 
observer, with evaluations being based on actual status and not on ability. According to its 
developers, ADL adequacy is expressed as an over-all ADL grade, which reflects the hierarchy of 
loss of functional skills. Grade A is the most independent and grade G is the most dependent 
grade. However, in practice, responses are often on a four-point scale with total scores ranging 
between 4 and 24 and higher values indicating greater dependency. To evaluate older persons’ 
eligibility for reimbursement of institutionalization, the six Katz ADL items are often 
complemented with two criteria on orientation in time and place, which leads to five categories of 
care dependency (O, A, B, C, and C dementia). 
In older persons admitted to an internal medicine ward, a ceiling effect was present in 44% (grade 
A), while a floor effect could be observed in 15% of in-patients (grade G) (192). Previous studies in 
older adults report good to excellent internal consistency (Cronbach’s alpha > 0.80) (193–195), and 
good inter-rater and intra-rater reliability (195). 
In the CRIME study, ADL dependencies were reported at admission and at discharge. In Chapter 
3.1, ADL total dependency corresponds to a Katz grade G. At admission, when ADL score reflects 
patient’s functional status in the two weeks preceding hospitalization, 36% had no dependency in 
any ADL, while 22% was totally dependent. 
Timed physical performance 
Gait speed 
Gait speed is a performance-based test of mobility. Walking tests can vary according to pace (usual 
or maximum speed), distance to walk (ranging from 4 to 500 m), starting protocol (static or 
moving), walking aid (permitted or not), etc. The test is timed, but Gait speed results can also be 
converted to meters per second.  
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Previous studies in older patients admitted to acute care report 19 to 36% of in-patients being 
unable to perform Gait speed (196,197). The test has shown good intra-rater and inter-rater reliability 
(> 0.90) in older persons living in the community (198), from primary care (ambulatory) clinic sites 
(189), and admitted to acute care (197). 
In the CRIME study, Gait speed was assessed at admission and at discharge. The patient was timed 
while he walked four meters at his usual speed. At admission, the test could not be executed in 
54% of patients. 
Timed Up and Go 
Timed Up and Go is a performance-based test, developed for frail community-dwelling older 
persons, as a measure of basic functional mobility (199). The patient is observed and timed while he 
stands up from a standard arm chair, walks to a line on the floor three meters away at a 
comfortable and safe pace, turns, walks back, and sits down again (199). The patient can use his 
customary walking aid (199). The test is timed with shorter time taken indicating better physical 
mobility and balance ability. 
The Timed Up and Go test is appropriate for older persons who are frailer or who use walking aids 
(200), however the test seems less feasible in cognitive impaired older persons (non-participation up 
to 36%) (200,201). The test does not suffer from ceiling or floor effects in healthy older adults (202). 
Most studies in community-dwelling older persons report good inter-rater and intra-rater reliability 
(ICC > 0.90) (199,200,203,204). In cognitively impaired older persons intra-rater reliability was only 
moderate (ICC = 0.50) (201).  
In the Merelbeke study, the Timed Up and Go test was assessed once annually from 1996 until 
1999, and twice in 2000. During all of these visits, 1 to 2% of subjects did not perform the test, due 
to various reasons. Intra-rater reliability was good (ICC = 0.88, CI95 = 0.81 – 0.92) in 204 subjects 
who were assessed in 2000. For Chapter 2.3, subjects who inconsistently used walking aids over 
the years, were excluded. 
Chair rising 
Chair rising is a performance-based test, developed for healthy persons aged 20 to 85 years, as a 
measure of lower extremity muscle strength (205). Variations in the test exist, with the Five Times Sit 
To Stand test the patient is instructed to stand up from a seated position and sit down again five 
times as quickly as possible (205). Simultaneous use of the upper extremities is not permitted, in fact 
subjects are asked to keep their upper limbs folded across the chest. The test is timed, with shorter 
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time taken indicating greater lower limb strength. Variations on the Chair rising test include timing 
a different number of repetitions or counting the number of repetitions completed in a given 
period of time. 
Previous large-scale studies in older community-dwelling adults report 6 to 18% of men being 
unable to perform Chair rising (206,207). The test has shown moderate inter-rater and intra-rater 
reliability in older persons (207). 
In the Merelbeke study, Chair rising was assessed twice at each visit until 2000. During all of these 
visits, 1 to 2% of subjects did not perform the test, due to various reasons. Each time, intra-rater 
reliability was good (ICC 0.81 – 0.94). 
 
Gait speed, Timed Up and Go, and Chair rising require lower limb strength and power, balance 
and mobility (208,209). Performance on these tests is influenced by musculoskeletal, neurological, 
sensory, cardiovascular and respiratory factors (210).  
Balance 
Standing balance 
Standing balance is a performance based test to measure static balance. It requires lower limb 
strength and good vestibular function (210), and is influenced by musculoskeletal, neurological, and 
sensory factors. In general, subjects’ ability to maintain balance is assessed when their base of 
support is reduced. Different protocols exist to assess and score Standing balance. According to the 
‘Frailty and Injuries: Cooperative Studies of Intervention Techniques-3’ scale, which was developed 
for community-dwelling people and nursing home residents, Standing balance is assessed by asking 
the patient to stand in three positions of increasing difficulty first with the eyes open and then 
closed for ten seconds (parallel stand = Romberg position, semi-tandem stand, and tandem stand = 
Sharpened Romberg position). Each stand is scored on a four-point scale based on degree of 
steadiness and amount of time the stand was held. The SPPB test uses the same positions to assess 
Standing balance, but the patients do not need to close their eyes and the scoring system differs 
(206). 
The test positions have good feasibility, with only 8% of community-dwelling older men being 
unable to perform any of the positions (206). However, there are substantial ceiling effects in 
community samples (211). 
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In the Merelbeke study, Standing balance was assessed at each visit in a way similar to the ‘Frailty 
and Injuries: Cooperative Studies of Intervention Techniques-3’ scale, except each stand was 
scored on a binary scale based on whether subjects’ could hold the stand for ten seconds (yes / no). 
Total score ranged from zero to six stands held. Across study waves, 0 to 4% of subjects did not 
perform the Standing balance test. A ceiling effect could be detected with up to 33% of subjects 
scoring 6/6. 
Muscle strength 
Handheld dynamometer 
Grip strength measured with a handheld dynamometer is a valid and reliable measurement of 
isometric muscle strength (198). Performance is influenced by both musculoskeletal and neurological 
factors (210,212). Measurements diverse regarding device and test protocol used. Devices can be 
categorized into hydraulic, pneumatic, mechanical, and strain hand dynamometers. Test protocols 
may include body position, handle position, hand dominance, training of assessors, number of 
assessments, interpretation of results, etc. (213). Grip strength has shown good feasibility in older 
patients admitted to acute care (197). Both Jamar® and Smedley dynamometers are accurate 
instruments (214) with excellent test-retest reliability (215). 
In the Merelbeke study, Grip strength was measured at all visits. Between 1996 and 2000, a 
Smedley-type hand dynamometer (Smith & Nephew Rolyan, Inc., Germantown, WI) was used 
(Chapter 2.2 and Chapter 2.3). Additionally in 1999 and 2000 a Jamar® hand dynamometer (MSD 
Europe bvba, Londerzeel Belgium) was also used. Results with the Jamar® hand dynamometer 
were used in Chapter 2.1, because the FNIH criteria were developed using this type of device. 
With both dynamometers, the same protocol was applied. Subjects were in a standing position with 
the elbow in full extension, moving the shoulder from 180° to 0° flexion while squeezing as hard as 
possible. Assessors were trained study nurses who gave encouragement during the assessment. Two 
consecutive trials (with unstandardized interval) of the dominant hand were performed and 
expressed to the nearest kilogram. Both methods had good intra-rater reliability (ICC = 0.90 – 0.94 
for Smedley and 0.90 – 0.95 for Jamar®).  
In the CRIME study (Chapter 3), Grip strength was measured using a North Coast Medical 
hydraulic hand dynamometer. Patients were seated with the wrist in a neutral position and the 
elbow flexed 90°. In case a subject was unable to sit, Grip strength was assessed lying at 30° in bed 
with the elbows supported. The score was the best result of two consecutive measurements, 
expressed to the nearest kilogram.   
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1.5.2 ADVERSE HEALTH OUTCOMES 
Mortality 
In the Merelbeke study, data on all-cause mortality were obtained through yearly postal 
questionnaires and, in case of no response, telephone contacts with proxies and treating general 
practitioners. For Chapter 2.2, all deaths before December 31st 2011 were coded as events in the 
survival analyses. For Chapter 2.1 and Chapter 2.3, mortality data were updated with responses 
from postal questionnaires received before January 1st 2015 and telephone calls performed before 
July 8th 2015. Subjects who were lost-to follow-up were coded as alive on the last date of contact. 
In the CRIME study, data on in-hospital all-cause mortality were obtained through daily review of 
patients’ clinical records during hospitalization. After discharge, participants’ status was assessed at 
three, six, and twelve months through ambulatory visits and telephone contacts. 
Length of hospital stay 
LoS of older in-patients in the CRIME study was defined as the number of days from admission to 
discharge or death. 
Institutionalization 
In the CRIME study, institutionalization comprised subjects who were living at home before 
hospital admission and were transferred to a residence for older people or to a nursing home at 
discharge. 
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1.5.3 STATISTICAL METHODOLOGY 
A description of the applied statistical methods can be found in each subsection of Chapter 2 and 
Chapter 3. The statistical methodology used to examine associations with all-cause mortality in 
Chapter 2 is Cox (proportional hazards) regression, which is the basis of survival analyses in the 
medical world (216). It might be seen as an extension of multiple logistic regression except the time 
to when an event occurs (rate), rather than simply whether an event occurs (proportion) is taken 
into account. In addition, Cox regression allows variable periods of follow-up for each individual 
and censoring of some survival times (217). Survival times are said to be (right) censored if the event 
of interest (which is death in our case) has not occurred before the time of last contact (218,219). 
The final model of a proportional hazards analysis will yield an equation in which the natural 
logarithm of the HR (the hazard function h(t) divided by the baseline hazard h0(t)) is expressed as a 
linear combination of k coefficients (β) and predictor variables (x).   
ln
ℎ(𝑡)
ℎ0(𝑡)
 =  𝛽1𝑥1 + ⋯ +  𝛽𝑘𝑥𝑘      (217,220,221) 
Coefficients of a proportional hazards model can be interpreted in a similar manner to those of a 
multiple logistic regression model. The HR (𝑒𝛽𝑖∆)) can be interpreted as “the instantaneous relative 
risk of an event per unit time for an individual with risk-factor level 𝑥𝑖 + ∆ compared with an 
individual with the risk-factor level 𝑥𝑖 , given that both individuals have survived to time t, and are 
the same on all other covariates” (217).  
An important assumption with proportional hazards regression involves the hazard to be 
proportional, meaning the coefficient does not change over time (β(t) = c). When this assumption 
is violated, the models can be extended with time-dependent coefficients (220,221), as was done in 
Chapter 2.3. 
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ABSTRACT 
Objective 
We aimed to evaluate the FNIH criteria for weakness and low muscle mass and the SOF frailty 
index for prediction of long-term all-cause mortality. 
Design 
Community-based cohort study.  
Setting 
Semi-rural community of Merelbeke (Belgium). 
Subjects 
Ambulatory men aged 74 and more (N = 191). 
Methods 
Weakness was defined on previously established criteria as low Grip strength (< 26 kg) or low Grip 
strength to BMI - ratio (< 1.00). Low muscle mass (DXA) was categorized as low ALM 
(predefined < 19.75 kg) or low ALMBMI (predefined < 0.789). Frailty status was assessed using the 
components of weight loss, inability to rise from a chair, and poor energy (SOF index). Survival 
time was calculated as the number of months from assessment in 2000 until death or up to 15 years 
of follow-up. 
Results 
Mean age of the participants was 78.4 ± 3.5 years. Combined weakness and low muscle mass was 
present in 3 to 8% of men, depending on the criteria applied. Pre-frailty and frailty was present in 
30 and 7% of men, respectively. After 15 years of follow-up, 165 men (86%) died. Both the 
presence of combined weakness and low ALMBMI (age-adjusted HR = 2.50, CI95 = 1.30 – 4.79), 
and the presence of SOF frailty (age-adjusted HR = 2.64, CI95 = 1.44 – 4.86) was associated with 
mortality.  
Conclusions 
Our findings confirm the predictive value for mortality of the non-distribution based FNIH criteria 
and SOF index in older community-dwelling Belgian men.  
Keywords 
Ambulatory older men; Mortality; FNIH sarcopenia; SOF frailty  
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INTRODUCTION 
Sarcopenia and frailty are geriatric syndromes that have received particular attention in the last 
decade, especially because of their association with negative health-related outcomes (54). However, 
no consensus exists so far on operational definitions for both syndromes. Definitions using criteria 
that do not rely on distribution-based cutoff points seem appealing for clinical practice, since the 
establishment of a reference population is not required.  
Sarcopenia is characterized by the age-related loss of muscle mass and muscle function (43,46). 
Several expert groups have proposed an operational definition for sarcopenia, using the medical 
literature and founding their criterion for low muscle mass on its distribution in healthy young (44,46) 
or well-functioning older (43) reference populations. Recently, the FNIH Biomarkers Consortium 
developed new criteria for diagnosis of weakness and low muscle mass in older adults (49), using a 
data-driven approach and founding their criteria on discriminative and predictive ability. They used 
Classification and Regression Tree analyses in pooled cross-sectional data from several cohort 
studies and included several candidate predictors of mobility impairment and weakness, amongst 
which also body-size adjusted measurements of Grip strength and ALM, respectively. Cutoff 
points for both Grip strength as well as Grip strength to BMI - ratio were retained from models to 
predict slow Gait speed, because the effect of BMI adjustment was only noticeable in women (50). 
For consistency, the same type of indicators was proposed in both men and women. Likewise, 
cutoff points for both ALM and ALMBMI were retained to discriminate the presence or absence of 
weakness (51). Although ALM was the best predictor of weakness overall, sensitivity analyses with 
ALMBMI identified one clear cutoff point in women, whilst they found two when ALM was 
unadjusted. Finally, the association of these criteria for weakness and low muscle mass with 
increased likelihood for incident mobility impairment and mortality was investigated (52). The 
combination of Grip strength and ALMBMI was the only one for which there was no heterogeneity 
of association with incident mobility impairment across different study samples in women. 
Nevertheless, mortality risk patterns were inconsistent and further validation of their cutoff points 
for weakness and low muscle mass in other populations is needed (52). 
Frailty is characterized by a physiologic decrease of reserve capacity and resistance to stressors (26). 
Several operational definitions have been proposed; the most extensively studied one is the physical 
frailty phenotype developed by Fried et al. (26) in the CHS, including weight loss, weakness, 
exhaustion, slowness, and low activity. In 2008, the SOF Research Group developed a more 
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straightforward index to identify frailty which includes only three components (weight loss, inability 
to rise from a chair five times without using the arms, and self-reported poor energy) and is more 
practical to assess in the clinical setting (30). No difference between the parsimonious SOF index 
and the more complicated CHS index was found in predictive accuracy for discriminating falls, 
disability, and death in both the female SOF and male MrOS Sleep studies (30,31). Nevertheless, 
inconsistent associations of the SOF index with mortality have been found depending on ethnicity 
and setting of the population examined (130,131,140,142).  
We aimed to evaluate the FNIH cutoff points for weakness and low muscle mass and the SOF 
frailty index for prediction of all-cause mortality in a well-described sample of apparently healthy 
community-dwelling older men in Belgium with long-term follow-up. 
SOF AND FNIH & MORTALITY 
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METHODS 
Study Population 
Men aged 70 – 85 years were recruited from the population register of a community of ± 20 000 
inhabitants (Merelbeke, Belgium). The recruitment has been described previously (222) and is briefly 
summarized in Figure 11. This cohort study started in 1996 with follow-up visits annually until 
2000, one visit in 2003, and thereafter annual follow-up by postal questionnaires and telephone 
contacts. Sarcopenia and frailty could be identified retrospectively based on data acquired at the 
fifth visit in 2000. All participants gave written informed consent. This study was conducted 
according to the Declaration of Helsinki and approved by the ethics committee of Ghent 
University Hospital.  
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Figure 11. Study Design.  
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Measurements 
Weight and height were measured in indoor clothing without shoes. BMI was calculated as weight 
in kilograms divided by the square of height in metres. The SF-36 was completed to evaluate self-
reported health (range 0 – 100) (223). Subjects were asked about their educational degree, residence, 
recreational physical activity, any falls in the previous year, medication use (range 0 – 8+), and 
smoking status. The GDS (range 0 – 30) was used to evaluate depressive symptoms (179). The first 
part of the RDRS-2 was used to rate the amount of assistance required in eight ADL (range 8 – 32) 
(190). Physical performance was assessed using the Timed Up and Go test (199) (fastest time of two 
consecutive measurements). Furthermore, participants had to complete five full stands from seated 
position as quickly as possible (224). Grip strength of the dominant hand was measured twice 
consecutively using Jamar® dynamometry (maximum value achieved). ALM was calculated as the 
sum of lean mass from both arms and legs, acquired from total body scans using DXA (Hologic 
QDR– 4500A, Hologic Inc., Bedford, MA, USA, software V8.26a).  
FNIH sarcopenia criteria 
Weakness and low muscle mass at the fifth visit were defined according to the FNIH criteria (49):  
Weakness as identified by maximum Grip strength < 26 kg or Grip strength to BMI - ratio 
< 1.00. 
Low muscle mass as identified by ALM < 19.75 kg or ALMBMI < 0.789.  
SOF frailty index 
Frailty status at the fifth visit was defined according to the SOF index (30,31). Subjects are considered 
to be frail if two or all of the following components are present, pre-frail if only one component is 
present, and robust if none of the components is present: 
Weight loss (irrespective of intent to lose weight) of 5% or more between the second and 
fifth visit (mean time between visits 3.0 ± 0.05 years). For subjects with missing data on 
weight at the second visit (N = 15), weight at the first visit was used. 
Inability to rise from a chair five consecutive times without using the arms. 
Poor energy as identified by a negative answer to the question "do you feel full of energy?" 
on the 30-item GDS (179).  
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Mortality 
Data on all-cause mortality were obtained through yearly postal questionnaires and by contacting 
proxies and the treating general practitioners via telephone. Survival time was calculated as the 
number of months from assessment in 2000 until death or up to 15 years of follow-up (until 
January 1st 2015 if there was a response to the postal questionnaire (N = 16), until July 8th 2015 if 
the proxy or treating general practitioner was contacted by telephone (N = 9), until last date of 
contact if the subject was lost to follow-up in 2015 (N = 1)). 
Statistical analysis 
Descriptive data are presented as mean ± SD, median and interquartile range (IQR), or total 
number and percentage. Differences between subjects were compared using Independent samples 
T tests, Mann-Whitney U tests, or Chi-square tests, depending on the type and distribution of the 
characteristic.  
Age-adjusted Cox proportional hazards models were used to analyse the associations of sarcopenia 
and frailty with all-cause mortality. The HRs with CI95 were estimated using as a reference men 
who are not weak and have normal lean mass or robust men, respectively. No violations of the 
proportional hazards assumption were detected. Moreover, multivariate analyses with forward 
selection of BMI category*, low education, living alone, smoking status, number of medications, 
and total score on the GDS were performed. *Analyses regarding the FNIH criteria were not 
adjusted for BMI category. Age-adjusted logistic regression models were computed to calculate area 
under the curve (AUC) and explained variability. All analyses were performed using SPSS software, 
version 20.0 (SPSS Inc., Chicago, IL). Statistical significance was indicated by a P value < 0.05; all P 
values were two-tailed. 
SOF AND FNIH & MORTALITY 
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RESULTS 
In total, 208 men attended the fifth visit (Figure 11); assessment of both sarcopenia and frailty was 
complete for 191 of them. Table 3 shows their characteristics. Mean age was 78 (± 4) years. 
Combined weakness and low muscle mass was present in 3 to 8% of men, depending on the 
criteria applied (Figure 12). Pre-frailty and frailty was present in 30 and 7%, respectively (Figure 
12). Weakness was more likely in men with frailty compared to robust (P < 0.001) or pre-frail men 
(P = 0.001). Similarly, inability to rise from a chair was more likely in men with weakness compared 
to men without weakness (P = 0.005). 
After 15 years of follow-up, 165 men (86%) died (Figure 11 and Table 3). Median survival time 
was 8.3 (IQR 4.3 – 12.4) years. 
Of 191 men, 61% had normal Grip strength and normal ALMBMI (42% was robust, 17% was pre-
frail and 2% was frail) and 63% was robust (5% had weakness alone, 15% had low ALMBMI alone, 
and 2% had both). The combination of frailty, weakness and low ALMBMI was present in 1.6% of 
men. 
  
Table 3. Characteristics of Men According To Their Sarcopenic and Frailty Status at Visit 5 (N = 191). 
CHARACTERISTIC NOT WEAK AND 
NORMAL ALMBMI 
(N = 117) 
NOT WEAK, BUT 
LOW ALMBMI 
(N = 47) 
WEAK, BUT 
NORMAL ALMBMI 
(N = 15) 
WEAK AND LOW 
ALMBMI 
(N = 12) 
ROBUST 
(N = 121) 
PRE-FRAIL 
(N = 57) 
FRAIL 
(N = 13) 
Age (y), mean ± SD 78 ± 3 79 ± 4 * 79 ± 3 82 ± 5 * 78 ± 4 78 ± 3 81 ± 4 * †† 
BMI (kg/m²)   ** ††† ‡‡‡   ** ‡ 
 < 25, N (%) 42 (36) 10 (21) 2 (13) 3 (25) 40 (33) 18 (32) 10 (77) 
25 to < 30, N (%) 60 (51) 26 (55) 2 (13) 6 (50) 60 (50) 32 (56) 2 (15) 
 ≥ 30, N (%) 15 (13) 11 (23) 0 (0) 3 (25) 21 (17) 7 (12) 1 (8) 
Self-reported health [0 – 100],  
median (IQR) 
65 (55 – 80) 60 (45 – 70) * 65 (45 – 75) 50 (35 – 60) ** 65 (55 – 80) 55 (45 – 70) *** 35 (23 – 53) *** 
†† 
Low education (elementary or 
less), N (%) 
56 (48) 26 (55) 9 (60) 9 (75) 56 (46) 35 (61) 9 (75) 
Living alone, N (%) 25 (21) 11 (23) 6 (40) 6 (50) * 24 (20) 20 (35) * 4 (31) 
Recreational physical activity < 
2h/week
₸
, N (%) 
332 (29) 20 (44) 3 (25) 7 (64) * 36 (31) 22 (40) 4 (40) 
Any fall in previous year, N (%) 14 (12) 6 (13) 4 (27) 5 (42) ** † 13 (11) 10 (18) 6 (46) ** † 
N° of medications, median (IQR) 3 (1 – 5) 4 (1 – 5) 2 (0 – 3) † 4 (3 – 5) ‡‡ 2 (1 – 4) 4 (2 – 6) *** 5 (3 – 6) ** 
Current smoker, N (%) 14 (12) 6 (13) 1 (7) 2 (17) 12 (10) 11 (20) 0 (0) 
GDS score [0 – 30], median (IQR) 4 (2 – 7) 6 (3 – 11) 5 (4 – 9) 7 (4 – 11) 4 (2 – 6) 7 (4 – 12) *** 15 (8 – 20) *** †† 
RDRS-2 [8 – 32], median (IQR) 8 (8 – 8) 8 (8 – 8) 8 (8 – 11) 9 (8 – 14) ** † 8 (8 – 8) 8 (8 – 8) 9 (8 – 11.5) *** †† 
Timed Up and Go (s), median 
(IQR) 
9.6 (8.3 – 11.0) 10.2 (9.2 – 12.2) 10.4 (9.5 – 14.3) 12.3 (9.9 – 14.9) 
** 
9.6 (8.2 – 10.7) 10.6 (9.4 – 12.8) 
** 
15.8 (12.1 – 18.9) 
*** ††† 
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Table 3. Characteristics of Men According To Their Sarcopenic and Frailty Status at Visit 5 (N = 191). [Continued] 
CHARACTERISTIC 
NOT WEAK AND 
NORMAL ALMBMI 
(N = 117) 
NOT WEAK, BUT 
LOW ALMBMI 
(N = 47) 
WEAK, BUT 
NORMAL ALMBMI 
(N = 15) 
WEAK AND LOW 
ALMBMI 
(N = 12) 
ROBUST 
(N = 121) 
PRE-FRAIL 
(N = 57) 
FRAIL 
(N = 13) 
Grip strength (kg), mean ± SD 37.4 ± 6.3 33.7 ± 4.8 *** 22.8 ± 2.6 *** 
††† 
22.7 ± 3.3 *** 
††† 
35.5 ± 7.3 33.7 ± 6.7 27.2 ± 8.3 *** †† 
Grip strength / BMI (m²), mean ± 
SD 
1.43 ± 0.24 1.22 ± 0.20 *** 1.03 ± 0.15 *** 
†† 
0.82 ± 0.16 *** 
††† ‡‡ 
1.34 ± 0.26 1.29 ± 0.30 1.13 ± 0.36 
ALM (kg), mean ± SD 23.08 ± 2.77 20.77 ± 2.55 *** 20.42 ± 2.84 ** 19.79 ± 3.22 *** 22.33 ± 2.98 22.00 ± 3.04 20.37 ± 2.76 * 
ALMBMI (m²), mean ± SD 0.88 ± 0.08 0.74 ± 0.03 *** 0.92 ± 0.09 ††† 0.70 ± 0.06 *** 
‡‡‡ 
0.84 ± 0.09 0.83 ± 0.10 0.85 ± 0.14 
Weak, N (%) 0 (0) 0 (0) 15 (100) *** ††† 12 (100) *** ††† 13 (11) 7 (12) 7 (54) *** †† 
WeakBMI, N (%) 2 (2) 5 (11) * 4 (27) *** 11 (92) *** ††† ‡‡ 8 (7) 9 (16) 5 (39) *** 
Low ALM, N (%) 12 (10) 16 (34) *** 9 (60) *** 5 (42) ** 24 (20) 13 (23) 5 (39) 
Low ALMBMI, N (%) 0 (0) 47 (100) *** 0 (0) ††† 12 (100) *** ‡‡‡ 32 (26) 22 (39) 5 (39) 
Weight loss, N (%) 12 (10) 5 (11) 3 (20) 3 (25) 0 (0) 14 (25) *** 9 (69) *** †† 
Inability to rise from a chair, N (%) 3 (3) 4 (9) 3 (20) ** 2 (17) * 0 (0) 5 (9) ** 7 (54) *** ††† 
Poor energy, N (%) 26 (22) 13 (28) 4 (27) 6 (50) * 0 (0) 38 (67) *** 11 (85) *** 
Deaths after 15y follow-up, N (%) 97 (83) 43 (92) 13 (87) 12 (100) 98 (81) 54 (95) * 13 (100) 
Follow-up time (months), median 
(IQR) 
120 (69 – 157) 87 (36 – 125) ** 97 (30 – 170) 48 (18 – 81) *** † 116 (63 – 165) 86 (41 – 137) * 66 (22 – 88) ** † 
P values correspond to Independent samples T tests, Mann-Whitney U tests, and Chi-square tests, depending on the type and distribution of the characteristic. 
* P < 0.05 ** P < 0.010 *** P < 0.001 comparison with men who are not weak and have normal ALMBMI / who are robust. 
† P < 0.05 †† P < 0.010 ††† P < 0.001 comparison with men who are not weak, but have low ALMBMI / who are pre-frail. 
‡ P < 0.05 ‡‡ P < 0.010 ‡‡‡ P < 0.001 comparison with men who are weak, but have normal ALMBMI. 
₸ 11 men had missing data on recreational physical activity. 
ALMBMI = Appendicular lean mass to Body mass index - ratio, SD = Standard deviation, BMI = Body mass index, IQR = Interquartile range, GDS = Geriatric 
Depression Scale, RDRS-2 = Rapid Disability Rating Scale-2, ALM = Appendicular lean mass. 
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FNIH sarcopenia criteria 
Low ALMBMI (age-adjusted HR = 1.47, CI95 = 1.05 – 2.07) was associated with all-cause mortality, 
but low Grip strength (age-adjusted HR = 1.31, CI95 = 0.85 – 2.02), low Grip strength to BMI - 
ratio (age-adjusted HR = 1.45, CI95 = 0.90 – 2.34), and low ALM (age-adjusted HR = 1.08, CI95 = 
0.75 – 1.55) were not. Figure 12 shows age-adjusted Cox proportional hazards models each time 
including one of the four different combinations of weakness and low lean mass criteria. The 
presence of both weakness and low lean mass defined by ALMBMI was associated with a twofold 
higher hazard of mortality (age-adjusted HR = 2.50, CI95 = 1.30 – 4.79). Multivariate forward 
regression, retaining number of medications in the analysis (HR = 1.16, CI95 = 1.07 – 1.24), did not 
alter significance of this finding (age and medication number-adjusted HR = 2.30, CI95 = 1.20 – 
4.43). 
After three years, the proportion of deceased men who had presented with weakness and low 
ALMBMI was 42% (positive predictive value), while the proportion of survivors who were not weak 
and had normal ALMBMI was 90% (negative predictive value). The age-adjusted AUC was 0.700 
and explained variability was 12.1%. After nine years, positive predictive value increased to 83%, 
but negative predictive value decreased to 54%. The age-adjusted AUC was 0.671 and explained 
variability was 13.1%. 
Analyses in men without weakness (N = 164) did not reveal a significant association of low 
ALMBMI with mortality (P = 0.121). Compared to men without weakness, only men with combined 
weakness and low muscle mass had an increased mortality hazard (P = 0.015). 
SOF frailty index 
Weight loss (age-adjusted HR = 1.99, CI95 = 1.27 – 3.11) and poor energy (age-adjusted HR = 
1.78, CI95 = 1.26 – 2.51) were associated with all-cause mortality, but not inability to rise from a 
chair (age-adjusted HR = 1.23, CI95 = 0.67 – 2.27). Both pre-frail and frail status was associated 
with higher mortality rates, independently from age (Figure 12). Multivariate forward regression, 
which retained number of medications in the analysis (HR = 1.11, CI95 = 1.03 – 1.21), did not alter 
significance of the association between frailty and mortality (age and medication number-adjusted 
HR = 1.95, CI95 = 1.01 – 3.77). 
After three years, the proportion of deceased men who had presented with frailty was 39% while 
the proportion of survivors who were robust was 87% (age-adjusted AUC was 0.675, explained 
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2.1 variability 8.4%). After nine years, positive predictive value increased to 92%, but negative 
predictive value decreased to 53% (age-adjusted AUC was 0.674, explained variability 15.6%).  
Figure 12. Association of sarcopenia and frailty states with all-cause mortality after 15-year 
follow-up of community-dwelling older Belgian men (N = 191). Age-adjusted hazard ratios 
with 95% confidence interval from Cox regression models. 
When the CI95 encompasses the value one, the association is not significant at the 95% significance level (P < 0.05).  
Ref = reference, HR = Hazard ratio, CI95 = 95% confidence interval, ALMBMI = Appendicular lean mass to Body 
mass index - ratio, BMI = Body mass index. 
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The age-adjusted survival curves show the association of the FNIH sarcopenia criteria and SOF 
frailty index with mortality rates (Figure 13).  
Figure 13. Survival Curves for Sarcopenia and Frailty States in Community-Dwelling Older 
Belgian Men (N = 191), predicted from age-adjusted Cox regression models. 
ALMBMI = Appendicular lean mass to Body mass index - ratio. 
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2.1 Both indices were independently associated with mortality when they were entered into the same 
Cox regression model (adjusted HR for combined weakness and low ALMBMI = 2.02, CI95 = 1.04 – 
3.90, adjusted HR for pre-frail state = 1.65, CI95 = 1.17 – 2.33, adjusted HR for frail state = 2.41, 
CI95 = 1.29 – 4.51). 
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DISCUSSION 
We evaluated the FNIH cutoff points for weakness and low muscle mass and the SOF frailty index 
for prediction of all-cause mortality in a sample of community-dwelling older Belgian men. The 
presence of combined weakness and low ALMBMI, as well as the presence of SOF frailty, was 
associated with twofold higher hazard of mortality, independently from age and medication 
number. Low ALM (without adjustment for BMI) was not associated with mortality hazard, both 
in age-adjusted and in age- and weakness-adjusted models. 
Currently, very few studies have evaluated the FNIH criteria for prediction of all-cause mortality 
(52,116,149). The FNIH Biomarkers Consortium (52) found no consistent association with mortality, 
however weakness appeared to be the predominant predictor over lean mass. We however found 
subjects with low ALMBMI having the highest mortality hazard regardless of their weakness status 
(Grip strength or Grip strength to BMI - ratio). But, when ALM was not adjusted for BMI, lean 
mass did not have any predictive value. Similarly, Woo et al. (116) found men with low Grip strength 
and low ALMBMI to have higher odds for mortality after 10 years compared with men without 
sarcopenia in a Chinese community-dwelling sample. Lastly, Hirani et al.(149) found low ALM and 
low Grip strength to be associated with mortality in Australian community-dwelling men, but their 
criteria were not adjusted for BMI. Their age-adjusted AUC for predicting 9-year mortality was 
0.68, which corresponds with our 0.67. 
In addition to being data-driven, the FNIH Biomarkers Consortium approach distinguishes itself 
from other expert group strategies, by consistently discriminating the contributions of muscle mass 
and function. This is in contrast with for example the IWGS approach (43), which combines its 
parameters into a single classification of sarcopenia. Regarding these independent contributions of 
muscle mass and function, our findings support the clinical paradigm in which first low Grip 
strength is established, before the presence or absence of low lean mass is assessed. In this final 
selection of older persons, low lean mass might be a possible cause of their weakness (49). 
The SOF index has been evaluated in different settings and populations for prediction of all-cause 
mortality. The index was associated with mortality in community-dwelling older Caucasians in the 
US (30,31) and Italy (225). Our findings confirm this association in Caucasian community-dwellers. 
Albeit our age-adjusted AUC for predicting 3-year mortality (0.68) was slightly lower than the 0.71 
found in the MrOS Sleep study (31). The index has been inconsistent in hospitalized patients (140,142) 
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2.1 and non-significant in community-dwelling older persons of Asian or African-American ethnicity 
(130,131). 
Our findings have some implications both for research and clinical practice. In research, reporting 
the sarcopenic and/or frailty status of older study participants can help characterizing their overall 
health, which might facilitate comparison across studies.  
For clinical practice, this interpretation is more complex, because both the FNIH criteria and the 
SOF index have demonstrated low positive predictive value (< 54%) and high negative predictive 
value (> 80%) for short-term mortality (3 years), and contrariwise for long-term mortality (9 years). 
This suggests that men without weakness and low muscle mass as well as robust men are likely to 
be in good health and function within the next three years; while men with weakness and low 
muscle mass and frail men are likely to be in poor health and function within the next nine years.  
Moreover, the FNIH criteria and the SOF index may help identifying older people in need of an 
intervention, both in research and clinical practice. Although the FNIH criteria and SOF index did 
not identify the same men (there was only 1.6% overlap between weakness, low ALMBMI and 
frailty), both might be used to target subjects for similar interventions such as exercise 
interventions, optimizing protein intake, and correcting vitamin D insufficiency.  
Several factors additionally promote the implementation of the FNIH criteria and SOF index in 
clinical practice. All measurements can be performed quickly and easily, with minimal professional 
training needed and with relatively low costs. The criteria do not rely on distribution-based cutoff 
points and thus no knowledge of the underlying distribution in a given population is required.  
However, several proposals for further research can be formulated. A first proposal is to examine 
the generalizability of these criteria to other ethnicities and settings, because the clinical relevance 
of both criteria might be limited to the population and setting in which they were developed. The 
FNIH criteria were derived from nine studies performed mostly in the US and some in Europe. 
Around 90% of all subjects were Caucasian. Similarly, the SOF index was developed using data 
from Caucasian women in the US. Applicability of both criteria to other ethnic groups is hence 
uncertain and might explain some of the divergent findings mentioned earlier. Moreover, both 
criteria were developed in ambulatory older persons and previous studies pointed out the 
inconsistent validity of the SOF index in hospital setting.  
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A second proposal relates to the range of existing operational definitions for both sarcopenia and 
frailty. Studies comparing the predictive accuracy of the FNIH criteria and SOF index with other 
instruments of sarcopenia and frailty, respectively, might help researchers and clinicians with the 
challenge of deciding which consensus definition to use. 
A third proposal might focus on the meaning of change / transitions in these syndromes. Both 
sarcopenia and frailty are used as outcome measures for interventions (126,147), since they are driving 
the disability cascade but are (unlike disability) still potentially reversible. Therefore, it is important 
to understand the effect on mortality risk of transitions from and to non-sarcopenic and robust 
states over time. Moreover, evidence is needed for a link between improvement in sarcopenia or 
frailty state and clinical outcomes in order to justify the use of these syndromes as outcome 
measurements in interventions (55). Our study has some limitations. First, our cohort study had a 
baseline participation rate of 47%, which is in accordance with other population-based studies (226). 
Unfortunately, no clinical data are available for the men who declined to participate and it is likely 
that these non-participating men had higher mortality rates than our participants (227). Second, 
analyses were restricted to all-cause mortality, because cause of death could not be validated based 
on death certificates, but relied on communication with the treating general practitioner.  
A major strength of this study is its long follow-up period of 15 years, which is the longest follow-
up for any mortality study implementing the FNIH criteria (previously max. 10 years (52,116)) or SOF 
index (previously max. 9 years (30,130)). This long follow-up contributes to the exceptionally high 
mortality rate of 86% in our study. Mortality rates in previous studies evaluating the FNIH or SOF 
criteria in men range from 8 to 32% and from 7 to 27%, respectively. The small survival rate in our 
study entails that few observations are censored in the analyses; this reduces the risk of bias in 
estimates and standard errors.  
Furthermore our study population seems to be a representative sample. This is indicated by the 
correspondence of our prevalences with those reported in other population-based studies 
implementing the FNIH criteria (prevalence varied between 1 and 8% (52,116,149)) or SOF index 
(prevalence of pre-frailty and frailty ranged from 19 to 50% and from 4 to 17%, respectively 
(30,31,129–131)).  
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2.1 KEY POINTS 
 This community-based, cohort study in ambulatory older Belgian men applied the FNIH 
criteria and the SOF index. 
 Combined weakness and low muscle mass was found in 3 to 8%. Pre-frailty and frailty was 
present in 30 and 7%, respectively. 
 The FNIH criteria for weakness and low muscle mass and the SOF index for frailty 
predicted 15-year all-cause mortality. 
 The non-distributional characteristics of these criteria facilitate their application in clinical 
setting. 
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ABSTRACT 
Background 
To assess and compare the predictive value of physical function measurements for all-cause 
mortality in older men, and to evaluate the Timed Up and Go test as a predictor in subjects with 
underlying comorbidity.  
Design 
Observational study of a population-based sample of 352 ambulatory older men aged 71 to 86 at 
study baseline. The RDRS-2, SF-36, Grip strength, Chair rising, Standing balance, and Timed Up 
and Go test were determined at baseline. Associations with all-cause mortality were assessed using 
Cox proportional hazards analyses. Age, BMI, smoking status, education, physical activity, and 
cognitive status were included as confounders. Follow-up exceeded 15 years. Comorbidity status 
was categorized into cardiovascular disease, chronic obstructive pulmonary disease (COPD), and 
diabetes mellitus. 
Results 
All examined physical function measurements were associated with all-cause mortality. The Timed 
Up and Go test was the best predictor (adjusted HR per SD increase = 1.58, CI95 = 1.40 – 1.79, P 
< 0.001) for global mortality and continued to be predictive in subjects with cardiovascular disease 
(adjusted HR per SD increase = 1.80, CI95 = 1.40 – 2.33, P < 0.001). 
Conclusions 
The assessment of physical function is important in the evaluation of older persons. We encourage 
the use of the Timed Up and Go test as a reliable, quick and feasible screening tool in clinical 
settings.  
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INTRODUCTION 
In the care of older patients, it is important to assess physical function (228,229). Physical function 
measurements may identify problems not observable in a routine physical examination (230), and 
moreover physical function measurements are able to predict health-related outcomes, such as 
hospitalization and mortality (120,189). Generally, physical function is assessed through functional 
status measurements (228). Well-introduced instruments are the ADL scale (191) and the instrumental 
ADL (IADL) scale (231). Other instruments include the RDRS-2 (190) and the Physical Function 
Index of the SF-36 (184,223). Besides, there has been a growing interest in objective measurements of 
physical function, such as muscle strength measurements and physical performance measurements. 
Compared to questionnaires, these objective measurements have clear face validity for the task 
being performed, better reproducibility and greater sensitivity to change in function (228). 
Furthermore, they are considered to be better predictors of health risks (189). Commonly used in 
clinical and research settings are Grip strength, Standing balance, and the Chair rising test, the latter 
two as part of the SPPB test (206). Few have compared the relative strength of physical function 
measurements in predicting global mortality. Yet, knowing which physical function measurement 
has the strongest predictive value for health-related risks, such as mortality risk, would support its 
use in clinical practice.  
The Timed Up and Go test includes both standing and walking, two physical ADL, therefore its 
concept (199) seems very appealing to implement. The Timed Up and Go test is quick and easy to 
conduct; it requires little equipment and no special training. Previous publications regarding the 
association of Timed Up and Go with mortality are limited. Moreover these studies all had short (≤ 
5 years) or intermediate (9 years) follow-up. Research concerning the predictive value of Timed Up 
and Go for all-cause mortality during a prolonged follow-up (> 15 years), has not been done. Also 
it is not known whether underlying comorbidity, such as cardiovascular disease, COPD or diabetes 
mellitus type 2, affects Timed Up and Go’s predictive ability.  
Taking into consideration the above mentioned aspects, we aimed to evaluate the association of six 
physical function measurements with all-cause mortality. The primary goal was to compare the 
predictive value for global mortality of RDRS-2 ADL, SF-36 Physical Function Index, Grip 
strength, Standing balance, Chair rising, and Timed Up and Go. A secondary goal was to assess the 
potential role of chronic diseases in the association of Timed Up and Go with mortality.  
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METHODS 
Study Population  
This longitudinal study was initiated in 1996 to investigate the process of aging, mainly focusing on 
hormonal changes and bone metabolism. The participants were men, recruited from the population 
register of a semi-rural community of 20 000 inhabitants (Merelbeke) near Ghent University 
Hospital (Belgium). Age between 70 and 85 years and willingness to participate were the only 
selection criteria at recruitment. From the 748 men in the age group investigated, 407 (54%) gave 
written informed consent, as approved by the ethics committee of the Ghent University Hospital; 
352 men (47%) took part in all key examinations. This participation rate is in accordance with other 
population-based studies (226). Reasons for non-participation comprised of lack of interest in 255 
subjects (34%), 36 felt unable to participate because of interfering diseases (5%), 20 died before 
start of the study (3%), 12 considered themselves too old to participate (2%), 8 moved to another 
area (1%), and there were various other reasons in 64 subjects (9%). For the present study there 
were no exclusion criteria. We report on data obtained by interviews and physical examinations at 
the start of the study. Reporting of the study conforms to the STROBE statement (232,233). Follow-
up is still on-going with the latest update finalized in December, 2011. Of the 352 subjects included 
at baseline, 77 men were still alive and 2 men were lost to follow-up in 2011. Baseline data on 
unrelated issues have previously been reported (153,155).  
Functional status measurements  
The first part of the RDRS-2 was used to rate the amount of assistance required in 8 activities (190) 
on four-point response scales. The summary score ranges between 8 and 32 and was used for all 
primary analyses. The full RDRS-2 (range 18 – 72) also contains a second part to assess the level of 
disability in ten activities. The SF-36 was likewise completed (223) and includes a Physical Function 
Index, composed of ten items covering a range of difficulties (184). 
Muscle Strength Measurements 
Grip strength 
Measurement of Grip strength was performed using a Smedley-type hand dynamometer (Smith & 
Nephew Rolyan, Inc., Germantown, WI) (214,234). Subjects held the dynamometer in the dominant 
hand with the arm hanging by the side. The score was the best result of two consecutive 
measurements, expressed to the nearest kilogram. Test-retest reliability for all participants was 
excellent (ICC = 0.92). 
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Physical Performance Measurements 
Standing balance 
Standing balance was adapted from the method applied in the SPPB test (206). Subjects were asked 
to stand in three positions for up to ten seconds each: parallel stand with the feet together side-by-
side, semi-tandem stand with the heel of one foot touching the big toe of the other foot, and 
tandem stand with the heel of one foot aligned to the toes of the other foot. Each position was 
scored from 0 to 2, based on degree of steadiness and amount of time the stand was held.  
Chair rising 
Subjects were instructed to complete five full stands from seated position as quickly as possible 
(205,224). The seat height for the chair was 45 cm. The minimum time to the nearest tenth of a 
second of two assessments was used as final score. Test-retest reliability for all participants was 
excellent (ICC = 0.92). Eight subjects were unable to perform the Chair rising test, mainly due to 
osteoarthritis symptoms or because they considered the test too difficult. 
Timed Up and Go  
The Timed Up and Go test was performed according to the method described by Podsiadlo & 
Richardson (199). Subjects were instructed to stand up from an armchair (seat height of 45 cm), walk 
at a comfortable and secure pace to a line on the floor three meters away, turn, return to the chair 
and sit down again. Test-retest reliability was tested in a subset of patients. ICC was 0.90, 
suggesting very good reliability. Four participants did not perform the Timed Up and Go test due 
to foot pain or other non-specified reasons. 
Total Mortality 
Data on all-cause mortality were obtained by contacting proxies and the treating general 
practitioners by telephone. The most recent update was completed on December 31st, 2011.  
Covariates 
All participants completed questionnaires to gain information on chronic diseases, medication use, 
educational degree, and current life style, including smoking habits and physical activity. Subjects’ 
weight and height were measured in light indoor clothing without shoes. BMI was calculated as 
weight in kilograms divided by the square of height in meters. Underlying comorbidity was 
abstracted from the self-reported diseases and use of medication. For evaluation of cognitive status, 
subjects had to remember five pictures of objects and were questioned three times after delay and 
without receiving cues (range 0 – 15) (235). Higher scores indicate better cognitive status.  
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Statistical analysis 
Descriptive data are presented as mean ± SD, median (first to third quartile) or percentage. 
Univariate associations between physical function measurements were studied by calculating 
Spearman’s correlation coefficients. Test-retest reliability of Grip strength, Chair rising and Timed 
Up and Go was examined using ICCs.  
Associations between physical function measurements and all-cause mortality were assessed by Cox 
proportional hazards models. The proportional hazards assumption was first verified by including 
time-dependent covariates into the Cox model. For subjects who were lost to follow-up in 2011, 
survival time until the last date of contact was entered. Cox regression analyses were also 
performed using the z-scores of the physical function measurements, to calculate the risk for 
mortality associated with 1 SD increase in physical function. Three sequential Cox models were 
built: in which there were no adjustments made, in which age was adjusted for, and in which age, 
BMI, smoking status, education, physical activity, and cognitive status were covariates, respectively. 
To further assess the association, survival curves adjusted for age were plotted according to tertiles 
of physical function. Three unequal groups had to be made for survival curves of RDRS-2 ADL 
(score = 8 for 270 men; 9 – 10 in 47 men; > 10 in 32 men).  
Independent samples T test or one-way analysis of covariance (ANCOVA) was performed where 
appropriate, to compare physical function and survival time between healthy subjects and subjects 
with comorbidity. Bar charts were used to present median survival time of subjects dichotomized 
by performance on Timed Up and Go; associated significances were calculated with the Mann-
Whitney U test.  
All analyses were performed using SPSS software, version 20.0 (SPSS Inc., Chicago, IL). Statistical 
significance was indicated by a P value < 0.05; all P values were two-tailed.  
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RESULTS 
Average follow-up duration was 184 ± 2 months. Seventy-eight percent (273) of the 352 men died 
during follow-up, with a median survival time of 110 months. Characteristics of the study 
population at baseline are described in Table 4. At inclusion, the age of the subjects ranged 
between 71 and 86 years. Fourteen men out of 352 (4%) were underweight (BMI < 20 kg/m²); 61 
(17%) reported the use of at least five medications; 72 (21%) were currently smoking, which is in 
accordance with the proportion of smoking, older men in Belgium at that time (236). Mean number 
of pack years was 34 ± 31. Three hundred twenty two men (92%) finished primary school, 154 
(44%) also completed lower secondary education and 71 men (20%) completed upper secondary 
education. With scores on the full RDRS-2 that can range from 18 to 72, a mean score of 22 
indicated that there was little disability in the study population. Merely 71 men (20%) reported to 
only occasionally perform some type of physical exercise, while 165 (47%) reported to exercise at 
least 1 h/week. All physical function measurements correlated significantly with each other (P < 
0.001). The Timed Up and Go time score had the best correlation with the Chair rising time score 
(Spearman’s correlation coefficient r = 0.60) and was inversely associated with Grip strength (r =  
-0.29) and Standing balance (r = -0.31). Correlation of Timed Up and Go with RDRS-2 ADL (r = 
0.42) and SF-36 Physical Function Index (r = -0.50) was also low. 
The predictive value of the physical function measurements for all-cause mortality was examined 
by Cox regression analyses. Since all time-dependent covariates were statistically non-significant in 
the Cox model, the proportional hazards assumption was met. Preceding univariate Cox regression 
analyses examined the effect of age, BMI, smoking status, education, physical activity, and cognitive 
status. Age was significantly associated with mortality (HR = 1.12, 95% confidence interval (CI95) = 
1.09 – 1.15, P < 0.001). The same was true for education, physical activity, and cognitive status (HR 
= 0.96, CI95 = 0.93 – 1.00, P = 0.043; HR = 0.86, CI95 = 0.77 – 0.96, P = 0.008; HR = 0.84, CI95 = 
0.78 – 0.89, P < 0.001; respectively). BMI and smoking status were not significantly associated (HR 
= 0.97, CI95 = 0.93 – 1.00, P = 0.054 and HR = 0.98, CI95 = 0.73 – 1.31, P = 0.878, respectively). 
Subsequently, models were built unadjusted, adjusted for age and additionally adjusted for BMI, 
smoking status, education, physical activity, and cognitive status.  
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Table 4. Characteristics of the study population at baseline. 
VARIABLE VALUE 
Age (y), mean ± SD 76 ± 4 
Weight (kg), mean ± SD 74.1 ± 11.9 
Body mass index (kg/m²), mean ± SD 26.3 ± 3.7 
Smoking status, N (%)  
Never 12 (3) 
Former 268 (76) 
Current 72 (21) 
Cognitive status, mean ± SD 13.3 ± 1.7 
RDRS-2 ADL, mean ± SD  8.7 ± 1.9 
SF-36 Physical Function Index, mean ± SD 73 ± 24 
Grip strength (kg), mean ± SD 24.3 ± 7.9 
Standing balance, mean ± SD 5.0 ± 1.0 
Chair rising (s), mean ± SD 13.8 ± 4.7 
Timed Up and Go (s), mean ± SD 12.2 ± 4.7 
Number of medications, median (IQR) 2 (1 – 4) 
Self-reported chronic diseases, N (%)  
Cardiovascular disease 111 (32) 
Chronic obstructive pulmonary disease 28 (8) 
Diabetes mellitus 25 (7) 
RDRS-2 = Rapid Disability Rating Scale-2, ADL = Activities of daily living, SF-36 = Short Form-36, IQR = 
Interquartile range. 
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As summary score on the eight ADL questions of the RDRS-2 indicated higher assistance levels, 
mortality risk increased (age-adjusted HR = 1.18, CI95 = 1.12 – 1.24, P < 0.001). Correspondingly, 
when less limitations were reported on the SF-36 Physical Function Index, mortality risk decreased 
(age-adjusted HR = 0.99, CI95 = 0.98 – 0.99, P < 0.001). Mortality risk also decreased as absolute 
levels of Grip strength and Standing balance increased (age-adjusted HR per 1 kg = 0.97, CI95 = 
0.96 – 0.99, P = 0.001; HR = 0.87, CI95 = 0.78 – 0.98, P = 0.020, respectively). As more time was 
needed to complete the Chair rising and Timed Up and Go test, mortality risk increased (age-
adjusted HR per 1 second increase for Chair rising = 1.08, CI95 = 1.06 – 1.11, P < 0.001; HR for 
Timed Up and Go = 1.10, CI95 = 1.07 – 1.12, P < 0.001). Mortality risk doubled for every eight 
seconds increase in time needed to perform the Timed Up and Go test (age-adjusted HR per eight 
seconds increase for Timed Up and Go = 2.08, CI95 = 1.70 – 2.54, P < 0.001). Table 5 shows the 
HRs associated with 1 SD increase in physical function. This allows direct comparison of the 
predictive ability between physical function measurements. In each model, Timed Up and Go 
performance exhibited the strongest HR. Every time, the results were attenuated when adjusting 
for covariates, as can be seen in Table 5. The age-adjusted survival curves in Figure 14 likewise 
show that the worst physical functioning participants had lower survival probability. The higher 
mortality rates existed not only after 15 years but during the full follow-up period. The HR 
comparing the lowest with the highest tertile for performance on Timed Up and Go was 2.09 (CI95 
= 1.53 – 2.85, P < 0.001) with adjustment for age. 
As can be seen in Table 6, subjects with cardiovascular disease or COPD performed poorer on the 
physical function measurements in comparison with healthy subjects. ANCOVA further revealed 
shorter survival time for subjects with cardiovascular disease (P = 0.001), COPD (P = 0.006), and 
diabetes (P = 0.006). This can also be observed in Figure 15. In subjects with COPD or diabetes, 
performance on Timed Up and Go had little influence on survival time (P = 0.281 and P = 0.309, 
respectively). In patients with cardiovascular disease however, Timed Up and Go remained to have 
a significant association with mortality (HR in the model adjusted for age, BMI, and smoking status 
per SD = 1.80, CI95 = 1.40 – 2.33, P < 0.001). 
 
 
 
 
Table 5. Hazard ratios for total mortality of physical performance measurements (per standard deviation increase). 
 MODEL 1A MODEL 2B MODEL 3C 
CHARACTERISTIC HR (CI95) P CHI² HR (CI95) P CHI² HR (CI95) P CHI² 
RDRS-2 ADL 1.44 (1.30 – 1.58)  < 0.001 62 1.37 (1.24 – 1.52)  < 0.001 105 1.19 (1.03 – 1.37) 0.016 77 
SF-36 Physical Function Index 0.66 (0.59 –0.74)  < 0.001 56 0.71 (0.63 –0.79)  < 0.001 97 0.83 (0.71 –0.97) 0.020 73 
Grip strength 0.72 (0.63 –0.81)  < 0.001 27 0.80 (0.70 –0.91) 0.001 70 0.85 (0.74 –0.99) 0.031 74 
Standing balance 0.77 (0.70 –0.86)  < 0.001 23 0.87 (0.78 –0.98) 0.020 67 0.90 (0.78 – 1.05) 0.186 71 
Chair rising 1.59 (1.41 – 1.80)  < 0.001 54 1.46 (1.28 – 1.65)  < 0.001 99 1.30 (1.10 – 1.52) 0.002 79 
Timed Up and Go 1.70 (1.53 – 1.90)  < 0.001 94 1.54 (1.37 – 1.74)  < 0.001 123 1.40 (1.19 – 1.66)  < 0.001 98 
a Unadjusted. 
b Adjusted for age. 
c Additionally adjusted for body mass index, smoking status, education, physical activity and cognitive status. 
HR = Hazard ratio, CI95= 95% confidence interval, RDRS-2 = Rapid Disability Rating Scale-2, ADL = Activities of daily living, SF-36 = Short Form-36. 
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2.2 
Figure 14. Adjusteda survival curves according to tertilesb of physical function. 
P values indicate significant differences in survival probability between best and worst functioning subjects. Survival 
curves diverge further with follow-up.  
a Adjusted for age.  
b For the Rapid Disability Rating Scale-2 questions on activities of daily living, three unequal groups had to be made.  
ADL = Activities of daily living. 
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Figure 15. Median survival time for subjects, dichotomized by performance on the Timed 
Up and Go test. 
Error bars represent the 95% confidence interval. In subjects with cardiovascular disease, performance on the Timed 
Up and Go test has an important influence on survival; this influence is not observed in subjects with chronic 
obstructive pulmonary disease or diabetes mellitus type 2. 
COPD = Chronic obstructive pulmonary disease. 
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Table 6. Physical performance of healthy subjects and subjects with comorbidities. 
 HEALTHY SUBJECTS 
(N = 200) 
SUBJECTS WITH CV DISEASE 
(N = 111) 
SUBJECTS WITH COPD 
(N = 28) 
SUBJECTS WITH DIABETES 
(N = 25) 
CHARACTERISTIC MEAN ± SD MEAN ± SD P MEAN ± SD P MEAN ± SD P 
RDRS-2 ADL 8.5 ± 1.7 8.9 ± 2.1 0.082a 9.3 ± 2.8 0.152a 9.8 ± 3.4 0.067a 
SF-36 Physical Function Index 78.8 ± 20.7 65.1 ± 26.1  < 0.001a 54.8 ± 29.9  < 0.001a 55.4 ± 29.3 0.001a 
Grip strength (kg) 25.4 ± 7.8 22.7 ± 7.2 0.033b 22.1 ± 9.6 0.041b 22.7 ± 8.6 0.464b 
Standing balance 5.1 ± 0.9 4.8 ± 1.2 0.008a 4.6 ± 1.0 0.003b 4.2 ± 1.3 0.003a 
Chair rising (seconds) 13.1 ± 3.8 15.2 ± 5.8 0.002a 15.7 ± 4.9 0.002b 14.3 ± 4.8 0.186a 
Timed Up and Go (seconds) 11.2 ± 2.9 14.0 ± 6.7  < 0.001a 13.6 ± 5.3 0.032a 14.8 ± 8.0 0.038a 
a Independent samples T test testing the null hypothesis that there is no difference in mean physical performance between healthy subjects and subjects with 
comorbidity. 
b ANCOVA testing the null hypothesis that there is no difference in mean physical performance between healthy subjects and subjects with comorbidity, taking the 
variability of age into account. 
CV = Cardiovascular, COPD = Chronic obstructive pulmonary disease, SD = Standard deviation; RDRS-2 = Rapid Disability Rating Scale-2, ADL = Activities of 
daily living, SF-36 = Short Form-36. 
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DISCUSSION 
In this study we assessed the predictive value of RDRS-2 ADL, SF-36 Physical Function Index, 
Grip strength, Standing balance, Chair rising, and Timed Up and Go, for all-cause mortality in 
older men. All physical function measurements showed an association with global mortality during 
the full follow-up period. Interestingly, the proportional hazards models including Timed Up and 
Go had the best fit and Timed Up and Go exhibited the strongest HR of all physical function 
measurements. These findings suggest that Timed Up and Go is the best predictor of global 
mortality. Timed Up and Go remained to be a significant predictor after presence of cardiovascular 
disease was taken into account.  
Our results confirm the previously reported association between physical function measurements 
and mortality among older persons. A former study likewise described an association between the 
SF-20 Physical Function Index and mortality (237). When comparing subjects with a SF-20 Physical 
Function Index score ≥ 81 with those with a score ≤ 39, an age-adjusted HR of 0.4 (CI95 = 0.4 – 
0.5) was found. Cesari et al. (238) analysed the association of ADL and IADL score with mortality, 
the unadjusted HRs per SD increase were 0.54 (CI95 = 0.45 – 0.65) and 0.48 (CI95 = 0.38 – 0.61), 
respectively (238). Their results indicate a stronger association of functional status measurements 
with mortality than our findings. Most studies regarding Grip strength found an independent 
association with mortality risk (239–242). In the study of Cesari et al. (238), 1 SD decrease in Grip 
strength was associated with a higher risk for mortality (unadjusted HR = 0.55, CI95 = 0.43 – 0.71), 
than in our study (unadjusted HR per SD = 0.72, CI95 = 0.63 – 0.81). Perhaps this could be 
explained by the difference in follow-up duration since there is evidence for a weaker association 
between Grip strength and mortality in studies with longer follow-up (120). Moreover, the shorter 
follow-up in the study of Cesari et al. (238) might explain their stronger HR corresponding with 1 SD 
increase in Standing balance-score (unadjusted HR = 0.55, CI95 = 0.44 – 0.68) (238), compared to 
ours (HR = 0.77, CI95 = 0.70 – 0.86). In the comparative study between the SPPB tasks and Grip 
strength of Cesari et al., Chair rising had the strongest association with mortality (238). Similarly, 
Chair rising was a better predictor than Grip strength and Standing balance in our study as well. 
Conversely, one study found Chair rising and Standing balance to be equally prognostic (118).  
Although the Timed Up and Go test has been examined mostly for evaluating balance, as a 
predictor of falls (203,243), there is some evidence for an association with mortality. Tice et al. found a 
strong association in postmenopausal women (237) and Hoshide et al. reported a correlation between 
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Timed Up and Go and cardiovascular mortality in the very old subjects at least 80 years of age (244). 
Lastly, according to Davis et al., Timed Up and Go was independently of sex and age associated 
with an increased risk of death (245). Our results can confirm the association of Timed Up and Go 
with global mortality in older men after 15-year follow-up.  
The Timed Up and Go test and Chair rising test, both being objective, timed physical performance 
measurements, confirm to be more predictive for mortality than the RDRS-2 ADL and SF-36 
Physical Function Index, both subjective reports of functional status. Other studies have stated that 
performance measurements were more able to predict outcomes, such as mortality than self-
reports of functional status (189), we only found this to be true for timed physical performance 
measurements. Among all six physical function measurements, Timed Up and Go appeared to have 
strongest predictive value for all-cause mortality. However, in case a subject is unable to stand or 
walk, alternative physical function measurements can be used and are valid; functional status 
measurements and Grip strength can be used to provide a good estimate of survival. 
In our study, most of the subjects with comorbidity had significantly poorer physical function than 
healthy subjects. This is in concordance with the known association of chronic diseases such as 
stroke, coronary heart disease, COPD, and diabetes, with steep strength decrease (246). The Timed 
Up and Go test continued to be a significant predictor of mortality in subjects with cardiovascular 
disease. The lack of predictive value of Timed Up and Go in subjects with COPD or diabetes in 
our study is most probably due to the small sample size. Previous studies did show functional 
capacity is a strong predictor of all-cause mortality in patients with cardiovascular disease (247), 
COPD (248), and type 2 diabetes mellitus (249).  
Some limitations of our study should be noted. Our study population is composed solely of men, 
of which only 47% took part in all key examinations. Although this participation rate seems in line 
with other population-based studies (226), non-participants revealed to have higher mortality than 
participants in the population-based HUNT study (227). Therefore, the 47% participation rate may 
result in selection bias. As mentioned above, the limited size of groups with comorbidity may have 
also influenced some or our results. An important physical performance measurement that was not 
addressed in our study is Gait speed. This timed measurement has frequently been associated with 
mortality in older patients. According to a pooled analyses by Studenski et al. the age-adjusted 
mortality risk per 0.1 m/s higher Gait speed ranges from 0.83 to 0.94 (250). When comparing Gait 
speed and Timed Up and Go, no differences were found in their predictive ability for decline in 
global health, new ADL difficulty, and falls (243). In the comparative study of Cesari et al. (238), four-
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meter Gait speed, categorized into four groups by increasing speed, had an unadjusted HR for 
mortality of 0.49 (CI95 = 0.38 – 0.63) per SD increase. Adjusted, its predictive ability (HR – CI95) 
was of the same magnitude as that of Grip strength and the SPPB Balance test. 
Strength of this study is the long follow-up. With an average of 184 months, our study has much 
longer follow-up than other related studies. This could have an important influence on our 
findings. As already mentioned, a weaker association between muscle strength and mortality has 
been found in studies with longer follow-up (120). As a result of this long follow-up period, there is 
also little censoring, which reduces bias. 
Although our study population consisted of independently functioning ambulatory older men, we 
believe that the Timed Up and Go test can be useful in signalling of functional decline. Moreover, 
after a low performance on the Timed Up and Go test, comprehensive geriatric assessment should 
take place in order to detect specific underlying problems. To perform the Timed Up and Go test, 
only an arm chair, a measuring tape in order to indicate the three-meter distance and a watch with a 
second-hand are required. Since the instructions are straight-forward, professional expertise or 
training is not required (199). The time score is objective and easy to record (199). In addition, the 
Timed Up and Go test has shown good reliability between observers and over time (199,203).  
Potential use of the Timed Up and Go test in clinical practice could be enhanced with the 
implementation of a clear cutoff point. Further research regarding physical function measurements 
in general should also focus on prediction of mortality following invasive procedures (e.g. 
chemotherapy), as this would enable targeted interventions. 
In this study we have presented the evaluation of six physical function measurements with regard 
to their predictive value for all-cause mortality. Our findings indicate that the Timed Up and Go 
test, a timed measurement of observed performance, is the best predictor of global mortality. We 
consequently encourage the use of Timed Up and Go as a reliable, quick and feasible screening tool 
in clinical settings.  
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ABSTRACT 
Background 
Low levels of physical function have been associated with higher mortality hazard in older persons. 
However, few studies have investigated the association between functional changes and subsequent 
mortality. This study aimed to examine whether 3-year functional changes independently predict 
subsequent all-cause mortality. 
Methods 
This population-based cohort study included 171 community-dwelling men aged ≥ 71 years at 
wave 2 (baseline of the present analysis), living in the semi-rural community of Merelbeke 
(Belgium). Physical function assessments included the SF-36 Physical Function Index, Grip 
strength, Chair rising, and Timed Up and Go. Changes over 3-year time were calculated using data 
obtained at four annual visits. 
Results 
After 15 years of follow-up, 149 men (87%) died. Median survival time was 8.2 (4.2 – 12.4) years. 
Physical function assessed at a single time point (at wave 2 or wave 5) was significantly associated 
with subsequent mortality hazard, independently from future or preceding 3-year changes. Greater 
functional declines during the 3-year follow-up were associated with higher mortality hazards. 
These associations were 1) more pronounced within the first seven years, 2) independent from 
baseline age, polypharmacy, depression, disability, and physical function, 3) no longer significant 
when closure physical function was taken into account.  
Conclusion 
Physical function assessed at a single time point is a robust predictor of all-cause long-term 
mortality in community-dwelling older men. Yet, repeated assessments of physical function can 
provide prognostic information beyond that available from single initial assessment. However, with 
repeated assessments, most prognostic information can be found in the final assessment of physical 
function.  
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INTRODUCTION 
Low levels of physical function have been associated with higher mortality hazard in older persons 
(222,251,252). These low levels of physical function include impairments (which may be detected 
through measurements of muscle strength), functional limitations (which can be assessed with 
physical performance measurements), as well as disabilities (which include reported measurements 
of ADL and physical domains of health-related quality of life). 
The majority of previous research used measurements of physical function at a single point in time 
to predict mortality. Nevertheless, physical function is dynamic and changes with time (62,63). On 
average physical function declines with age (253–256). According to the European Male Ageing Study, 
annual decline in Gait Speed and Grip strength in community-dwelling men turns significant from 
the age of 70 years (83). Functional decline in community-dwelling older persons has been associated 
with incident disability (257), but few studies have investigated its association with subsequent 
mortality and they have yielded inconsistent results. At present evidence is still lacking that 
functional changes would affect mortality hazard (55,120,251). 
A better understanding of the clinical effects and consequences of functional changes would help 
to justify physical function as a relevant outcome in clinical trials and to adapt and tailor care in the 
clinical setting accordingly. Identifying persons at risk of death may allow interventions to be more 
targeted and efficient.  
In this study, we aimed to examine whether 3-year functional changes - not caused by any active 
intervention - in four assessments of physical function (SF-36 Physical Function Index, Grip 
strength, Chair rising, and Timed Up and Go) independently predict subsequent 15-year all-cause 
mortality in community-dwelling older men. 
 
 
 
84 
METHODS 
Study Population 
The study population consisted of participants who attended both the second and fifth wave of a 
cohort study, which was initiated to investigate the process of aging, mainly focusing on hormonal 
changes and bone metabolism. This population-based observational study started in 1996 with 
follow-up visits annually until 2000, one visit in 2003, and subsequent annual follow-up by postal 
questionnaires and telephone contacts (still ongoing) (Figure 16). Ambulatory, non-
institutionalized men aged 70 to 85 years were recruited from the population register of Merelbeke, 
a semi-rural community of ± 20 000 inhabitants in East Flanders, Belgium. Details concerning 
recruitment have been described previously (162,168,222). We used the second wave in 1997 as this 
analysis’ baseline since the serial testing of physical performance by the same group of four study 
nurses began at this point. During each wave, all participants were assessed within 3.5 months. The 
study was performed according to the Declaration of Helsinki. All participants gave their written 
informed consent for participation in this study, which the ethics committee of Ghent University 
Hospital approved (project 96/22). 
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Figure 16. Study design. 
Measurements 
Participants’ weight (nearest 0.1 kg) and height (nearest 0.1 cm) were measured in light clothing 
without shoes. BMI was calculated as weight in kilograms divided by squared height in metres. 
Participants were asked about their educational level, marital and residential status (living with 
spouse, with family or alone), recreational physical activity (how much time during the week they 
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were exercising in the past years), concomitant medication use (range 0 – 8+; polypharmacy was 
defined as ≥ 5 medications), and history of falls in the previous year. Standing balance was 
evaluated by instructing participants to stand in three positions (parallel, semi-tandem, and tandem 
stand) first with the eyes open and then closed for up to ten seconds each (range 0 – 6). Cognition 
was evaluated through a 5-item recall performed three times (range 0 – 15). Higher scores indicate 
better cognitive status. The 30-item GDS was used to evaluate depressive symptoms (range 0 – 30, 
a score ≥ 11 is a possible indicator of depression) (179), the first part of the RDRS-2 to rate the 
amount of assistance required in eight ADL (range 8 – 32, higher scores indicate more assistance 
needed, a score > 8 is considered an indicator of disability) (190) and the SF-36 to evaluate self-
reported health and physical function (range 0 – 100) (223). 
Educational level was recorded at the first visit, whereas the other correlates were assessed by four 
dedicated study nurses at the second visit, which is our analysis’ baseline. 
Assessments of physical function 
Assessments of physical function were performed at each wave by the same group of study nurses. 
Self-reported physical function was assessed using the ‘Physical Function Index’ of the SF-36 
questionnaire (184), which consists of ten items asking about mobility limitations at the present time. 
The total sum of the three-point scale responses is transformed to a total score ranging between 0 
and 100 with higher values indicating better physical function.  
Performance-based physical function was assessed using the Grip strength, Chair rising, and Timed 
Up and Go tests. Grip strength was measured with a Smedley type hand dynamometer (Smith & 
Nephew Rolyan Inc., Germantown, WI, USA). Participants were in a standing position with the 
elbow in full extension, moving the shoulder from 180° to 0° flexion while squeezing as hard as 
possible. Assessors were trained study nurses who gave encouragement during the assessment. The 
used score was the second result of two trials (with unstandardized interval) of the dominant hand, 
expressed to the nearest kilogram (214,234). Performance on the Chair Stand test was assessed twice in 
a row, using a standard chair with seat height of 45 cm. Participants were instructed to complete 
five full stands from seated position as quickly as possible (fastest time expressed to the nearest 
hundredth of a second) (205,224). The Timed Up and Go test was assessed according to the method 
described by Podsiadlo & Richardson (199). Participants were instructed to stand up from an 
armchair (seat height of 45 cm), walk at a comfortable and secure pace to a line on the floor three 
meters away, turn, return to the chair and sit down again (time expressed to the nearest hundredth 
of a second).  
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Functional change 
Functional change over four assessment points within three years was estimated for each 
participant separately using the formula for the slope of an ordinary least-squares (OLS) regression 
line. 
𝑇ℎ𝑟𝑒𝑒 − 𝑦𝑒𝑎𝑟 𝑐ℎ𝑎𝑛𝑔𝑒 =
3 ∗ 365 ∗ ∑ (𝑃𝐹𝑖 − 𝑃𝐹̅̅ ̅̅ )(𝑑𝑎𝑦𝑠𝑖 − 𝑑𝑎𝑦𝑠̅̅ ̅̅ ̅̅ ̅)
𝑛
𝑖=1
∑ (𝑑𝑎𝑦𝑠𝑖 − 𝑑𝑎𝑦𝑠̅̅ ̅̅ ̅̅ ̅)²
𝑛
𝑖=1
 
PF = physical function 
n = number of assessment points in time 
days = number of days since baseline assessment at wave 2 
Assessments were completed at all four waves in 158 men, at three waves in 12 men and at two 
waves in 1 man. Missing data for in-between assessments were not replaced; instead the slope of 
change was estimated without these data. 
Mortality 
We obtained data on all-cause mortality through yearly postal questionnaires and by contacting 
proxies and the treating general practitioners via telephone. Survival time was calculated as the 
number of months from assessment in 2000 until death or up to 15 years of follow-up (until 
January 1st 2015 if there was a response to the postal questionnaire (N = 15), until July 8th 2015 if 
the proxy or treating general practitioner was contacted by telephone (N = 7), until last date of 
contact if the participant was lost to follow-up in 2015 (N = 1)). 
Statistical analysis 
Normally distributed data are presented as mean ± SD, and differences between groups were 
compared using Independent samples T tests. Non-normally distributed data are presented as 
median (IQR), and differences between groups were compared using Mann-Whitney U tests. 
Countable variables are presented as total number and percentage of the sample. Differences 
between groups were compared using Chi-square tests. 
Cox proportional hazards models were used to analyse associations with all-cause mortality. Date 
of participants’ fifth visit was considered as zero time for subsequent survival. For participants who 
did not attend the fifth wave (and were included in the sensitivity analyses), July 1st 2000 was 
considered as zero time. Interaction terms between baseline physical function and functional 
change were not significant. The proportional hazards assumption which requires coefficients not 
to change over time was assessed by plotting estimates of β(t) and by using the cox.zph function in 
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RStudio. Because the effect of decline in SF-36 Physical Function Index, Grip strength, and Chair 
rising was not constant over time, a time-dependent covariate was constructed using the time-
transform functionality of coxph in RStudio and additional analyses were performed examining the 
associations with shorter-term (7-year) mortality (221). HRs for continuous measures are computed 
in such way to correspond with a unit of worse function / functional decline. Wald statistics were 
provided to indicate the models’ fit. 
All analyses were performed using RStudio, Version 0.99.484 – © 2009-2015 RStudio, Inc. 
Statistical significance was indicated by a P value < 0.05. 
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RESULTS 
A total of 198 men attended both the second and the fifth visit of this longitudinal study. However, 
assessment of functional changes was incomplete due to protocol deviations for 27 men (Figure 
16). Participants’ characteristics at baseline are shown in Table 7. Participants included in our 
analysis (N = 171) differed from excluded men who had missing data (N = 57) or who died before 
the fifth wave (N = 35) in terms of younger age, higher likelihood to perform at least two hours of 
recreational physical activity per week, lesser likelihood to have fallen in the previous year and to 
have balance problems, higher self-reported Physical Function Index, and faster Timed Up and Go 
time. In addition, compared with the men who died before the fifth wave, included men had lower 
scores on the GDS, lesser likelihood for depression and disability, and higher self-reported general 
health.  
Median (IQR) survival time after the second wave was 11.3 (7.3 – 15.4) years for included 
participants, 2.1 (1.5 – 2.5) years for men who died before 2000 (P < 0.001) and 9.5 (6 – 12.4) years 
for men with missing data (P = 0.035).  
Median (IQR) 3-year change in SF-36 Physical Function Index was -4.71 (-18.58 – +0.11) points, in 
Grip strength +0.25 (-4.02 – +2.23) kg, in Chair rising -0.85 (-2.14 – +0.15) seconds, and in Timed 
Up and Go -0.02 (-1.18 – +1.22) seconds.  
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Table 7. Characteristics of men at the second wave of this cohort study (N = 263). 
BASELINE CHARACTERISTIC PARTICIPANTS IN WAVE 2 
  INCLUDED  
IN THIS ANALYSIS 
NOT INCLUDED  
IN THIS ANALYSIS A 
DECEASED BEFORE  
WAVE 5 
N  171 (65%) 57 (22%) 35 (13%) 
Age (y), mean ± SD 75 ± 3 78 ± 4 *** 78 ± 5 ** 
BMI (kg/m²), mean ± SD 26.5 ± 3.3 26.3 ± 4.0 25.6 ± 3.7 
Low education (elementary or less),  
N (%) 
81 (47) 37 (65) 18 (51) 
Living alone, N (%) 31 (18) 8 (14) 8 (23) 
Recreational physical activity  
< 2h/week, N (%) 
33 (19) 21 (4) * 12 (34) * 
N° of medications, median (IQR) 2 (1 – 4) 2 (1 – 3) 3 (1 – 5) 
Polypharmacy, N (%) 24 (14) 6 (11) 10 (29) 
Any fall in previous year, N (%) 20 (12) 12 (21) * 9 (26) * 
Balance < 5/6 points, N (%) 18 (11) 18 (32) *** 13 (37) *** 
Cognitive recall [0 – 15], median (IQR) 13 (12 – 14) 13 (11 – 14) 13 (12 – 14) 
Cognitive recall < 13/15, N (%) 61 (36) 23 (40) 15 (43) 
GDS score [0 – 30], median (IQR) 4 (2 – 7) 6 (3 – 7) 6 (4 – 11) ** 
Depression, N (%) 21 (12) 6 (11) 10 (29) * 
Disability, N (%) 18 (11) 5 (9) 11 (31) ** 
Self-reported health [0 – 100], median 
(IQR) 
65 (55 – 80) 65 (55 – 75) 60 (45 – 70) * 
Physical Function Index [0 – 100], 
median (IQR) 
85 (75 – 95) 75 (60 – 93) ** 70 (51 – 85) *** 
Grip strength (kg), mean ± SD 31.0 ± 7.5 29.4 ± 7.7 29.1 ± 7.8 
Chair rising (s), median (IQR) 10.8 (9.5 – 12.4) 11.5 (10.0 – 13.8) 12.7 (11.1 – 17.2) *** 
Timed Up and Go (s), median (IQR) 10.4 (8.9 – 12.2) 11.9 (10.0 – 14.5) ** 12.9 (10.6 – 16.9) *** 
*** P < 0.001 ** P < 0.01 * P < 0.05 compared with the men who were included in this analysis. 
A this group consists of men with incomplete physical function data at the second and/or fifth wave. 
SD = Standard deviation, BMI = Body mass index, IQR = Interquartile range, GDS = Geriatric Depression Scale.  
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After 15 years of follow-up, 149 out of 171 participants (87%) died. Median survival time after the 
fifth wave was 8.3 (4.3 – 12.4) years.  
Cox proportional hazards models including a time-dependent object found 3-year functional 
decline in SF-36 Physical Function Index (β = 0.06, HR = 1.06 (1.02 – 1.10)), Grip strength (β = 
0.20, HR = 1.22 (1.06 – 1.41)), Chair rising (β = 0.41, HR = 1.50 (1.12 – 2.02)), and Timed Up and 
Go (β = 0.26, HR = 1.30 (1.05 – 1.61)) to be associated with mortality hazard at zero time, 
independent from age and baseline physical function. However, a significant time-attenuated effect 
for decline in SF-36 Physical Function Index (β = -0.01, HR = 0.99 (0.98 – 0.998)), Grip strength 
(β = -0.04, HR = 0.96 (0.93 – 0.998)), and Chair rising (β = -0.08, HR = 0.92 (0.85 – 0.995), but 
not Timed Up and Go (β = -0.04, HR = 0.96 (0.91 – 1.02)) was detected. For example, a greater 3-
year decline in Chair rising with 1 second/3 year was associated with 50% higher mortality hazard 
at zero time, but with only 26% higher mortality hazard at 15 years (= exp(0.41-0.08*log(180 
months)). This time-attenuated effect turned significant after seven year for changes in SF-36 
Physical Function, Grip strength, and Chair rising, but not for changes in Timed Up and Go.  
Cox proportional hazards models with fixed covariates found both physical function at a single 
time point assessment (either baseline (M1 in Table 8) or closure at wave 5 (M3 and M5 in Table 
8) and 3-year functional decline estimated from repeated assessments (M1 in Table 8) to be 
associated with higher subsequent 7-year mortality hazard, independent from age. For example, 
men of similar age with a similar 3-year decline had on average a 16% higher mortality hazard for 
every 1 second increase in baseline Chair rising performance. Men of similar age with a similar 
baseline Chair rising performance had on average 20% higher mortality hazard for every 1 
second/3 year greater decline in 3-year Chair rising change.  
Figure 17 shows age- and baseline function-adjusted survival curves stratified by tertile of 3-year 
functional changes (SF-36 Physical Function Index [33rd percentile = -11.93; 66th percentile = -
0.26], Grip strength [-2.65; 1.49 kg], Chair rising [-1.62; -0.27 seconds], Timed Up and Go [-0.79; 
0.81 seconds]). 
Associations between functional decline and 7-year mortality were still significant in supplementary 
analyses adjusted for baseline polypharmacy, disability, and depression in addition to age and 
physical function at baseline (M2* in Table 8), but were no longer significant when closure 
physical function at wave 5 was taken into account (M3 and M4* in Table 8).  
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Sensitivity analyses were performed including participants who attended wave 2 and had at least 
two measurements without protocol deviations (attendance of wave 5 was not specifically 
required). Similar results were obtained by these analyses, which included up to 30 extra 
participants (results not shown). 
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Table 8. Seven-year all-cause mortality hazard predicted by physical function at single time 
point assessment (baseline or closure) and 3-year functional estimated from repeated 
assessments in community-dwelling older men (N = 171, deaths = 73). 
  
FUNCTION AT WAVE 2   3-YEAR FUNCTIONAL 
DECLINE 
  
FUNCTION AT WAVE 5   WALD 
MODEL HR (CI95) P HR (CI95) P HR (CI95) P 
 Physical Function Index (0 – 100)           
 M1 1.02 (1.003 - 1.03) 0.011 1.02 (1.01 - 1.03) 0.002  -   -  29 
M2* 1.01 (0.998 - 1.03) 0.086 1.02 (1.01 - 1.03) 0.003  -   -  33 
M3  -   -  1.00 (0.98 - 1.02) 0.535 1.01 (1.003 - 1.03) 0.011 29 
M4*  -   -  1.01 (0.99 - 1.03) 0.354 1.01 (0.998 - 1.03) 0.087 33 
M5 1.00 (0.98 - 1.01) 0.622  -   -  1.02 (1.01 - 1.03) 0.003 29 
M6* 0.99 (0.98 - 1.01) 0.433  -    -  1.02 (1.01 - 1.03) 0.003 32 
Grip Strength (kg)           
 M1 1.04 (1.01 - 1.08) 0.014 1.09 (1.04 - 1.14) < 0.001  -   -  33 
M2* 1.04 (1.001 - 1.08) 0.043 1.10 (1.05 - 1.15) < 0.001  -   -  39 
M3  -   -  1.05 (0.99 - 1.11) 0.101 1.04 (1.001 - 1.07) 0.042 29 
M4*  -   -  1.05 (0.995 - 1.12) 0.071 1.03 (0.995 - 1.07) 0.087 35 
M5 0.97 (0.93 - 1.02) 0.272  -   -  1.07 (1.02 - 1.12) 0.004 27 
M6* 0.96 (0.91 - 1.02) 0.17  -   -  1.08 (1.03 - 1.13) 0.003 33 
Chair Rising (s)           
 M1 1.16 (1.08 - 1.25) < 0.001 1.20 (1.09 - 1.32) < 0.001  -   -  35 
M2* 1.17 (1.08 - 1.27) < 0.001 1.23 (1.10 - 1.36) < 0.001  -   -  43 
M3  -   -  1.04 (0.93 - 1.15) 0.504 1.15 (1.06 - 1.23) < 0.001 33 
M4*  -   -  1.04 (0.94 - 1.14) 0.463 1.17 (1.08 - 1.27) < 0.001 43 
M5 0.99 (0.90 - 1.09) 0.799  -   -  1.17 (1.06 - 1.28) 0.001 33 
M6* 0.99 (0.90 - 1.07) 0.622  -   -  1.20 (1.09 - 1.32) < 0.001 42 
Timed Up and Go (s)           
 M1 1.15 (1.05 - 1.26) 0.003 1.16 (1.08 -1.25) < 0.001  -   -  37 
M2* 1.16 (1.04 - 1.29) 0.008 1.18 (1.08 - 1.28) < 0.001  -   -  41 
M3  -   -  1.02 (0.92 - 1.14) 0.659 1.14 (1.04 - 1.25) 0.01 34 
M4*  -   -  1.03 (0.93 - 1.15) 0.568 1.14 (1.02 - 1.27) 0.017 40 
M5 1.00 (0.90 - 1.11) 0.954  -   -  1.15 (1.07 - 1.25) < 0.001 34 
M6* 0.99 (0.89 - 1.11) 0.908  -   -  1.17 (1.07 - 1.28) < 0.001 38 
HR = Hazard ratio, CI95 = 95% confidence interval. 
M1, M3, M5: adjusted models included age at wave 2. 
M2*, M4*, M6*: fully adjusted models included age, polypharmacy, depression, and disability at wave 2. 
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Figure 17. Age- and baseline physical function-adjusted survival curves stratified by tertile 
of 3-year functional change. 
Yellow lines correspond with tertiles of highest functional decline, red lines with mid tertiles of functional change, 
and blue lines with tertiles of least functional decline / improvement.  
HR = Hazard ratio, 95% confidence intervals are reported between brackets. 
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DISCUSSION 
In this study, the association of 3-year functional changes - not caused by any active intervention - 
with subsequent long-term all-cause mortality was evaluated in a sample of apparently healthy 
community-dwelling older men.  
Physical function assessed at a single time point (either baseline or closure at wave 5) was 
significantly associated with subsequent mortality hazard, independently from future or preceding 
3-year functional changes. Greater functional declines during the 3-year follow-up were associated 
with higher mortality hazards. These associations were 1) more pronounced within the first seven 
years, 2) independent from age, polypharmacy, depression, disability, and physical function at 
baseline, 3) no longer significant when physical function at wave 5 was taken into account.  
Few studies so far have examined the association between functional and subsequent mortality in 
healthy community-dwelling older persons and they have yielded inconsistent results (62–64,66,258–260). 
In addition, there are many discrepancies regarding how functional change was evaluated, the time 
span over which change was assessed, and the duration of mortality follow-up. Different studies 
who included a self-reported measure of physical function derived from the SF-36 questionnaire 
found change (258) or at least decline (259) in the physical component summary score predicted 4-year 
mortality, but neither decline nor improvement on the Physical Function Index within one year was 
associated with 5- or 8-year mortality (62,63). Studies including a performance-based measure of 
physical function most often used Gait speed. Patterns of change (62,63,260), but not always slopes of 
Gait speed (64,66) were associated with subsequent mortality risk. When the SPPB was used, patterns 
of decline but not of improvement within one year were associated with subsequent mortality rate 
(62,63). In the CHS the highest quintile of Grip strength decline, but not of Chair rising decline was 
associated with higher subsequent 7-year mortality risk (66). These inconsistent associations with 
mortality indicate the importance of which physical function assessment is considered and how its 
change over time is evaluated (number of assessments over time, patterns vs. slope of change). 
Our findings have two important implications. First, physical function assessments at a single time 
point - baseline or closure - were significantly associated with mortality independently from future 
or preceding functional changes (Table 7) which supports their robustness and their use in clinical 
practice. Second, in addition to age and single baseline function, ensuing 3-year functional changes 
added significant value to the prediction of mortality. This indicates assessing physical function 
repeatedly over time can provide prognostic information beyond that available from initial 
assessment (261). In addition to closure physical function (at wave 5) preceding 3-year functional 
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changes did no longer contribute to the prediction of mortality. This indicates that when physical 
function is repeatedly assessed over time, most prognostic information can be found in the final 
assessment. Our results are in line with the findings of Sabia et al. (64). 
Further research questions emerging from our findings relate to the longitudinal use of the SF-36 
Physical Function Index, Grip strength, Chair rising, and Timed Up and Go test as markers of 
(altered) mortality risk in older community-dwelling persons. Notably in this study, the observed 
functional changes were not caused by any active intervention. As such, it remains to be 
demonstrated whether functional changes, caused by active intervention, have similar predictive 
capacity and could therefore be used as surrogate end points of mortality hazard in clinical trials. It 
might also be further examined whether undergoing meaningful change in physical function or 
reaching a threshold for closure physical function is best associated with mortality. 
Our study has several innovative aspects. It is to our knowledge the first European study in 
community-dwelling older men to report on the association between objectively measured 
performance change and subsequent mortality risk and is the first to assess rate of change in Timed 
Up and Go performance in that sense. Moreover, four assessment points over 3-year time, 
performed by the same group of four dedicated and experienced study nurses, allow an accurate 
estimate of rate of functional change. The subsequent 15-year follow-up, which is the longest for 
any related mortality study, contributes to the high mortality rate of 86% in our analysis. The small 
number of survivors, who are censored in the analysis, reduces the risk of bias in estimates and 
standard errors.  
Our study, however, has also some limitations. First, results might be influenced due to selection 
bias, because only men who participated in both the second and fifth wave of this longitudinal 
study could be included in the analyses (Table 7). Sensitivity analyses, including participants who 
attended wave 2 and had at least two measurements without protocol deviations led to similar 
results. Second, mortality was not confirmed by death registry data, but relied on communication 
with the treating general practitioner and/or proxy. Third, this study was performed in apparently 
healthy community-dwelling men, so our findings might not be generalizable to a more health-
deprived population. Fourth, the study sample is relatively small. By adjusting only for age, 
polypharmacy, depression, disability, and physical function at baseline in the survival analyses, we 
might have omitted important confounders. Related to the time-attenuated effect we observed, 
Sabia et al. (64) similarly reported that the association of change in fast walking speed with mortality 
was more pronounced in the first four year compared to the full 8-year follow-up. Nevertheless, it 
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possible that our observed attenuated effect results from the decreasing sample of men who are still 
alive after certain follow-up. 
In conclusion, physical function assessed at a single time point is a robust predictor of all-cause 
long-term mortality in community-dwelling older men. Yet, repeated assessments of physical 
function can provide prognostic information beyond that available from single initial assessment 
for subsequent mortality hazard. However, with repeated assessments, most prognostic 
information lays in the final assessment of physical function.  
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LEARNING POINTS 
 Physical function assessments at a single time point are robust predictors of all-cause long-
term mortality in community-dwelling older men. 
 Nevertheless, older community-dwelling men can experience functional changes over 3-year 
time, not caused by any active intervention. 
 In this respect, repeated assessments of physical function can provide prognostic 
information beyond that available from single initial assessment for subsequent mortality 
hazard. However, with repeated assessments, most prognostic information lays in the final 
assessment of physical function.  
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ABSTRACT 
Background 
The identification of older patients at risk of poor hospital outcomes (e.g. longer hospital stay, in-
hospital mortality, and institutionalization) is important to provide an effective healthcare service. 
Objective 
To identify factors related to older patients’ clinical, nutritional, functional, and socio-demographic 
profiles at admission to an acute care ward that can predict poor hospital outcomes. 
Design and setting 
The CRIME project was a multicentre, observational study performed in geriatric and internal 
medicine acute care wards of seven Italian hospitals. 
Subjects 
One thousand one hundred twenty-three consecutively admitted patients aged 65 years or older. 
Methods 
Hospital outcomes were LoS, in-hospital mortality, and institutionalization.  
Results 
Mean age of participants was 81 years, 56% were women. Median LoS was 10 (7 – 14) days, 41 
patients died during hospital stay and 37 were newly institutionalized. Number of drugs before 
admission, metastasized cancer, renal failure or dialysis, infection, falls at home during the last year, 
pain, and Gait speed were independent predictors of LoS. Total dependency in ADL and inability 
to perform Grip strength test were independent predictors of in-hospital mortality. Malnutrition 
and total dependency in ADL were independent predictors of institutionalization. 
Conclusions 
Our results confirm that not only diseases, but also multifaceted aspects of ageing such as physical 
function and malnutrition are strong predictors of hospital outcomes and suggest that these 
variables should be systematically recorded.  
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INTRODUCTION 
The identification of geriatric patients at risk of poor hospital outcomes (e.g. longer hospital stay, 
in-hospital mortality, institutionalization) is important to provide an effective health care service 
(262). Predicting hospital outcomes at admission may facilitate the healthcare organization, as it 
allows staff to optimally manage healthcare resources. Additionally, providing information 
regarding prognosis may help the individual patient in terms of planning care (262–265).  
Most studies rely on routinely collected data such as age, gender, and clinical diagnosis when 
looking at outcomes of hospitalized older adults. However, a systematic literature review by 
Campbell et al. (266) underlined the need to take into account multifaceted aspects such as nutritional 
and functional status. Indeed, these aspects are rarely considered in clinical research. For example, 
very few studies performed in the acute care setting have included physical performance measures. 
Nevertheless these measures cover multiple facets and have been shown to predict hospital 
outcomes (196,263,267).  
The aim of the present study was to identify which factors on admission can predict hospital 
outcomes in older patients admitted to an acute care ward. In pursuit of this objective, we used a 
multi-component approach. First, we addressed multiple hospital outcomes, i.e. LoS, in-hospital 
mortality, and institutionalization. Second, we analyzed prospectively collected data, including both 
socio-demographic factors and multifaceted aspects of ageing e.g. nutritional status, functional status, and 
physical performance measurements.  
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METHODS 
Ethics statement 
The study complies with the ethical rules for human experimentation that are stated in the 
Declaration of Helsinki. All participating hospitals had obtained approval for the study from their 
ethical committee. Written informed consent was obtained from either the patient or the surrogate 
legal representative.  
Study population 
The CRIME study was a multicentre, observational study, aimed to assess prescribing patterns in 
older adults hospitalized in Italy and to produce recommendations for pharmacological prescribing 
in older complex patients. Details about these results of the CRIME project are reported elsewhere 
(123,171,172,174,268). Researchers of three academic hospitals in Italy (Università Cattolica in Rome, 
University of Perugia, and University of Ferrara) and researchers of four centres of the INRCA 
(situated in Ancona, Cosenza, Fermo, and Rome) recruited patients, who were consecutively 
admitted to geriatric and internal medicine acute care wards. Age of at least 65 years and willingness 
to participate were the only inclusion criteria. Between June 2010 and May 2011, 1123 hospitalized 
older in-patients were enrolled in the study.  
Data collection 
A questionnaire was designed to assess the participants at admission and at daily intervals until 
discharge. Study researchers had received a two-day training course in which they were well-
instructed about how to correctly collect and report questionnaire data. The researchers were 
ordinary clinical staff, external research staff, or a combination of both. They used a variety of 
information sources, including direct observation, clinical records, and interviews with the patients, 
family, friends or formal service providers.  
Patient-related data included socio-demographic factors and medical history. Type of admission 
was classified into admission through the emergency room and elective admission (if previously 
planned). Comorbidity score was the count of a set of 50 medical diagnoses comprising 
cardiovascular, endocrine, genitourinary, musculoskeletal, neurological, and malignant diseases at 
admission or hospital-acquired. Additionally, presence of clinical conditions (falls at home during 
the last year, pain, pressure ulcers, and incontinence) was reported. Furthermore, nutritional status 
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(BMI), cognitive status (30-item Mini-Mental State Examination (MMSE) (269)), and affective status 
(15-item GDS (270)) were evaluated. 
Dependency in six ADL (191) (transferring, bathing, dressing, eating, bowel and bladder continence, 
and personal hygiene) was reported to assess functional status. Gait speed was assessed by having 
the participant walk at his/her usual pace over a four-meter course. This test has shown a high test-
retest reliability (189). Grip strength was measured using a North Coast Medical hand dynamometer. 
Patients were seated with the wrist in a neutral position and the elbow flexed 90°. In case a subject 
was unable to sit, Grip strength was assessed lying at 30° in bed with the elbows supported. Data 
on Grip strength was missing for 21 patients.  
Analytical approach 
LoS was defined as the number of days from admission to discharge (or death). For the analyses 
regarding LoS, continuous ADL score was used. Gait speed performance was categorized into 
unable to perform the test, < 0.8 m/s, and ≥ 0.8 m/s (271). Grip strength categories were: unable to 
perform the test at admission, < 21 kg in women or < 37 kg in men, and ≥ 21 kg in women or ≥ 
37 kg in men (272). New institutionalization comprised subjects who lived at home before admission 
and were transferred to a residence for older people or to a nursing home at discharge. For the 
analyses regarding mortality and institutionalization, ADL total dependency (6/6 dependencies) 
was used and only two categories of Gait speed performance and Grip strength were considered 
(able vs. unable to perform the test), due to the limited number of deaths and institutionalizations. 
Participants were considered ‘unable’ to perform a test, if they could not follow instructions to 
complete the test, if they could not complete the test because of their health condition (i.e. 
drowsiness or severe cognitive impairment), or in the case of Gait speed, if the researchers 
considered it unsafe to perform the test.  
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Statistical analyses 
Descriptive data are presented as mean ± SD, median (IQR) or percentage, where appropriate. 
Multiple linear regression was used to predict LoS. Models were adjusted for centre, gender, age, 
and type of admission. Model validity was tested for the linearity of the regression function, the 
constancy of variance, and the independence and normality of error terms. LoS was natural log-
transformed, because the untransformed variable was highly skewed. The approximate 
interpretation of β is: LoS changes by 100 * β percent for a one unit increase in the independent 
variable. Change in average LoS was calculated as follows: β * (mean LoS) = β * 11.17 days. 
Subsequent analyses included all significant predictors of LoS in a multivariate regression model 
with forward selection procedure and forced retention of centre, gender, age, and type of 
admission.  
Multiple logistic regression was used to predict in-hospital mortality and institutionalization. 
Models were adjusted for centre and age. Subsequent analyses included all significant predictors of 
in-hospital mortality or institutionalization in a multivariate regression model with forward 
selection procedure and forced retention of centre and age. The Nagelkerke R² statistic (273) was 
used to assess the amount of variation in in-hospital mortality and institutionalization, ‘explained’ 
by the variables.  
Subjects who died in-hospital were excluded from the analyses of institutionalization. Of patients 
who were hospitalized more than once during the enrolment period, only data concerning the first 
hospitalization was considered. 
All analyses were performed using SPSS software, version 19.0 (SPSS Inc., Chicago, IL). Statistical 
significance was indicated by a P value < 0.05; all P values were two-tailed. 
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RESULTS 
Study population 
In total, 1123 participants were enrolled in the CRIME study. Age ranged between 65 and 102 
years (mean 82 ± 7 years). Slightly more than half of the participants (56%, N = 629) were female. 
Subjects had a mean BMI of 26 ± 5 kg/m², 4% (N = 41) were underweight (BMI < 18.5 kg/m²). 
Functional status fluctuated between both ends of the spectrum, with 36% (N = 404) having no 
ADL impairments and 22% (N = 252) being totally dependent in ADL. Mean Gait speed 
performance was 0.65 ± 0.25 m/s. Grip strength performers had a mean of 20 ± 9 kg. Further 
characteristics of the study population are described in Table 9. 
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Table 9. Characteristics of the study population (N = 1123). 
VARIABLE VALUE 
SOCIO-DEMOGRAPHIC FACTORS  
Age (y), mean ± SD 82 ± 7 
Gender (female), N (%) 629 (56) 
Elective admission, N (%) 551 (49) 
Living alone, N (%) 279 (25) 
MEDICAL HISTORY  
No of drugs before admission, mean ± SD 6 ± 3 
 ≥ 2 hospital admissions during the last year, N (%) 216 (19) 
MEDICAL DIAGNOSES  
Comorbidity score, median (IQR) 5 (3 – 6) 
Ischemic heart disease, N (%) 356 (32) 
Heart failure, N (%) 307 (27) 
Cerebrovascular accident, N (%) 236 (21) 
Parkinson's disease, N (%) 68 (6) 
Dementia (Alzheimer or other), N (%) 230 (21) 
Diabetes mellitus, N (%) 333 (30) 
Metastasized cancer, N (%) 47 (4) 
Renal failure or dialysis, N (%) 286 (26) 
Infection, N (%) 119 (11) 
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Table 9. Characteristics of the study population (N = 1123).[Continued]  
VARIABLE VALUE 
CLINICAL CONDITIONS  
Falls at home during the last year, N (%)) 278 (25) 
Pain, N (%) 589 (52) 
Pressure ulcers, N (%) 57 (5) 
Urinary incontinence or catheter, N (%) 468 (42) 
Faecal incontinence, N (%) 157 (14) 
Malnutrition (BMI < 18.5 kg/m²), N (%) 41 (4) 
COGNITIVE AND AFFECTIVE STATUS  
30-item Mini-Mental State Examination category, N (%)  
Unable 186 (17) 
 < 24 460 (41) 
 ≥ 24 415 (37) 
15-item Geriatric Depression Scale, median (IQR) 4 (2 – 7) 
FUNCTIONAL STATUS AND PHYSICAL PERFORMANCE  
ADL score ( /6), median (IQR) 1 (0 – 5) 
ADL total dependency, N (%) 252 (22) 
Gait speed category, N (%)  
Unable 603 (54) 
 < 0.8 m/s 381 (34) 
 ≥ 0.8 m/s 139 (12) 
Grip strength category,% (N)  
Unable 306 (27) 
 < 21 kg ♀, < 37 kg ♂ 700 (62) 
 ≥ 21 kg ♀, ≥ 37 kg ♂ 96 (9) 
SD = Standard deviation, BMI = Body mass index, IQR = Interquartile range, ADL = Activities of daily living.  
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Length of hospital stay 
LoS varied from one to 65 days, with 75% of subjects staying in hospital between seven and 
fourteen days (median 10 days). Factors predictive of LoS in initial analyses were number of drugs 
before admission, more than one hospital admission during the last year, comorbidity score, 
presence of metastasized cancer, renal failure or dialysis, infection, falls at home during the last 
year, pain, ADL score / total dependency and Gait speed category / inability (Table 12). 
Subsequent multivariate analyses, which included these significant variables, identified number of 
drugs before admission, metastasized cancer, renal failure or dialysis, infection, falls at home during 
the last year, pain, and Gait speed category as independent predictors of LoS (Table 10).  
Table 10. Independent predictors of length of hospital stay. 
 VARIABLES B (CI95) 
LENGTH OF HOSPITAL STAY No of drugs before admission (/3) 0.04 (0.01 – 0.07) 
 Metastasized cancer 0.31 (0.15 – 0.47) 
 Renal failure or dialysis 0.16 (0.08 – 0.23) 
 Infection 0.16 (0.05 – 0.27) 
 Falls at home during the last year 0.12 (0.04 – 0.19) 
 Pain 0.07 (0.00 – 0.14) 
 Gait speed category -0.07 (-0.12 – -0.01) 
Analyses of length of hospital stay included number of drugs before admission, more than one hospital admission 
during the last year, comorbidity score, presence of metastasized cancer, renal failure or dialysis, infection, falls at 
home during the last year, pain, Activities of daily living score and Gait speed category in a multivariate regression 
model with forward selection procedure and forced retention of centre, gender, age, and type of admission. 
β = Coefficient, CI95 = 95% confidence interval. 
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In-hospital mortality 
Forty one (4%) patients died in hospital. Factors predictive of in-hospital mortality in initial 
analyses were age, infection, falls at home during the last year, pressure ulcers, urinary or faecal 
incontinence, MMSE category, ADL score / total dependency, Gait speed inability, and Grip 
strength inability (Table 13). Subsequent multivariate analyses, which included these significant 
variables, identified ADL total dependency and Grip strength inability as independent predictors of 
in-hospital mortality (Table 11). This multivariate model explained 28.5% of the variability in in-
hospital mortality. 
Institutionalization 
Thirty seven patients (3%) were newly institutionalized after discharge. Factors predictive of 
institutionalization in initial analyses were age, cerebrovascular accident, dementia, metastasized 
cancer, pain, urinary incontinence, malnutrition, MMSE category, ADL score / total dependency, 
Gait speed inability, and Grip strength inability (Table 14). Subsequent multivariate analyses, which 
included these significant variables, identified malnutrition and ADL total dependency as 
independent predictors of institutionalization (Table 11). This model explained 32.9% of the 
variability in institutionalization.  
Table 11. Independent predictors of in-hospital mortality and institutionalization. 
 VARIABLES OR (CI95) 
IN-HOSPITAL MORTALITY ADL total dependency 3.8 (1.5 – 9.8) 
 Grip strength inability 5.6 (2.0 – 16) 
INSTITUTIONALIZATION Malnutrition (BMI < 18.5 kg/m²) 7.6 (2.0 – 29) 
 ADL total dependency 8.0 (2.8 – 23) 
Analyses of in-hospital mortality included infection, falls at home during the last year, pressure ulcers, urinary or 
faecal incontinence, MMSE category, ADL total dependency, Gait speed inability, and Grip strength inability with 
forward selection procedure and forced retention of centre and age. 
Analyses of institutionalization included cerebrovascular accident, dementia, metastasized cancer, pain, urinary 
incontinence, malnutrition, MMSE category, ADL total dependency, Gait speed inability, and Grip strength inability 
with forward selection procedure and forced retention of centre and age. Subjects who died in-hospital were 
excluded from the analyses. 
OR = Odds ratio, CI95 = 95% confidence interval; ADL = Activities of daily living, BMI = Body mass index. 
 
 
 
 
112 
DISCUSSION 
In this multicentre study, we aimed to identify factors related to older patients’ clinical, nutritional, 
functional, and socio-demographic profiles at admission to an acute care ward that can predict LoS, 
in-hospital mortality, and institutionalization. 
The observed median LoS of ten days in this study is in line with previous reports of multicentre 
Italian and European studies (274,275). The number of drugs before admission was predictive of 
longer LoS. This corresponds with the reported association between polypharmacy and poor 
hospital outcomes (265,266). Along with other studies, we found the occurrence of infection (276), 
having a history of falls at home (262,277), and slower Gait speed (196,267,277–279) were associated with 
longer LoS. The predictive value of falls may not only be explained by poor walking mobility, as the 
association between falls and LoS persists after adjustment for Gait speed in the multivariate 
analyses. The presence of pain has not been reported as a predictor of LoS in the acute care setting 
previously, but this finding is consistent with a reported association between pain perception and 
LoS in older patients with hip fracture (280). 
The observed percentage of in-hospital mortality (4%) and new institutionalization (3%) in this 
study are in line with previous reports of multicentre Italian and European studies (274,275,281). The 
presence of malnutrition and ADL total dependency both led to an eight-fold increase in 
institutionalization rate. Previous studies likewise found malnutrition to be independently predictive 
of institutionalization (263,282,283). This may be explained in part by the fact that malnutrition in older 
hospitalized patients is a result of several medical and social conditions that chronically affect them, 
rather than an indicator of an acute illness (282). In agreement with other studies, we found that 
ADL total dependency was independently predictive of in-hospital mortality (265,275,282) and 
institutionalization (263,275). Inability to perform the Grip strength test led to a five-fold increase in 
mortality hazard. Grip strength is both a marker of functional and nutritional status (263). 
The added value of physical performance measurements over self-reported measurements has been 
questioned (196,267,284,285). In our study, Gait speed was a better predictor of LoS than ADL score. 
Likewise, other studies found the association between functional status and LoS less discriminating 
compared with Gait speed (196,267). Self-reported functional status measures, such as ADL score, are 
not designed to capture the entire range of function in older adults (196) and may display ceiling 
effects (284). Therefore, in older persons with few ADL dependencies, physical performance 
measures might be more valuable (284). On the other hand, ADL total dependency as a measure of 
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functional status was more discriminating for in-hospital mortality and institutionalization than 
Gait speed performance. First, the Gait speed test displayed a floor effect in the weakest patients. 
Only few subjects who died in-hospital or who were newly institutionalized could perform the Gait 
speed test (N = 1 and 4, respectively) at admission. Second, functional status encompasses physical 
function, cognitive status, and incontinence; these all have predictive value for institutionalization.  
This study has both strengths and limitations. Overall, 1541 eligible patients were screened and 
1123 (73%) agreed to participate in the study (171). These non-participants might have had poorer 
hospital outcomes than participants and hence might bias our results. Despite the multicentre 
design of our study, findings may not be representative for all older patients admitted to an acute 
care ward, because the centres involved were exclusively Italian facilities and they were not 
randomly chosen. Outcomes studied (in-hospital mortality, new institutionalization, and especially 
LoS) can be highly influenced by the characteristics of the hospital and their staff. However, the 
aim of the present study was to assess factors related to older patients’ profiles rather than 
organizational characteristics. In addition, analyses were adjusted for ‘centre’ in order to take into 
account the effect of centres' characteristics on study outcomes. One strength of this study is that 
data was prospectively collected on multifaceted variables, which are otherwise unavailable in 
administrative datasets and in many chart-based studies. It is interesting to note that routinely 
available socio-demographic factors were not predictive of any hospital outcome. Similar findings 
have been reported by other studies (262,265,277). We believe that such a multi-dimensional approach 
to identify predictors of hospital outcomes in older in-patients might add value to the organization 
of healthcare in comparison with single-component assessments.  
The ageing ratio in Italy has been increasing over the past decades, with 146.5 persons aged 65 and 
over compared to 100 persons aged 0 – 14 in 2010 (286). Mean life expectancy at the age of 65 has 
reached 22.1 years for women (with 10 healthy life years) and 18.3 years for men (with 10.2 healthy 
life years) (287). In 2010, over 10 million persons were admitted to acute care in Italy, of which 40% 
were aged 65 and older (288). There were 287 acute care beds in hospitals per 100 000 inhabitants 
(289). This number has decreased over the last years, which may be explained by the shift in 
resources from the hospital to the community through the realization of integrated home care and 
residential health care facilities. The number of facilities is increasing over the years with 6153 
residential health care facilities in 2010 (290), of which 3749 provided health care for older persons 
(291). However, Italy still has a low number of residential beds for older persons compared to other 
Western countries. This may be due to the Italian family structure, which traditionally considers 
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care of older people as a responsibility of the family (292) and it may explain the low rate of 
institutionalization observed in our study sample.  
One of Italy’s challenges to satisfy the needs of frail older people is the presence of Geriatric 
Evaluation Units in Health agencies to perform comprehensive geriatric assessments (292). If older 
patients at risk of poor hospital outcomes could be identified at admission, than appropriate 
resources could be made available during hospitalization, enabling a more effective healthcare 
service (262). This can be achieved by implementing a comprehensive geriatric assessment at 
admission to evaluate physical performance, functional dependency, nutritional status, 
polypharmacy, and falls. Our results may therefore have not only important implications for the 
organization and quality of clinical practice but also for its economic aspects. 
Based on our results, in addition to nutrition optimization, we encourage exercise and physical 
therapy interventions, which may help to prevent falls and to improve physical performance. We 
endorse that patients’ drug use is carefully reviewed in order to discontinue potentially 
inappropriate medication (274), particularly by withdrawing drugs of little added value and limiting 
those related to falling.  
Our results confirm that not only diseases, but also multifaceted aspects of ageing such as physical 
function and malnutrition are strong predictors of hospital outcomes and suggest that these 
variables should be systematically recorded (275,293).  
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SUPPORTING INFORMATION 
Table 12. Predictors of length of hospital stay. Data reported are from different linear 
regression models predicting length of hospital stay (natural log-transformed). Each model 
included centre, age, gender, and type of admission as covariates. 
 VARIABLE Β (CI95) P CHANGE IN 
AVERAGE LOS 
(DAYS) 
SOCIO-DEMOGRAPHIC FACTORS    
Age (years) 0.00 (-0.00 – 0.01) 0.10 0.04 
Gender (female) 0.01 (-0.05 – 0.08) 0.69 0.15 
Elective admission -0.06 (-0.15 – 0.02) 0.15 -0.70 
Living alone 0.03 (-0.05 – 0.10) 0.49 0.30 
MEDICAL HISTORY    
No of drugs before admission 
(/3)*** 
0.07 (0.04 – 0.10) < 0.001 0.74 
 ≥ 2 hospital admissions during the 
last year*** 
0.09 (0.01 – 0.18) 0.04 1.01 
MEDICAL DIAGNOSES    
Comorbidity score*** 0.03 (0.01 – 0.05) < 0.001 0.34 
Ischemic heart disease 0.04 (-0.03 – 0.11) 0.28 0.42 
Heart failure 0.07 (-0.01 – 0.14) 0.09 0.75 
Cerebrovascular accident 0.06 (-0.14 – 0.02) 0.16 0.65 
Parkinson's disease -0.02 (-0.15 – 0.11) 0.77 -0.22 
Dementia (Alzheimer or other) -0.01 (-0.10 – 0.08) 0.80 -0.12 
Diabetes mellitus 0.05 (-0.02 – 0.12) 0.17 0.55 
Metastasized cancer*** 0.31 (0.15 – 0.47) < 0.001 3.48 
Renal failure or dialysis*** 0.18 (0.11 – 0.26) < 0.001 2.02 
Infection*** 0.18 (0.07 – 0.29) 0.002 2.00 
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Table 12. Predictors of length of hospital stay. Data reported are from different linear 
regression models predicting length of hospital stay (natural log-transformed). Each model 
included centre, age, gender, and type of admission as covariates. [Continued] 
 VARIABLE  Β (CI95) P CHANGE IN 
AVERAGE LOS 
(DAYS) 
CLINICAL CONDITIONS    
Falls at home during the last year*** 0.12 (0.05 – 0.20) 0.002 1.35 
Pain*** 0.11 (0.04 – 0.18) 0.002 1.21 
Pressure ulcers 0.03 (-0.12 – 0.18) 0.68 0.35 
Urinary incontinence or catheter 0.07 (-0.00 – 0.14) 0.06 0.77 
Faecal incontinence 0.10 (0.00 – 0.20) 0.05 1.12 
Malnutrition (BMI < 18.5 kg/m²) -0.11 (-0.28 – 0.06) 0.20 -1.25 
COGNITIVE AND AFFECTIVE STATUS    
30-item MMSE category  -0.04 (-0.10 – 0.01) 0.09 -0.49 
15-item Geriatric Depression Scale 0.01 (-0.01 – 0.02) 0.43 0.06 
FUNCTIONAL STATUS AND PHYSICAL PERFORMANCE   
ADL score*** 0.02 (0.00 – 0.04) 0.02 0.23 
ADL total dependency 0.09 (0.00 – 0.18) 0.05 1.01 
Gait speed category*** -0.10 (-0.15 – -0.04) < 0.001 -1.06 
Gait speed inability*** 0.12 (0.05 – 0.20) 0.001 1.34 
Grip strength category -0.02 (-0.09 – 0.04) 0.53 -0.23 
Grip strength inability -0.04 (-0.12 – 0.04) 0.32 -0.45 
The approximate interpretation of β is: Length of hospital stay changes by 100 * β percent for a one unit increase in 
the independent variable.  
Change in average length of hospital stay was calculated as follows: β * (mean length of hospital stay) = β * 11.17 
days. 
β = Coefficient LN (length of hospital stay), CI95 = 95% confidence interval, LoS = length of hospital stay, BMI = 
Body mass index, MMSE = Mini-Mental State Examination, ADL = Activities of daily living. 
*** Statistical significance was indicated by a P value < 0.05. 
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Table 13. Predictors of in-hospital mortality. Data reported are from different logistic 
regression models predicting in-hospital mortality. Each model included centre and age as 
covariates. 
VARIABLE OR (CI95) P 
SOCIO-DEMOGRAPHIC FACTORS   
Age (years)*** 1.10 (1.05 – 1.17) < 0.001 
Gender (female) 0.72 (0.37 – 1.39) 0.33 
Elective admission 0.54 (0.21 – 1.38) 0.20 
Living alone 1.09 (0.50 – 2.35) 0.83 
MEDICAL HISTORY   
No of drugs before admission (/3) 1.09 (0.80 – 1.48) 0.60 
 ≥ 2 hospital admissions during the last year 0.70 (0.31 – 1.56) 0.38 
MEDICAL DIAGNOSES   
Comorbidity score 1.03 (0.89 – 1.19) 0.71 
Ischemic heart disease 1.14 (0.58 – 2.23) 0.70 
Heart failure 1.34 (0.66 – 2.75) 0.42 
Cerebrovascular accident 0.83 (0.40 – 1.72) 0.62 
Parkinson's disease 0.59 (0.14 – 2.58) 0.48 
Dementia (Alzheimer or other) 1.17 (0.59 – 2.33) 0.65 
Diabetes mellitus 0.89 (0.42 – 1.90) 0.77 
Metastasized cancer 0.00 (0.00 – .) 1.00 
Renal failure or dialysis 1.79 (0.91 – 3.50) 0.09 
Infection*** 2.69 (1.21 – 5.99) 0.02 
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Table 13. Predictors of in-hospital mortality. Data reported are from different logistic 
regression models predicting in-hospital mortality. Each model included centre and age as 
covariates. [Continued] 
VARIABLE  OR (CI95) P 
CLINICAL CONDITIONS   
Falls at home during the last year*** 0.39 (0.16 – 0.97) 0.04 
Pain 1.17 (0.55 – 2.55) 0.69 
Pressure ulcers*** 4.93 (1.89 – 12.9) 0.001 
Urinary incontinence or catheter*** 4.12 (1.64 – 10.3) 0.003 
Faecal incontinence*** 2.92 (1.45 – 5.90) 0.003 
Malnutrition (BMI < 18.5 kg/m²) 2.26 (0.77 – 6.65) 0.14 
COGNITIVE AND AFFECTIVE STATUS   
30-item MMSE category*** 0.42 (0.24 – 0.75) 0.003 
15-item Geriatric Depression Scale 1.09 (0.83 – 1.44) 0.53 
FUNCTIONAL STATUS AND PHYSICAL PERFORMANCE   
ADL score*** 1.08 (1.02 – 1.14) 0.005 
ADL total dependency*** 5.60 (2.45 – 12.8) < 0.001 
Gait speed inability*** 14.8 (1.91 – 114) 0.010 
Grip strength inability*** 8.03 (3.17 – 20.3) < 0.001 
*** Statistical significance was indicated by a P value < 0.05. 
OR = Odds ratio, CI95 = 95% confidence interval, BMI = Body mass index, MMSE = Mini-Mental State 
Examination, ADL = Activities of daily living. 
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Table 14. Predictors of institutionalization. Data reported are from different logistic 
regression models predicting new institutionalization. Each model included centre and age 
as covariates. Subjects who died in-hospital were excluded from the analyses. 
VARIABLE OR (CI95) P 
SOCIO-DEMOGRAPHIC FACTORS   
Age (years)*** 1.10 (1.04 – 1.16) 0.001 
Gender (female) 1.25 (0.61 – 2.57) 0.54 
Elective admission 1.61 (0.60 – 4.32) 0.34 
Living alone 0.96 (0.43 – 2.14) 0.93 
MEDICAL HISTORY   
No of drugs before admission (/3) 1.03 (0.73 – 1.43) 0.88 
 ≥ 2 hospital admissions during the last year 1.69 (0.79 – 3.60) 0.18 
MEDICAL DIAGNOSES   
Comorbidity score 1.05 (0.91 – 1.22) 0.53 
Ischemic heart disease 0.72 (0.34 – 1.52) 0.39 
Heart failure 1.09 (0.50 – 2.37) 0.82 
Cerebrovascular accident*** 2.10 (1.03 – 4.29) 0.04 
Parkinson's disease 1.83 (0.59 – 5.74) 0.30 
Dementia (Alzheimer or other)*** 3.47 (1.64 – 7.74) 0.001 
Diabetes mellitus 1.08 (0.51 – 2.28) 0.85 
Metastasized cancer*** 3.10 (1.14 – 8.48) 0.03 
Renal failure or dialysis 1.13 (0.54 – 2.36) 0.75 
Infection 1.90 (0.84 – 4.29) 0.13 
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Table 14. Predictors of institutionalization. Data reported are from different logistic 
regression models predicting new institutionalization. Each model included centre and age 
as covariates. Subjects who died in-hospital were excluded from the analyses. [Continued] 
VARIABLE  OR (CI95) P 
CLINICAL CONDITIONS  0.33 
Falls at home during the last year 1.43 (0.70 – 2.93) 0.33 
Pain*** 2.47 (1.04 – 5.86) 0.04 
Pressure ulcers 2.74 (0.54 – 13.9) 0.22 
Urinary incontinence or catheter*** 2.47 (1.12 – 5.45) 0.03 
Faecal incontinence 2.28 (0.98 – 5.28) 0.06 
Malnutrition (BMI < 18.5 kg/m²)*** 4.51 (1.42 – 14.34) 0.01 
COGNITIVE AND AFFECTIVE STATUS   
30-item MMSE category*** 0.33 (0.18 – 0.59) < 0.001 
15-item Geriatric Depression Scale 1.10 (0.95 – 1.28) 0.21 
FUNCTIONAL STATUS AND PHYSICAL PERFORMANCE   
ADL score*** 1.60 (1.27 – 2.01) < 0.001 
ADL total dependency*** 5.65 (2.44 – 13.1) < 0.001 
Gait speed inability*** 5.34 (1.69 – 16.9) 0.004 
Grip strength inability*** 3.22 (1.35 – 7.70) 0.01 
*** Statistical significance was indicated by a P value < 0.05. 
OR = Odds ratio, CI95 = 95% confidence interval, BMI = Body mass index, MMSE = Mini-Mental State 
Examination, ADL = Activities of daily living. 
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ABSTRACT 
Objectives 
Changes in physical performance during hospital stay have rarely been evaluated. In this study, we 
examined functional changes during hospital stay by assessing both physical performance and 
ADL. Additionally, we investigated characteristics of older patients associated with meaningful in-
hospital improvement in physical performance. 
Methods 
 The CRIME project recruited 1123 patients aged ≥ 65 years, consecutively admitted to geriatric or 
internal medicine acute care wards of seven Italian hospitals. We analyzed data from 639 
participating participants with a MMSE score ≥ 18/30. Physical performance was assessed by Gait 
speed and Grip strength, and functional status by ADL at hospital admission and at discharge. 
Meaningful improvement was defined as a measured change of at least 1 SD. Multivariable logistic 
regression models predicting meaningful improvement, included age, gender, type of admission 
(through emergency room or elective), and physical performance at admission. 
Results 
Mean age of the study participants was 79 years (range 65 – 98), 52% were female. Overall, mean 
Gait speed and Grip strength performance improved during hospital stay (Gait speed 
improvement: 0.04 ± 0.20 m/s, P < 0.001; Grip strength improvement: 0.43 ± 5.66 kg, P = 0.001), 
no significant change was observed in ADL. Patients with poor physical performance at admission 
had higher odds for in-hospital improvement.  
Conclusion 
Overall, physical performance measurements show an improvement during hospital stay. The 
margin for meaningful functional improvement is larger in patients with poor physical function at 
admission. Nevertheless, most of these patients continue to have poor performance at discharge. 
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INTRODUCTION 
Functional changes in older persons with an acute illness can be expected during hospital stay 
(294,295). However, changes in physical performance during hospital stay have scarcely been 
evaluated. In the existing literature, in-hospital functional changes have been almost exclusively 
reported by changes in functional status (296–299), e.g. using the Barthel index (300) and Katz ADL 
index (191). Functional status measurements are self-reported and their accuracy can be affected by 
the complex circumstances of hospital stay. Sager et al. (301) found discrepancies between patient’ 
assessments and performance-based measurements of the ability to do ADL in a substantial 
proportion of hospitalized older persons. Bathing and dressing were the two activities in which 
agreement rates were the lowest. For example, patients who need help dressing because they are 
tethered to an intravenous pole, may have a clouded judgment about the ability to perform this 
ADL independently (298). 
Alternatively, physical performance measurements can be used to assess physical function in older 
adults. Physical performance measurements can even identify more limitations in physical function 
than self-reported subjective measurements (61). Furthermore, physical performance measurements 
are more sensitive to change and might be more useful for longitudinal evaluations (267). Finally, 
physical performance measurements are more able to predict outcomes than self-reported 
measurements (189). Results of functional change during hospital stay might be different for physical 
performance measurements compared with ADL index (298,301). 
Past studies have mainly focused on functional decline of acutely ill older patients during hospital 
stay (302–304). Functional decline is strongly associated with nursing home admission (305) and 3-
month mortality (299). Nevertheless, functional improvement after hospital admission has also been 
reported (297–299).  
This study had two objectives. The first objective was to examine functional changes during 
hospital stay in older patients admitted to geriatric or internal medicine acute care wards by 
assessing both physical performance and functional status. The second objective was to investigate 
which characteristics of older patients are associated with meaningful in-hospital improvement in 
physical performance. 
 
 
 
 
124 
METHODS 
Ethics statement 
The study complies with the ethical rules for human experimentation that are stated in the 
Declaration of Helsinki. All participating hospitals (Gemelli Hospital, Università Cattolica del Sacro 
Cuore in Rome / University of Perugia / University of Ferrara / INRCA in Ancona / INRCA in 
Cosenza / INRCA in Fermo / INRCA in Rome) had obtained approval for the study from their 
ethical committee. Written informed consent was obtained from all participants.  
Data source & study population  
Data from the CRIME project were used. The CRIME project was initiated to assess prescribing 
patterns in older adults hospitalized across Italy and to produce recommendations for appropriate 
pharmacological prescribing in older complex patients. Details about the methodology of the 
CRIME project are reported elsewhere (170–172).  
CRIME participants were patients aged 65 years or more, consecutively admitted to geriatric or 
internal medicine acute care wards of the seven above mentioned hospitals. Between June 2010 and 
May 2011, a total number of 1123 hospitalized older in-patients were enrolled in the CRIME 
project.  
Data collection 
A questionnaire was designed to assess the participants within 24 hours of admission and at daily 
intervals until discharge. Study researchers had received a two-day training course in which they 
were well-trained about how to correctly collect and report questionnaire data. The study 
researchers used a variety of information sources, including direct observation, clinical records, and 
interviews with the patients, family, friends or formal service providers. The questionnaire included 
demographics, type of admission (through emergency room or elective if planned previously), 
anthropometrics, socio-economics, cognitive status (30-item MMSE (269)), psychological status (15-
item GDS), drug use, medical diagnoses, and geriatric conditions (pain, falls, delirium, and pressure 
sores). Data on drug use, medical diagnoses, and geriatric conditions were updated daily. 
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Physical function measurements  
Physical function was assessed within the first 24 hours after hospital admission and the day of 
discharge by the study researchers. Gait speed was assessed by having the participant walk at 
his/her usual pace over a four-meter distance. This test has shown a high test-retest reliability (189). 
For the present study the fastest walk of two measurements was used in the analyses. Not all 
patients were ambulatory at admission. For this reason Gait speed assessment was not performed 
in 228 patients.  
Measurement of Grip strength was performed using a North Coast Medical hand dynamometer. 
Patients were seated with the wrist in a neutral position and the elbow flexed 90°. In case a subject 
was unable to sit, Grip strength was assessed lying at 30° in bed with the elbows supported. The 
highest value of two consecutive measurements obtained with the dominant hand was used in the 
analyses. A distinction was made between subjects unable to perform Grip strength and subjects 
who did not execute the test despite being capable. 
Dependency in ADL (transferring, bathing, dressing, eating, bowel and bladder continence, and 
personal hygiene) was reported to assess functional status just before admission. Scores ranged 
from no to six dependencies. 
Analytical approach 
In order to exclude patients not able to complete the physical performance measurements because 
of cognitive problems or inability to understand instructions, analyses were limited to patients with 
an MMSE score ≥ 18/30. This is in line with other projects focusing on physical performance in 
older persons (254). Further, patients who died during hospital stay (N = 25) were excluded from the 
analyses. This left an analytical sample of 639 subjects. Various sub-analyses have been performed, 
for example, by excluding subjects unable to perform Gait speed or Grip strength at admission or 
by excluding subjects with high performance at admission (Gait speed ≥ 0.80 m/s or Grip strength 
≥ 20.0 kg / 30.0 kg for women / men). 
Functional change was computed in the way that positive values indicate a functional 
improvement. In order to capture functional change in subjects unable to perform a test at 
admission or discharge, the value corresponding to the first percentile of admission performance of 
participants was assigned to these subjects and to those with a performance below the first 
percentile (Gait speed 0.23 m/s, Grip strength 5.0 kg). Subjects who did not perform Grip strength 
despite being capable, were treated as missing variables (N = 4). Meaningful improvement in 
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physical performance was defined as a measured change of at least 1 SD, this equals a 0.20 m/s 
increase in Gait speed and 5.0 or 7.0 kg increase in Grip strength for women or men, respectively. 
For functional status, change in the ability to do at least 1 ADL was considered meaningful. 
To visualise the functional change according to admission performance, subjects were categorised 
into three groups according to physical performance at admission. Gait speed categories were: 
unable to perform the test, less than 0.8 m/s, and at least 0.8 m/s (271). Grip strength categories 
were: unable to perform the test, less than 20.0 kg in women or 30.0 kg in men, and at least 20.0 kg 
in women or 30.0 kg in men (271). 
Statistical methodology  
Continuous variables were expressed as mean ± SD or median (first to third quartile), where 
appropriate. Countable variables were presented as absolute number and percentage of the study 
population. In-hospital change in physical function was examined with paired samples T tests or 
related samples Wilcoxon signed rank tests, where appropriate. Multivariable logistic regression was 
used to predict meaningful improvement in Gait speed and Grip strength. Regression models 
included age, gender, type of admission, and physical performance at admission (continuous 
variable). Additional analyses also included LoS (days), MMSE score, comorbidity (sum), or 
number of drugs during stay. Hosmer-Lemeshow goodness-of-fit tests indicated no signs of a bad 
model fit. All analyses were performed using SPSS software, version 19.0 (SPSS Inc., Chicago, IL). 
Differences according to type of admission in ability to perform physical performance 
measurements and in physical performance of participants were examined with Chi-square tests 
and Independent samples T tests, respectively. The relationship between comorbidity and physical 
performance at admission was assessed using linear regression analyses. Statistical significance was 
indicated by a P value < 0.05; all P values were two-tailed. 
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RESULTS 
Patient Characteristics  
Age ranged between 65 and 98 years. Men and women were nearly equally represented (48% men). 
Slightly more than half of the patients were electively admitted (55%). Detailed characteristics of 
our sample are reported in Table 15. Most prevalent diseases were hypertension (N = 523; 82%), 
ischemic heart disease (N = 206; 32%), heart failure (N = 156; 25%), diabetes mellitus (N = 195; 
31%), osteoarthritis (N = 239; 37%), COPD (N = 237; 37%), and renal failure (N = 147; 23%). 
Table 15. Characteristics of the study population (N=639). 
 VALUE 
Age (y), mean ± SD 79 ± 7 
Gender (female), N (%) 331 (52) 
Elective admission, N (%) 349 (55) 
Gait speed category at admission, N (%)  
Unable to perform the test 228 (36) 
< 0.8 m/s 291 (46) 
≥ 0.8 m/s 120 (19) 
Grip strength category at admission, N (%)  
Unable to perform the test 78 (12) 
< 20 kg ♀ / < 30 kg ♂ 368 (58) 
≥ 20 kg ♀ / ≥ 30 kg ♂ 189 (30) 
ADL dependencies, median (IQR) 1 (0 – 2) 
Length of hospital stay (days), median (IQR) 9 (6 – 14) 
MMSE, median (IQR) 25 (22 – 28) 
Geriatric Depression Scale (15-item), median (IQR)* 4 (2 – 7) 
Comorbidity sum, median (IQR) 4 (3 – 6) 
N° drugs during stay, median (IQR) 9 (7 – 13) 
*Geriatric Depression Scale data were missing for 48 subjects. SD = Standard deviation, ADL = Activities of daily 
living, IQR = Interquartile range, MMSE = Mini-Mental State Examination.  
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Within patients admitted from the emergency room, 49% (N = 141) and 22% (N = 53) was unable 
to perform Gait speed or Grip strength, respectively. These proportions are substantially higher (P 
< 0.001) than those in patients admitted electively (N = 87; 33% and N = 25; 8%). In patients able 
to perform, mean Grip strength and Gait speed performance did not significantly differ according 
to type of admission. 
Changes during Hospital Stay in Physical Performance and Functional Status  
Overall, mean Gait speed and Grip strength performance improved significantly during hospital 
stay (Table 16), but most patients had no meaningful change in Gait speed (N = 552; 86%) or 
Grip strength (N = 558; 88%). Thirty-six percent of subjects (N = 228) were unable to perform 
Gait speed at admission, of these 23% (N = 52) regained their ability with a mean Gait speed of 
0.69 ± 0.28 m/s at discharge. Twelve percent was unable to perform Grip strength at admission, of 
these 41% (N = 78) had regained function at discharge (mean Grip strength = 17.48 ± 10.61 kg). 
The mean and SD of Grip strength change was larger in men than in women (1.02 ± 6.65 kg vs. -
0.12 ± 4.50 kg). Table 16 provides more details concerning the changes in physical performance 
during hospital stay. Sub-analyses excluding subjects unable to perform Gait speed or Grip strength 
at admission led to similar mean changes. 
Table 16. In-hospital change in physical performance. 
  ADMISSION 
SCORES 
IN-HOSPITAL CHANGE 
 
N MEAN SD MEAN SD 
% CHANGE VS. 
ADMISSION SDa 
P 
MEANINGFUL 
IMPROVEMENT 
% (N)b 
Gait speed (m/s) 639 0.52 0.3 0.04 0.20 13.79 < 0.001 10 (62) 
Grip strength (kg) 635 19.16 10.4 0.43 5.66 4.15 0.001 7 (45) 
a Percent change vs. SD of the mean was calculated with the following formula: 100 * mean change / SD of mean at 
admission. 
b Meaningful improvement was defined as ≥ 0.20 m/s Gait speed and ≥ 5.0 kg ♀ / ≥ 7.0 kg ♂ Grip strength 
SD = Standard deviation. 
Globally, functional status, expressed by ADL score, did not significantly change during hospital 
stay, only 38 subjects improved in ADL (P = 0.058). The great majority of the subjects (N = 581; 
91%) obtained the same score of admission at discharge (median admission score = 1 (0 – 2) 
dependencies).   
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Characteristics Associated with Meaningful Changes during Hospital Stay 
As illustrated in Figure 18, in-hospital change in physical function varied according to admission 
performance. Subjects who were unable to perform Gait speed at admission or with slow Gait 
speed (< 0.8 m/s) improved in mean Gait speed performance during stay, but remained to have 
poor function at discharge. Similarly, subjects who were unable to perform Grip strength or with 
weak Grip strength at admission improved in mean Grip strength performance during stay, but still 
performed poorly at discharge. Subjects with high Grip strength performance at admission had a 
significant decline during hospital stay. 
Figure 18. Change in physical performance measurements according to admission 
performance. Error bars represent 95% confidence intervals.  
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Table 17 shows the results from multivariable logistic regression analyses predicting meaningful 
improvement in Gait speed or Grip strength during hospital stay. These models illustrate an 
association of admission performance with functional improvement during hospital stay. The odds 
for in-hospital improvement decreased when patients were electively admitted and when they had 
higher performance at admission. Additionally, the odds for Gait speed improvement during stay 
decreased with older age. Sub-analyses excluding subjects with high performance at admission led 
to similar results. Additional analyses including one extra covariate found LoS (days), MMSE score, 
and number of drugs during stay not to be predictive of functional improvement. Higher 
comorbidity was associated with higher odds for meaningful improvement in Grip strength (Odds 
ratio (OR) = 1.02, CI95 = 1.04 – 1.33, P = 0.009). Comorbidity sum was also significantly 
associated with Grip strength performance at admission (β = -0.51, CI95 = -0.84 – -0.19, P = 
0.002). 
Table 17. Associations with meaningful improvement in physical performance during 
hospital stay. 
 GAIT SPEED IMPROVEMENT GRIP STRENGTH IMPROVEMENT 
 OR CI95 P OR CI95 P 
Age (years) 0.95 0.92 – 0.99 0.022 0.98 0.93 – 1.02 0.320 
Gender (male) 1.48 0.87 – 2.55 0.148 1.70 0.89 – 3.26 0.110 
Elective admission 0.42 0.24 – 0.74 0.003 0.46 0.23 – 0.93 0.030 
Admission performance (m/s or kg) 0.19 0.06 – 0.57 0.003 0.86 0.82 – 0.91 <0.001 
Data reported are from multivariable logistic regression models predicting improvement of ≥ 0.20 m/s in Gait speed 
and improvement of ≥ 5.0 kg ♀ / ≥ 7.0 kg ♂ in Grip strength. 
OR = Odds ratio, CI95 = 95% confidence interval. 
  
FUNCTIONAL CHANGES DURING HOSPITAL STAY 
 
 
3.2 
131 
DISCUSSION 
The first objective of this study was to examine functional changes during hospital stay in older 
patients admitted to acute care. Because functional change has scarcely been evaluated by physical 
performance measurements, we have assessed both Gait speed and Grip strength performance at 
admission and at discharge.  
Physical performance measurements have mostly been used in community-dwelling older persons, 
where a Gait speed of 0.8 m/s has been accepted to define low Gait speed (271). Ostir et al. (196) 
assessed Gait speed in acutely ill older patients admitted to acute care. They found 64% of patients 
could complete the Gait speed test, with a mean performance of 0.5 ± 0.3 m/s (196). Their results 
are in perfect agreement with ours. Common gender-specific thresholds for Grip strength to 
identify mobility limitations are 20 kg / 30 kg (271) and 21 kg / 37 kg (272) for women / men. 
Due to older in-patients’ acute illness, high catabolism, bed rest, sleep deprivation, and 
polypharmacy, hospital stay is a risk factor for functional decline (294,295). Nevertheless, we found an 
overall mean improvement in physical performance during hospital stay, while median functional 
status (ADL score) did not change significantly.  
The detected improvement in physical performance might be part of a functional recovery 
trajectory, where functional improvement is preceded by functional decline before hospital 
admission as a consequence of the acute medical illness (297,298). Stabilization of the acute medical 
condition may outweigh the negative consequences of hospital stay on physical function (306). 
The overall improvement in physical performance, observed in our study, is in line with the results 
of Volpato et al. (267) who reported in-hospital change in performance on the SPPB (206) of 92 
patients; 63% had better performance at hospital discharge. Similarly, Bodilsen et al. (306) reported an 
improvement during hospital stay in mean physical performance of 33 patients, quantified by the 
Timed Up and Go test. Furthermore, Purser et al. (279) reported a mean improvement in Gait speed 
during stay of 0.03 m/s in frail older veterans. 
Unlike two others studies (306,307), we could validate a significant improvement in mean Grip 
strength performance during hospital stay. These other studies either excluded subjects unable to 
perform physical performance measurements (306) or assessed changes after only one week of 
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hospital stay (307). In our study, subjects unable to perform had the greatest functional change and 
65% of subjects stayed in hospital longer than seven days. 
The second objective of this study was to investigate which patient characteristics are associated with 
meaningful in-hospital improvement. In our study, improvement in physical performance was 
related to admission performance, with poor performers experiencing meaningful improvements 
more frequently than good performers. These poor performers might have had a functional 
recovery trajectory with greater functional decline before admission. Since, in the study of Palleschi 
et al. (297), greater functional decline before hospital stay was a significant predictor of in-hospital 
functional improvement. In addition, a floor effect may clarify the observed improvement in poor 
performers, given that subjects unable to perform at admission could not further decline. When 
interpreting these results, one must consider that regression toward the mean might be responsible 
for improvement in poor performers and decline in good performers. 
Older subjects had lower odds for Gait speed improvement. Similarly, in the study of Covinsky et 
al. (298), older patients were more likely to fail to recover in ADL function during hospital stay.  
Subjects who were electively admitted had lower odds to improve performance. Patients admitted 
from the emergency room often present with severe acute conditions, which may have led to a 
steep decline in physical performance before hospital admission. During hospital stay they can 
recover from the acute conditions and consequently improve their level of physical performance 
during stay. Patients admitted electively are less likely to present severe acute conditions. Therefore, 
they are less likely to improve during stay. Similarly, subjects with higher comorbidity might have a 
larger margin to recover from an acute condition than those with few diseases. 
Performance-based versus patient-reported physical function 
As reported in other studies, performance-based and patient-reported measurements of physical 
function appear to assess distinct and only partially overlapping domains of physical function 
(308,309). Diehr et al. (310) found Gait speed to be the most sensitive indicator of age-related decline in 
older adults. In our study, changes in Gait speed and Grip strength could be detected over the 
short period of time in hospital. On the contrary, the 6-item ADL scale did not seem suitable to 
assess in-hospital changes. Our results suggest that physical performance measurements might be 
more sensitive to demonstrate functional changes during hospital stay, than self-reported functional 
status. Use of physical performance measurements in the acute care setting should be encouraged, 
as physical performance measurements may provide important clinical information in acutely ill 
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older subjects. Multifaceted aspects of aging are integrated in physical functions measurements, 
including disease processes, nutritional status, and fitness (189). In addition, low physical 
performance may reflect a state of frailty. 
Limitations & Strengths 
Our results have implications for the feasibility of physical performance measurements in the acute 
care setting. We assigned a continuous value equivalent to the worst percentile of performance, to 
those patients who were unable to perform Gait speed and Grip strength. Just like Purser et al. (279), 
we found this to be a feasible way of tracking continuous improvement over time. Although this 
recoding may have introduced bias, we found that excluding those unable to perform led to similar 
mean changes. Unfortunately, the reason why subjects were unable to perform was not recorded. 
However, the exclusion of subjects with an MMSE below 18 removed patients not able to 
complete the test because of cognitive problems or inability to understand instructions. Therefore 
physical problems were the main reason why subjects were unable to perform physical 
performance measurements.  
An important variable not recorded is main reason of admission. The severity of the disease that 
led to hospital admission might very well be a confounding factor. However, we believe this factor 
is partially captured in the type of admission. Patients admitted from the emergency room often 
present with severe acute conditions, while patients admitted electively are less likely to present 
severe acute conditions. The high proportion of subjects unable to perform within patients 
admitted from the emergency room endorses this theory. Unfortunately, we do not have the data 
to fully explore these findings. 
The percentage of subjects with meaningful change was relatively low. Our definitions of 
meaningful change (0.20 m/s Gait speed and 5.0 or 7.0 kg Grip strength women / men) seem 
roughly in line with those reported elsewhere (311–313). Substantial meaningful change in four-meter 
Gait speed observed in community-dwelling older adults was estimated at 0.10 m/s (311), while 
substantial meaningful improvement in Gait speed observed during recovery from hip fracture was 
estimated between 0.17 to 0.26 m/s (312). Estimates of meaningful change in Gait speed may differ 
based on the direction of change or between patient populations (312). Regarding Grip strength, a 
change of more than 6.0 kg was suggested as necessary to detect a genuine change in Grip strength 
95% of the time (313). It is conceivable that patients with relatively high performance on admission 
could not be able to demonstrate such meaningful improvement during hospital stay due to ceiling 
effects in physical performance measurements. Sub-analyses have confirmed that predictive factors 
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for functional change did not alter when subjects with high performance at admission were 
excluded.  
Our study was restricted to functional changes from admission until discharge. Given the 
possibility that patients are admitted in the night, a 24-hour window was allowed to perform the 
first assessment. Medical therapy could have taken place between admission and assessment that 
could affect patients’ physical performance. After hospital discharge, functional changes might still 
occur as part of the functional recovery trajectory. Volpato et al. (314) reported an improvement in 
50% of patients in performance on the SPPB (206) during the first month after discharge.  
A strength of this study is the availability of comprehensive data. We present objective data in the 
clinical setting where physical performance measurements have received little attention (314). Our 
data demonstrate the feasibility of physical performance measurements in acute care setting. 
Furthermore, we provide a better understanding of the dynamic nature of physical performance in 
older people with an acute illness during hospital stay. The multicentre design of the study 
improves generalisability of our results to acute care settings across Italy and Europe.  
Further research 
Both in community-dwelling and hospitalized older subjects, physical function measurements have 
shown their predictive value in terms of various adverse health-related outcomes, such as mortality, 
institutionalization, and healthcare costs (222,293,315). Our results suggest that the interpretation of 
physical performance at a single time point is not straightforward. More research is needed to 
determine how functional changes can add value to the prediction of hospital outcomes. Functional 
trajectories might even be more prognostic than single and static measurements of physical 
function (299).  
Conclusions 
This study was one of the few that observed in-hospital change in physical performance of older 
subjects. Overall, physical performance measurements show an improvement during hospital stay. 
The margin for meaningful functional improvement is larger in patients with poor physical 
performance at admission. Nevertheless most of these patients continue to have poor performance 
at discharge. 
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4.1 MAIN FINDINGS & CONTRIBUTIONS IN COMMUNITY-DWELLING OLDER MEN 
4.1.1 SOF FRAILTY & MORTALITY 
In Chapter 2.1 we evaluated the simple SOF frailty index for prediction of subsequent 15-year all-
cause mortality in a well-described sample of apparently healthy community-dwelling older men in 
Belgium. As this frailty index has a non-distribution based character, its clinical relevance might 
have been limited to the population and setting in which it was developed, being community-
dwelling older women in the US. This theory was supported by the non-significant association with 
mortality found in Asian and African American community-dwellers (130,131). Furthermore the 
initially significant association with mortality found in Belgian in-patients admitted to an acute 
geriatric ward, turned non-significant when the model was adjusted for multiple risk factors (142). 
In the Merelbeke study population, pre-frailty and frailty as defined by the SOF index was present 
in 30 and 7% of men, respectively. Of the individual SOF components, ≥ 5% weight loss (age-
adjusted HR = 1.99, CI95 = 1.27 – 3.11) and poor energy (age-adjusted HR = 1.78, CI95 = 1.26 – 
2.51) were significantly associated with all-cause mortality, but not inability to rise from a chair five 
times without using the arms (age-adjusted HR = 1.23, CI95 = 0.67 – 2.27). Other studies 
oppositely have found higher mortality odds or hazards in those unable to do Chair rising (120,316), 
albeit they were compared to older persons in the fastest quarter of performance instead of to all 
older persons able to perform the test. In comparison with robust men of the same age, pre-frail 
older men had on average 1.72 times higher mortality hazard (age-adjusted HR = 1.72, CI95 = 1.23 
– 2.42) and frail older men had on average 2.64 times higher mortality hazard (age-adjusted HR = 
2.64, CI95 = 1.44 – 4.86). 
Our population-based study was the first in community-dwelling European men, as can be 
deducted from Table 18, which summarizes all studies to date examining the SOF frailty index as 
predictor of all-cause mortality. Furthermore, the Merelbeke study has had the longest mortality 
follow-up and hence the highest mortality rate by far. Prevalence of pre-frailty and frailty was in 
line with rates reported in other studies in community-dwelling older adults. 
A consideration regarding the concept of this study is that no comparisons of predictive accuracy 
were made with other frailty indices. Due to the retrospective nature of our research questions, the 
SOF frailty index was the only validated frailty instrument that could be applied retrospectively to 
the Merelbeke database without any modifications. 
  
Table 18. Studies examining the association of the SOF frailty index with mortality. 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] FOLLOW-
UP MAX, 
YEARS 
MORTA-
LITY RATE 
SOF 
INDEX 
PREVA-
LENCE 
ASSOCIA-
TION WITH 
MORTALITY 
Ensrud, 
2008 (30) 
US 6701 100% ≥ 69 
(77 ± 5) 
Community-dwellers listed in four 
areas (no African Americans) [SOF] 
9 41% Pre-
frail 
Frail 
36% 
17% 
S 
Ensrud, 
2009 (31) 
US 3132 0% ≥ 67 
(76 ± 6) 
Community-dwellers residing in six 
communities (community-based 
mailings and advertising) [MrOS 
Sleep] 
3 (mean) 7% Pre-
frail 
Frail 
43% 
13% 
S 
Bilotta, 
2012 (225) 
Italy 265 71% ≥ 65 
(82 ± 7) 
Outpatients consecutively referred to 
a geriatric clinic by the general 
practitioner 
1 9% Pre-
frail 
Frail 
35% 
37% 
S 
Pilotto, 
2012 (140) 
Italy 2033 57% ≥ 65 
(80 ± 8) 
In-patients admitted to 20 Italian 
geriatric units, due to acute disease or 
relapse of a chronic disease 
1 month 
1 
9% 
25% 
Pre-
frail 
Frail 
40% 
27% 
S 
 
Joosten, 
2014 (142) 
Belgium 189 57% ≥ 70 
(84) 
In-patients consecutively admitted to 
the acute geriatric ward of a tertiary 
care hospital 
6 months 13% Pre-
frail 
Frail 
52% 
33% 
S / NS 
Jung,  
2014 (131) 
Korea 663 51% ≥ 65 
(76 ± 9) 
Community-dwellers residing in one 
city (random sample + volunteers) 
[Korean Longitudinal Study in Health 
and Aging] 
6 14% Pre-
frail 
Frail 
50% 
9% 
NS 
Malmstrom, 
2014 (130) 
US 779 58% 49 – 65 
(57) 
Community-dwelling African 
Americans from two areas [African 
American Health] 
9 15% Pre-
frail 
Frail 
32% 
9% 
NS 
De Buyser, 
2016 (317) 
Belgium 198 0% 74 – 89 
(79 ± 4) 
Community-dwellers registered in one 
municipality (population register) 
15 86% Pre-
frail 
Frail 
30% 
7% 
S 
SD = Standard deviation, SOF = Study of Osteoporotic Fractures, S = Significant, NS = Not significant. 
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4.1.2 FNIH SARCOPENIA & MORTALITY 
In Chapter 2.1 we also evaluated the data-driven FNIH cutoff points for weakness and low muscle 
mass for prediction of subsequent 15-year all-cause mortality in a well-described sample of 
apparently healthy community-dwelling older men in Belgium. These non-distribution based 
criteria were only recently (2014) developed in community-dwelling older adults, predominantly 
living in the US. However, their association with mortality was inconsistent and further validation, 
including studies in European older adults, was still needed, since clinical relevance of the criteria 
might have been limited to the original population and setting. 
In the Merelbeke study population, the combination of weakness and low muscle mass, as defined 
by the FNIH criteria, was present in 3 to 8% of men. Of the individual criteria, only low ALMBMI 
(age-adjusted HR = 1.47, CI95 = 1.05 – 2.07) was associated with all-cause mortality. However, in 
the absence of weakness the association of low ALMBMI with mortality disappeared. This supports 
the clinical paradigm in which first low Grip strength is established, before ALMBMI is assessed. In 
comparison with men of the same age who have normal muscle mass and strength, men with both 
weakness and low lean mass had on average 2.5 times higher mortality hazard (age-adjusted HR = 
2.50, CI95 = 1.30 – 4.79). 
Our study was the first in community-dwelling European men, as can be deducted from Table 19, 
which summarizes all studies to date in men examining the FNIH criteria as predictors of all-cause 
mortality. Furthermore, the Merelbeke study has had the longest mortality follow-up and hence the 
highest mortality rate by far. Prevalence of combined weakness and low muscle mass was in line 
with rates reported by Woo et al. (116) and Hirani et al. (149). 
A consideration regarding the concept of this study is that no comparisons of predictive accuracy 
were made with other sarcopenia definitions. Due to the lack of data on Gait speed, most well-
recognized operational definitions could not be applied retrospectively to the Merelbeke database 
without modifications. 
 
 
 
Table 19. Studies examining the association of the FNIH criteria with mortality in men. 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] FOLLOW-UP 
MAX, YEARS 
MORTALITY 
RATE 
FNIH CRITERIA PREVALENCE ASSOCIATION WITH 
MORTALITY + AGE-
ADJUSTED HR (CI95) 
McLean,  
2014 (52) 
US 3006 ≥ 65 
(73 ± 6) 
Community-dwellers residing in six 
communities (community-based 
mailings and advertising) [Osteoporotic 
Fractures in Men study] 
10 22% GS + ALM 
GS + ALMBMI 
GSBMI+ ALM 
GSBMI+ ALMBMI 
1% 
1% 
 < 1% 
2% 
0.74 (0.24 – 2.32) 
1.27 (0.65 – 2.46) 
1.07 (0.34 – 3.33) 
1.8 (1.21 – 2.68) 
McLean,  
2014 (52) 
US 894 ≥ 76 
(78 ± 3) 
Community-dwellers residing in two 
towns (random sample of Medicare-
eligible older adults) [Health, Aging, and 
Body Composition Study] 
10 11% GS + ALM 
GS + ALMBMI 
GSBMI+ ALM 
GSBMI+ ALMBMI 
3% 
3% 
3% 
6% 
2.88 (1.33 – 6.22) 
1.51 (0.61 – 3.71) 
2.27 (0.99 – 5.22) 
0.93 (0.43 – 2.01) 
Woo,  
2015 (116) 
China 2000 ≥ 65  
(72) 
Community-dwellers recruited from 
notices in community centres for older 
adults and housing estates [MrOS 
(Hong Kong)] 
10 25% GS + ALMBMI 8% *1.78 (1.23 – 2.59) 
Hirani,  
2015 (149) 
Australia 1659 ≥ 70  
(77) 
Community-dwellers registered in one 
defined urban geographical region 
(Electoral Roll) [Concord Health and 
Ageing in Men Project] 
7 – 9 31% GS + ALM 5% 1.54 (1.17 – 2.03) 
De Buyser, 
2016 (317) 
Belgium 200 74 – 89 
(79 ± 4) 
Community-dwellers registered in one 
municipality (population register) 
15 86% GS + ALM 
GS + ALMBMI 
GSBMI+ ALM 
GSBMI+ ALMBMI 
7% 
6% 
3% 
7% 
1.09 (0.61 – 1.94) 
2.50 (1.30 – 4.79) 
1.72 (0.75 – 3.97) 
1.87 (1.07 – 3.26) 
SD = Standard deviation, FNIH = Foundation for the National Institutes of Health, HR = Hazard ratio, CI95= 95% confidence interval, GS = Grip strength, 
ALM = Appendicular lean mass, ALMBMI = Appendicular lean mass to Body mass index - ratio, BMI = Body mass index, S = Significant, NS = Not significant. 
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4.1.3 PHYSICAL FUNCTION & MORTALITY 
In Chapter 2.2, we evaluated and compared the RDRS-2 ADL, SF-36 Physical Function Index, 
Grip strength, Standing balance, Chair rising, and Timed Up and Go for prediction of subsequent 
15-year all-cause mortality in a well-described sample of apparently healthy community-dwelling 
older men in Belgium. There was already evidence of associations between physical function and 
all-cause mortality. However, with the exception of those for SF-36 Physical Function Index and 
Grip strength, most studies had relatively short follow-up. Whether similar associations would be 
found after participants were followed for longer than 10 years was unclear (120). 
In the Merelbeke study population at baseline, over 75% of men obtained the best minimum value 
on the first part of the RDRS-2, indicating no assistance was needed for ADL. Mean score on the 
SF-36 Physical Function Index was 73 ± 24, which is quite high given subjects’ older age. Mean 
Grip strength was 24.3 ± 7.9 kg, which is fairly low as it would indicate that weakness (< 26 kg 
according to FNIH (50)) was present in about half of men (given the Gaussian distribution). 
Although we must keep in mind that these results were obtained with a Smedley type dynamometer 
as opposed to a Jamar® dynamometer. The majority of men were able to stand in three positions of 
increasing difficulty, albeit the tandem stand could not always be held for 10.0 seconds with the 
eyes closed. Mean performance at baseline on the Chair rising and Timed Up and Go tests was 13.8 
± 4.7 and 12.2 ± 4.7 seconds, respectively.  
All six physical function measurements were significantly associated with subsequent 15-year 
mortality. With every improvement of 1 SD, mortality hazard decreased with 37% for ADL, 29% 
for SF-36 Physical Function Index, 20% for Grip strength, 13% for Standing balance, 46% for 
Chair rising, and 54% for Timed Up and Go (age-adjusted HRs). Models including the Timed Up 
and Go test had the best fit and the highest decrease of mortality hazard with increasing 
standardized physical function. Men who took over 12.5 seconds to complete the Timed Up and 
Go test had over two times higher mortality hazard compared with similar aged men who 
completed the test in under 10.0 seconds (age-adjusted HR = 2.09, CI95 = 1.53 – 2.85, P < 0.001). 
 
 
 
Table 20. Studies examining the association of Rapid Disability Rating Scale-2 score (on activities of daily living) with 
mortality. 
FIRST AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE (MEAN ± 
SD), YEARS 
RECRUITMENT FOLLOW-
UP MAX, 
YEARS 
MORTALI
TY RATE 
ASSOCIATI
ON WITH 
MORTALITY 
Linn,  
1982 (190) 
US 845 0%  
(68) 
Patients transferred from a general medical 
hospital to community nursing homes 
0.5 33% S 
Valizadeh,  
2012 (318) 
Iran 102  ≥ 50 In-patients consecutively admitted with low 
trauma hip fracture 
1 16% S 
De Buyser, 
2013 (222) 
Belgium 352 0% 71 – 86 
(76 ± 4) 
Community-dwellers registered in one 
municipality (population register) 
15 78% S 
Vilalte-Franch,  
2013 (319) 
Spain 491 71%  
(75 ± 7) 
Outpatients with probable Alzheimer’s disease 
referred from public primary care to a memory 
unit at a hospital 
2.5 12% S 
SD = Standard deviation, S = Significant. 
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When examining the literature, we found to be the only population-based study in community-
dwelling older adults to have evaluated the first part of the RDRS-2 for prediction of mortality 
(Table 20). Both in research and in clinical practice, the 6-item Katz ADL index is most commonly 
used to assess functional status by observing difficulties in bathing, dressing, toilet use, transferring, 
continence, and feeding. The first part of the RDRS-2 misses the item on continence, but contains 
three additional activities, namely mobility, grooming, and practical tasks (such as managing money 
and telephoning, which are considered to be more IADL). We believe an extended scale to asses 
functional status with rating of perceived level of difficulty, might be more appropriate in healthy 
community-dwelling older adults, who present high ceiling effects on basic ADL questionnaires 
with limited response scale. In congruence, a study in community-dwelling older adults found that 
extending the Katz index with items on IADL increases predictive validity towards hospitalization, 
institutionalization, and death within one year (320). 
The significant association of the SF-36 Physical Function Index with long-term mortality in our 
study population contributes to the limited literature available in community-dwelling older 
subjects not selected on the basis of a specific disease. Like our study, studies in population-based 
samples of community-dwelling older persons found a significant association with 3-year mortality 
(321,322).  
Grip strength has been examined many times as predictor of mortality and it can be said that Grip 
strength predicts future all-cause mortality across a range of populations (323). In community-
dwelling populations, a meta-analysis performed by Cooper et al. (120) found an unadjusted summary 
HR per 1 kg increase of 0.97 (CI95 = 0.97 – 0.98) (14 studies), which is in line with our age-adjusted 
HR of 0.97 (CI95 = 0.96 – 0.99). The large PURE study with median follow-up of four years found 
a 37% increase in all-cause mortality hazard per SD reduction in Grip strength (251), which is higher 
than our 20% increase. Our weaker association might be due to our longer follow-up (120). 
Other studies on Standing balance, although not always measured in a comparable way, found 
some evidence that poorer performance was associated (albeit not always significantly) with higher 
mortality rates in community-dwelling older adults (120).  
Studies examining the association of Chair rising time with all-cause mortality in community-
dwelling subjects aged 70 and over (5 studies, N = 28 036) found a significant difference in 
mortality hazard between the lowest and highest quarter of performance (summary HR = 1.96, CI95 
= 1.56 – 2.46) (120). 
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Other studies in community-dwelling subjects also found a significant association between Timed 
Up and Go performance and mortality. Table 21 summarizes all studies to date examining Timed 
Up and Go performance as predictor of all-cause mortality. Our study was first to be conducted in 
Europe and to have long follow-up (and high mortality rate). After publication of our results, a 
Scandinavian study with comparable follow-up time (14 years) and mortality rate (71%) reported a 
very similar unadjusted HR of 1.10 per second increase (CI95 = 1.06 – 1.14) in community-dwelling 
older women (324) (our age-adjusted HR for Timed Up and Go was 1.10, CI95 = 1.07 – 1.12). 
While many studies have examined the association of physical function with mortality, few have 
directly compared measurements. Cesari et al. (238) were first to compare several physical 
performance measurements for prediction of subsequent 2-year mortality in community-dwellers 
aged 80 years and over. Similarly, they found all tested physical function variables were able to 
predict mortality. The Chair rising test was a stronger predictor over Grip strength and Standing 
balance, Timed Up and Go was not assessed. Similarly, Arnau et al. (325) found the Chair rising test 
in itself to be just as useful as the complete SPPB test to predict mortality in persons aged 70 years 
and over without severe dependence. In contrast, Goldman et al. (326) found a stronger association 
for Grip strength than Chair rising in community-dwelling older persons. However, their analyses 
were adjusted for ADL which reflected lower extremity function; without adjustment the advantage 
of Grip strength weakened. The stronger associations for Chair rising and Timed up and Go over 
Grip strength and Standing balance, may perhaps be partially explained by the fact that these 
former timed physical performance measurements require both lower limb strength and balance 
(208,209). 
Previous studies have questioned the extra value of physical performance tests in addition to self-
reported ADL or mobility limitations. In older persons with high self-reported function (no 
disability), physical performance tests still detect wide variation in performance and can further 
discriminate mortality hazard (206,284,326). The added value of physical performance measurements 
among persons with ADL dependency is more controversial (284,326). From a reversed perspective, 
Markides et al. (327) found adding ADL assessment to the SPPB test, did not have extra value for 
prediction of 2-year mortality in community-dwelling older Mexican Americans. 
A consideration regarding the concept of this study is that no comparisons could be made with 
Gait speed. Indeed, as timed measurements of physical performance appeared to be most 
predictive, it would have been interesting to have data on Gait speed at our disposal.  
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Table 21. Studies examining the association of Timed Up and Go performance with mortality. 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] FOLLOW-UP 
MAX, YEARS 
MORTALITY 
RATE 
ASSOCIA-
TION 
Beloosesky, 
2004 (328) 
 171  ≥ 60 Outpatients admitted to a geriatric rehabilitation 
day unit after inpatient rehabilitation of hip 
fracture 
4 14% NS 
Tice,  
2006 (329) 
US 17748 100% 
 
≥ 55 
(68 ± 6) 
Community-dwellers living in 11 metropolitan 
areas (advertisements + population-based 
listings) [Breast and Bone Follow-up Study of 
the Fracture Intervention Trial] 
9 11% S 
Wong,  
2008 (330) 
Vancouver 147 53% ≥ 75 
(84 ± 6) 
Outpatients admitted to two acute care for 
elders-units at a teaching hospital 
0.5 (post-
discharge) 
13% S 
Hoshide,  
2008 (244) 
Japan 489 64% 
 
≥ 80 
(84 ± 5) 
Outpatients from 25 institutions 6 15% S 
Davis,  
2011 (245) 
Canada 1295 57% 
 
70 – 105 
(85 ± 7) 
Community-dwellers from 36 study centres 
(community-sample via records of provincial 
health insurance plans or the Enumerated 
Composite record) [Canadian Study of Health 
and Aging (second wave)] 
5 44% S * 
De Buyser, 
2013 (222) 
Belgium 352 0% 71 – 86 
(76 ± 4) 
Community-dwellers registered in one 
municipality (population register) 
15 78% S 
Idland,  
2013 (324) 
Norway 300 100% ≥ 75 
(81) 
Community-dwellers from one community 
(random sample via census files) 
14 71% S 
Robinson,  
2013 (331) 
US 272 2% ≥ 65 
(74 ± 6) 
In-patients undergoing elective colorectal and 
cardiac operations 
1 – 6 7% S 
Roshanrava
n, 2013 (332) 
US 362 16% 
 
≥ 18 
(61 ± 13) 
Outpatients with chronic kidney disease not on 
dialysis 
3 12% S 
Ferrat,  
2015 (333) 
France 985 49% ≥ 70 
(80 ± 6) 
Out- and in-patients with newly diagnosed solid 
or hematologic malignancies, referred to two 
geriatric oncology clinics in teaching hospitals by 
specialists [ELPACA06] 
1 41% S 
SD = Standard deviation, S = Significant, NS = Not significant. 
* Significant in analyses adjusted for age and sex, but not for frailty. 
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4.1.4 CHANGES IN PHYSICAL FUNCTION & MORTALITY 
In Chapter 2.3, we evaluated 3-year changes in SF-36 Physical Function Index, Grip strength, 
Chair rising, and Timed Up and Go for prediction of subsequent 15-year all-cause mortality in a 
well-described sample of apparently healthy community-dwelling older men in Belgium. While 
physical function is increasingly being used as outcome measure in clinical trials, evidence is needed 
that changes in physical function will lead to relevant changes in clinical outcomes. 
In a subsample of the Merelbeke study population, which only included men with reliable physical 
function data at the second and fifth wave, median 3-year change (IQR) in SF-36 Physical Function 
Index was -4.71 (-18.58 – +0.11) points, in Grip strength +0.25 (-4.02 – +2.23) kg, in Chair rising -
0.9 (-2.14 – +0.15) seconds, and in Timed Up and Go -0.02 (-1.18 – +1.22) seconds. A decline in 
all physical function measurements was significantly associated with higher subsequent mortality 
hazard. With every unit of greater 3-year decline, subsequent 7-year mortality hazard increased on 
average with 2% for SF-36 Physical Function Index, 4% for Grip strength, 16% for Chair rising, 
and 15% for Timed Up and Go (age- and baseline function-adjusted HRs). After seven years, a 
time-attenuated effect became significant for change in SF-36 Physical Function Index, Grip 
strength, and Chair rising, but not for change in Timed Up and Go. Interestingly, both baseline 
function and closure function (at the fifth wave) remained significantly associated with mortality 
when they were entered (separately) into a model including 3-year change in physical function, 
indicating the robustness of single time-point physical function measurements. 
Our study was one of the first in community-dwelling European older men, as can be deducted 
from Table 22, which summarizes studies examining change in physical function as predictor of 
all-cause mortality. Moreover, we were first to assess the impact of change in Timed Up and Go on 
mortality. Furthermore, the Merelbeke study has had the longest mortality follow-up and highest 
mortality rate by far.  
A consideration regarding the concept of this study is that the observed changes in physical 
function were not linked to any active intervention. In order to demonstrate that physical function 
assessments can be used as surrogate end points of mortality hazard in clinical trials, interventional 
trials with long follow-up are needed. 
 
  
 
147 
14
7
 
4
.1
 
Table 22. Studies examining the association of change in physical function with mortality. 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± 
SD), YEARS 
RECRUITMENT [STUDY] PHYSICAL 
FUNCTION 
MEASUREMENT 
ASSESSMENT OF 
CHANGE 
FOLLOW-
UP MAX, 
YEARS 
MORTALITY 
RATE 
ASSOCIATION 
Perera, 
2005 (62) 
US 439 44% ≥ 65 
(73 ± 6) 
Community-dwellers recruited 
from a veteran’s affairs 
hospital-based ambulatory 
care site and a Medicare health 
management organization 
serving a common geographic 
area; with MMSE > 16 and 
Gait speed between 0.2 and 
1.3 m/s 
Gait speed,  
SPPB,  
SF-36 Physical 
Function 
Index,  
ADL 
Meaningful 
decline from 
baseline 
assessed 
quarterly within 
1 year  
5 20% S only for 
decline in Gait 
speed 
Buchman, 
2007 (65) 
US 837 75%  
(81 ± 7) 
Community-dwellers with one 
or more follow-up evaluations 
and without dementia [Rush 
Memory and Aging Project] 
Composite 
measure of 
motor 
performance 
Change 
estimated with 5 
measuring 
points over 4 
years, using 
OLS regression 
2 (mean) 10% S 
Hardy,  
2007 (63) 
US 439 44% ≥ 65 
(74 ± 6) 
Community-dwellers recruited 
from a veteran’s affairs 
hospital–based ambulatory 
care site and a Medicare health 
management organization 
serving a common geographic 
area; with MMSE > 16 and 
Gait speed between 0.2 and 
1.3 m/s 
Gait speed,  
SPPB,  
SF-36 Physical 
Function 
Index, 
ADL 
Pattern of 
meaningful 
improvement 
from baseline 
assessed 
quarterly within 
1 year 
(persistent, 
transient, or 
never) 
8 43% S only for 
persistent 
improvement 
in Gait speed 
Kroenke, 
2008 (258) 
US 40 337 100% 46 – 71 Nurses without serious 
illnesses or medical 
procedures [Nurses' Health 
Study] 
SF-36 physical 
component 
summary score 
Categories of 4-
year delta 
change 
4 2% S across 
categories of 
change 
Otero-
Rodriguez, 
2010 (259) 
Spain 2373 58% ≥ 60 Non-institutionalized older 
persons (population-based 
sample) 
SF-36 physical 
component 
summary score 
Categories of 2-
year delta 
change 
4 9% S for 
categories of 
decline 
  
 
 
 
Table 22. Studies examining the association of change in physical function with mortality. [Continued] 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± 
SD), YEARS 
RECRUITMENT [STUDY] PHYSICAL 
FUNCTION 
MEASUREMENT 
ASSESSMENT OF 
CHANGE 
FOLLOW-
UP MAX, 
YEARS 
MORTALITY 
RATE 
ASSOCIATION 
Hirsch,  
2012 (66) 
US 4182 52% ≥ 65 
(79) 
Older persons recruited from 
four communities 
(population-based sample) 
[Cardiovascular Health Study] 
Gait speed, 
Chair rising,  
Grip strength 
Quintiles of 
annual change 
estimated with 7 
measuring 
points over 6 
years, using 
linear mixed-
effects models 
7 46% S only for 
highest 
quintile of 
change 
(decline) in 
Grip strength  
White,  
2013 (260) 
US 2158 52% 70 – 79  
(74 ± 3) 
Caucasian Medicare 
beneficiaries and black 
community-dwellers residing 
in and around two cities 
without mobility difficulty or 
terminal cancer (Random 
sample) [Health ABC study] 
Gait speed Trajectory 
pattern of 
decline 
estimated with 3 
measuring 
points over 2 
years, using 
multinomial 
models (slow, 
moderate, and 
fast decline) 
10 25% S only for fast 
decline 
Sabia,  
2014 (64) 
France 2094 62% 65 – 85  
(73 ± 5) 
Community-dwellers sample 
registered in one city (electoral 
rolls) [3C Study] 
Gait speed Annual change 
estimated with 2 
measuring 
points over 4 
years, using 
OLS regression 
8 15% S for 
continuous 
change and 
for categories 
of substantial 
decline 
De 
Buyser,  
2016  
Belgium 171 0% 71 – 86 
(75 ± 3) 
Community-dwellers 
registered in one municipality 
(population register) 
SF-36 Physical 
Function 
Index, 
Grip strength 
Chair rising 
Timed Up and 
Go 
Change 
estimated with 4 
measuring 
points over 3 
years, using 
OLS regression 
15 87% S 
SD = Standard deviation, MMSE = Mini-Mental State Examination, SPPB = Short Physical Performance Battery, SF-36 = Short Form-36, ADL = Activities of 
daily living, ABC = Aging and Body Composition, OLS = Ordinary least-squares, S = Significant. 
MAIN FINDINGS & CONTRIBUTIONS IN OLDER IN-PATIENTS 
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4.2 MAIN FINDINGS & CONTRIBUTIONS IN OLDER IN-PATIENTS 
4.2.1 PHYSICAL FUNCTION & HOSPITAL OUTCOMES 
In Chapter 3.1 we identified factors related to older patients’ clinical, nutritional, functional and 
socio-demographic profiles, which can predict LoS, in-hospital mortality, and institutionalization in 
a sample of in-patients admitted to acute care. Most studies on hospital outcomes of older patients 
so far have relied on routinely collected data such as age, gender, and clinical diagnosis. However 
multifaceted aspects such as functional status and physical performance, which are rarely 
considered in clinical research, need to be taken into account as well (266). 
In the CRIME study population, 22% of patients were dependent in six ADL, 54% were unable to 
perform Gait speed, and 27% were unable to perform Grip strength at admission. Both Gait speed 
and ADL provided prognostic information on LoS according to initial analyses. When both were 
simultaneously entered into a forward selection multivariate regression model, only Gait speed 
category (unable, < 0.8 m/s, or ≥ 0.8 m/s) was kept into the model as one of the independent 
predictors. Regarding factors predictive of in-hospital mortality, all three physical function 
measurements were significantly associated in initial analyses, albeit Gait speed and Grip strength 
had to be dichotomized into able / unable because very few subjects who died in-hospital, could 
perform these tests at admission. Subsequent forward selection multivariate regression retained 
ADL total dependency and Grip strength inability as independent predictors. Likewise, all three 
physical function measurements were significantly associated with new institutionalization in initial 
analyses; but only ADL total dependency was retained in the final adjusted model.  
Some studies reporting on the association of physical function with hospital outcome in older in-
patients admitted to acute care are described in Table 23. Table 24 helps envisage the frequency 
and consistency of associations between either reported or performance-based physical function 
measures and LoS, mortality, and institutionalization, which have been reported previously. 
Regarding predictors of LoS, both reported and performance-based physical function measures 
have been investigated. While performance-based measures of physical function were consistently 
associated with LoS, associations of reported measures of physical function were less persistent. 
Regarding predictors of mortality and institutionalization, almost exclusively reported measures of 
ADL or IADL have been investigated.  
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In the CRIME study population, in-hospital mortality and institutionalization seemed to occur 
almost entirely in subjects at the lowest end of the physical performance spectrum, namely in those 
unable to perform the tests. In these patients, ADL score could further distinguish a gradient risk 
for in-hospital mortality and institutionalization. 
A consideration regarding the concept of this study might relate to the available data on mortality 
after discharge, which were not taken into account in the analysis. These data were used for related 
research on EWGSOP sarcopenia, which was associated with both in-hospital mortality and 
mortality in the year after discharge in the CRIME study (123). 
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Table 23. Some studies on the association of physical function with hospital outcome in older in-patients admitted to acute 
care. 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] PHYSICAL FUNCTION 
MEASUREMENT 
HOSPITAL OUTCOME   
(% OR MEDIAN OR MEAN ± SD) 
Covinsky,  
1997 (315) 
US 823 68% ≥ 70 
(81) 
Medical in-patients at a general 
medical service of a teaching 
hospital 
6 ADL items: dependent in all 6 
ADL (24%) vs. dependent in 0 
ADL (26%) at admission 
Mortality in-hospital (7%) 
Mortality within 1 year (32%) 
Institutionalization to a nursing 
home within 90 days (17%) 
Inouye,  
1998 (293) 
US 207 59% ≥ 70 
(79 ± 6) 
In-patients consecutively 
admitted to six general medicine 
(non-intensive care) floors of a 
university teaching hospital 
7 ADL items referent to two 
weeks prior to admission: any 
impairment (39%) 
7 IADL items referent to two 
weeks prior to admission: any 
impairment (65%) 
Mortality within 90 days (14%) 
Mortality within 2 years (39%) 
Alarcón,  
1999 (265) 
Spain 353 66%  
(82 ± 7) 
In-patients admitted to an acute 
geriatric ward 
Barthel index at admission 
Red Cross Hospital Functional 
Disability Scale at admission 
LoS prolonged > 28 days (9%) 
Mortality in-hospital (11%) 
Institutionalization (3%) 
Di Iorio,  
1999 (334) 
Italy 402 54% ≥ 65 
(81) 
In-patients consecutively 
admitted to four acute geriatric 
care units for at least four days 
Katz index at admission 
(2.2 ± 2.9 – 3.1 ± 3.3) 
Lawton scale at admission 
(3.2 ± 2.2 – 4.0 ± 2.1) 
Ability to perform six 
performance tests prior to 
discharge 
(4.2 ± 1.3 – 4.9 ± 1.4) 
LoS (9.4 ± 3.3 days – 14.1 ± 7.2 
days)  
Campbell,  
2005 (275) 
Europe 1626 58% ≥ 65 
(74) 
Non-elective medical in-patients 
from eight centres in six 
European countries 
Barthel index at day 3: score 0 – 9 
(23%) vs. score 16 – 20 (50%) 
LoS (12 days) 
Mortality in-hospital (9%) 
Institutionalization (6%) 
Purser,  
2005 (279) 
US 1388 2% ≥ 65 
(74 ± 6) 
Medical or surgical in-patients 
from eleven Veteran Affairs 
Medical Centres 
Gait speed at admission (0.5 ± 
0.2 m/s) (only 26% completed 
the test in 90seconds or less) 
LoS (10.1 days) 
  
  
Table 23. Some studies on the association of physical function with hospital outcome in older in-patients admitted to acute 
care. [Continued] 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] PHYSICAL FUNCTION 
MEASUREMENT 
HOSPITAL OUTCOME   
(% OR MEDIAN OR MEAN ± SD) 
Gan,  
2006 (278) 
Australia 2463 61%  
(82 ± 8) 
In-patients consecutively 
admitted to a multidisciplinary 
acute care unit for frail older 
people 
Timed Up and Go time at 
admission (28 s) 
Timed Up and Go ability at 
admission (38%) 
LoS (8 – 11 days) 
Kerr,  
2006 (263) 
US 110 57% 75 – 101 
(84) 
In-patients admitted to a 
Medical Admissions Unit 
(clinical setting not surgical) at 
Southampton University 
Hospitals NHS Trust  
Grip strength at admission 
(median 29 kg for men, 16 kg for 
women): < 25 kg in men and < 
15 kg in women vs. > 31 kg in 
men and > 18 kg in women 
Barthel index at admission 
LoS from admission until 
discharge to usual residence (9 
days) 
Lang,  
2006 (277) 
France 908 64% ≥ 75 
(84 ± 6) 
In-patients hospitalized through 
an emergency department in 
any medical ward except an 
Acute Care for elders unit at 
nine hospitals 
5 ADL items referent to 2 weeks 
before admission (32% with at 
least 3 impairments)  
5 ADL items referent to 
inclusion between the 4th and 7th 
day (69% with at least 3 
impairments) 
Timed Get Up and Go: walking 
difficulty between the 4th and 7th 
day (82%) 
One-leg-balance: risk of fall 
between the 4th and 7th day (52%) 
LoS prolonged > 30 days (15%) 
Los prolonged > f-DRG 
adjusted limit (5%) 
Carpenter,  
2007 (335) 
England 1942 55%  
(74) 
In-patients consecutively 
admitted from the emergency 
department with one or more of 
the following conditions: stroke, 
fracture neck of femur, 
myocardial infarction, acute 
respiratory infection, COPD, 
and falls 
ADL Hierarchy Scale based on 
four ADL items: not dependent 
(12%) vs. dependent in 1 – 3 
ADL (22%) and dependent in 4 – 
6 ADL (66%) at admission 
LoS (observed minus predicted) 
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Table 23. Some studies on the association of physical function with hospital outcome in older in-patients admitted to acute 
care. [Continued] 
FIRST 
AUTHOR, 
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT [STUDY] PHYSICAL FUNCTION 
MEASUREMENT 
HOSPITAL OUTCOME   
(% OR MEDIAN OR MEAN ± SD) 
Volpato,  
2008 (267) 
Italy 92 49% 65 – 94 
(78) 
In-patients who were able to 
walk and had an MMSE ≥ 18, 
admitted to the section of 
internal medicine and geriatrics 
at one university hospital with a 
clinical diagnosis of congestive 
heart failure, COPD, 
pneumonia, and minor stroke. 
SPPB at admission (6.0 ± 2.7): 
score 0 – 4 vs. score 8 – 12 
Katz index referent to admission: 
any difficulty (53%) 
LoS (9.8 ± 4.8 days) 
Matzen,  
2012 (336) 
Denmark 4527 64% ≥ 65 
(82 ± 7) 
In-patients admitted to an acute 
geriatric unit at a university 
hospital 
Barthel index at admission: score 
80 – 100 vs. score 0 – 24, score 
25 – 49 and score 50 – 79 
Mortality in-hospital (8%) 
Mortality within 12 months 
(55%) 
Ostir,  
2012 (196) 
US 322 64% ≥ 65 
(76 ± 7) 
In-patients admitted to an ACE 
hospital unit at a university 
teaching hospital 
Gait speed at admission: ≥ 0.6 
m/s (22%) vs. < 0.40 m/s (21%) 
and unable to complete (64%) 
7 ADL items at admission: no 
disability vs. 1 – 2 disabilities, 3 – 
4 disabilities, and ≥ 5 disabilities 
LoS (4.1 ± 3.8 days) 
Home discharge (83%) 
De Buyser,  
2014 (337) 
Italy 1123 56% ≥ 65 
(81 ± 7) 
In-patients consecutively 
admitted to geriatric and 
internal medicine acute care 
wards of seven hospitals 
Gait speed at admission: ≥ 0.8 
m/s (12%) vs. < 0.8 m/s (34%) 
and unable (54%) 
Grip strength admission: able vs. 
unable (27%) 
6 ADL items referent to 
preceding 2 weeks: total 
dependency (22%) 
LoS (10 days) 
Mortality in-hospital (4%) 
Institutionalization at discharge 
(3%) 
SD = Standard deviation, ADL = Activities of daily living, IADL = Instrumental activities of daily living, LoS = Length of hospital stay, DRG = Diagnosis-related 
group, COPD = Chronic obstructive pulmonary disease, MMSE = Mini-Mental State Examination, ACE = Acute care for elderly, SPPB = Short Physical 
Performance Battery.  
  
Table 24. Association of physical function with hospital outcome in older in-patients admitted to acute care. 
OUTCOME → LENGTH OF HOSPITAL STAY MORTALITY DISCHARGE DESTINATION 
ASSOCIATION → SIGNIFICANT NS SIGNIFICANT NS SIGNIFICANT NS 
PREDICTOR ↓       
REPORTED MEASURES       
ADL – prior to admission  (277) (337) (337) (293)  (337)  
ADL  (265) (263) (335) (196) (277) (267) (334) (265) (315) (336)  (196) (315)  
ADL – at day 3 (275)  (275)  (275)  
IADL – prior to admission   (293)    
IADL  (334)      
Functional Disability scale   (265) (265)  (265)  
PERFORMANCE-BASED MEASURES       
Gait speed score  (196) (279) (337)    (196)  
Timed Up and Go score  (278)      
Timed Up and Go difficulty – between day 4 and 7 (277)      
One-Leg-balance score – between day 4 and 7 (277)      
SPPB score (267)      
Gait speed ability (196) (337)   (337) (196) (337) 
Timed Up and Go ability  (278)      
Ability to perform 6 tests – prior to discharge (334)      
Grip strength ability  (263) (337) (337)   (337) 
All measurement are referent to admission, unless otherwise stated. Significance of the association with most adjustments was used. 
ADL = Activities of daily living, IADL = Instrumental activities of daily living, NS = Not significant. 
MAIN FINDINGS & CONTRIBUTIONS IN OLDER IN-PATIENTS 
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4.2.2 FUNCTIONAL CHANGES DURING HOSPITAL STAY 
In Chapter 3.2 we examined functional changes during hospital stay in older patients admitted to 
geriatric or internal medicine acute care wards. While previous studies almost exclusively assessed 
functional changes via ADL questionnaires, our study also examined changes in Gait speed and 
Grip strength. Additionally, we investigated characteristics of older patients that were associated 
with meaningful in-hospital improvement in physical performance.  
In a subsample of the CRIME study population, which only included patients with an MMSE ≥ 18, 
we found that at least half of in-patients were dependent in one or more ADL two weeks before 
admission. On average, functional status did not change, since at discharge 91% of patients 
obtained the same score as pre-admission. On admission, 36% of patients were unable to perform 
Gait speed and 12% could not execute Grip strength. Mean physical performance improved 
significantly in-hospital, however this improvement was only meaningful (≥ 1 SD) in 10% and 7% 
of patients for Gait speed and Grip strength, respectively. Meaningful improvement in 
performance was most common in subjects who were unable to perform the particular test at 
admission, nevertheless discharge performance was still very low compared with patients who were 
able to perform the respective test at admission. In addition, patients admitted from the emergency 
room were more likely to improve their performance than electively admitted patients. This 
perhaps could be attributed to the pre-hospital decline (297,338) and subsequent functional recovery 
trajectory of some ER patients, while electively admitted patients are less likely to have declined 
before admission. Finally, the odds of improvement also decreased with older age (298). 
Some studies reporting functional changes of older in-patients are described in Table 25. In-
hospital functional improvement was nearly always more prevalent than decline. In fact, functional 
decline is reported most commonly in the weeks prior to admission, probably due to patients’ acute 
illness. The functional recovery trajectory continues after discharge, although not all patients 
eventually regain the same level of function as reported two weeks before admission. Studies with 
follow-up after discharge still found declined ADL from preadmission in 41 – 49% of patients after 
one month (339,340) and in 12% after three months (341). Follow-up studies on physical performance 
could detect further improvement from hospital discharge after one year (279), but not after merely 
one month (306). Although practically more challenging than ADL follow-up by telephone, it would 
be interesting to further explore this recovery of physical performance after discharge. 
Nevertheless, the functional changes occurring in hospital only have shown to have predictive 
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value towards adverse health risks. The lack of function regain during hospitalization was found to 
be associated with greater risk for nursing home admission within one month after discharge (305) 
and higher mortality rate at three months (299). 
A consideration regarding the concept of this study is that these in-hospital changes have not been 
linked to adverse outcomes at hospital discharge. Very few mortality and institutionalization events 
occurred in this subsample of the CRIME study population. 
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Table 25. Functional changes of older in-patients. 
FIRST 
AUTHOR,  
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT PHYSICAL 
FUNCTION 
MEASUREMENT 
FUNCTIONAL DECLINE FUNCTIONAL 
IMPROVEMENT 
       PRE-
HOSPITAL 
IN-HOSPITAL IN-HOSPITAL 
Fortinsky,  
1999 (305) 
US 551 66% ≥ 70 
(80) 
General medical in-patients admitted 
to a teaching hospital 
5 ADL items 39% 15 – 28% 26 – 71% 
Blè,  
2003 (302) 
Italy 65 48% ≥ 65 
(75 ± 5) 
In-patients admitted to the internal 
medicine department of a university 
hospital; who were not mobility 
disable 
Barthel index 
items on mobility  
 34%  
Covinsky,  
2003 (298) 
US 2293 64% ≥ 70 
(79.5) 
Medical in-patients nonelectively 
admitted to the general medical 
services of two hospitals; who were 
not totally dependent pre-admission 
5 ADL items 43% 17% 20 – 65% 
Brown,  
2004 (304) 
US 474 56% ≥ 70 
(79 ± 6) 
In-patients consecutively admitted to 
the medicine service at a teaching 
hospital; who were not totally 
dependent at admission 
5 non-mobility 
ADL 
 29%  
Bautmans,  
2005 (307) 
Belgium 63 67%  
(84 ± 6) 
In-patients consecutively admitted at 
the geriatric ward of an academic 
hospital 
Grip strength   NS 
Purser,  
2005 (279) 
US 1388 2% ≥ 65 
(74 ± 6) 
Medical or surgical In-patients in a 
Department of Veterans Affairs, 
who were designated as frail 
Gait speed   S 
Volpato,  
2008 (267) 
Italy 92 49% 65 – 94 
(78) 
In-patients admitted to the section of 
internal medicine and geriatrics at 
one university hospital; who were 
able to walk and had an MMSE ≥ 
18, presenting with a clinical 
diagnosis of congestive heart failure, 
chronic obstructive pulmonary 
disease, pneumonia, or minor stroke. 
SPPB   20% 63% 
  
  
Table 25. Functional changes of older in-patients. [Continued] 
FIRST 
AUTHOR,  
YEAR 
COUNTRY N WOMEN AGE RANGE 
(MEAN ± SD), 
YEARS 
RECRUITMENT PHYSICAL 
FUNCTION 
MEASUREMENT 
FUNCTIONAL DECLINE FUNCTIONAL 
IMPROVEMENT 
       PRE-
HOSPITAL 
IN-HOSPITAL IN-HOSPITAL 
Corsonello,  
2009 (303) 
Italy 506 54% ≥ 65 
(80 ± 6) 
In-patients consecutively admitted to 
11 acute care medical wards 
7 ADL items   11% 10% 
Sleiman,  
2009 (299) 
Italy 1119 60%  
(81 ± 8) 
In-patients admitted to the high 
dependency area of an acute geriatric 
ward, who presented functional 
changes during hospitalization 
Barthel index ≥ 61%  66% 
Palleschi,  
2011 (297) 
Italy 1048 55% ≥ 65 
(80 ± 8) 
In-patients consecutively admitted to 
acute care geriatric and general 
medicine units of five hospitals 
Barthel index 44% 1% ≥ 26% 
29% 
Zisberg,  
2011 (339) 
Israel 525 50% ≥ 70 
(79 ± 6) 
In-patients non-electively admitted 
to one of five general medical units 
of a tertiary care teaching hospital, 
who were not disable 
Modified Barthel 
Index  
 
50%  ≥ 4% 
46% 
Merino 
Martín,  
2012 (341) 
Spain 186 41% 65 – 100 
(76 ± 7) 
Medical and surgical in-patients 
admitted (electively or through the 
ER) to a public teaching hospital  
Katz index  
Lawton's scale 
17%  
25% 
 
Bodilsen,  
2013 (306) 
Denmark 33 46% ≥ 65 
(83 ± 8) 
Inpatient admitted to a university 
hospital for an acute medical illness, 
able to walk (random sample) 
Grip strength 
Timed Up and 
Go 
 NS  
S 
De Buyser,  
2014 (268) 
Italy 639 52% 65 – 98 
(79 ± 7) 
In-patients consecutively admitted to 
geriatric and internal medicine acute 
care wards of seven hospitals, who 
had an MMSE ≥ 18 
ADL 
Grip strength 
Gait speed 
3%  
  S 7% 
S 10% 
Palleschi,  
2014 (338) 
Italy 1281 54% ≥ 65  
(85 ± 8) 
In-patients consecutively admitted to 
acute care geriatric and general 
medicine units of five hospitals 
Barthel index 42%   
SD = Standard deviation, ADL = Activities of daily living, SPPB = Short Physical Performance Battery, MMSE = Mini-Mental State Examination. 
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4.3 IMPLICATIONS & PERSPECTIVES 
4.3.1 PHYSICAL FUNCTION & ITS PURPOSE 
As predictor of mortality and adverse health outcomes 
Our findings from Chapter 2 indicate that the SOF index for frailty, the FNIH criteria for 
weakness and low muscle mass, and assessments of physical function (RDRS-2 ADL, SF-36 
Physical Function Index, Grip strength, Standing balance, Chair rising, and Timed Up and Go) can 
be used as predictors of mortality and adverse health outcomes in a Caucasian male older 
community-dwelling population. Equally, physical function assessments (Gait speed, Grip strength, 
and ADL) can also predict hospital risks of an older population admitted to acute care (Chapter 
3.1). In this respect, physical function (related) assessments can be used to characterize older adults 
in primary care or older participants in research manuscripts. Further research might focus on 
health risks other than mortality and hospital outcome. Associations with disability (342) and health-
related quality of life (59,343) have already been established. 
While the above mentioned associations with mortality relate to assessments at a single point in 
time, our findings from Chapter 2.3 and Chapter 3.2 indicate that physical function has a dynamic 
nature, hence reassessment of physical function over time might be warranted and informative. In 
healthy community-dwelling older men, reassessment every few years can help predict mortality 
risk more accurately than single baseline assessment (Chapter 2.3). In hospitalized older patients, 
reassessment at discharge can already show meaningful improvement from admission (Chapter 
3.2). Evidence that improvement in physical function during hospital stay can predict hospital outcome 
is currently limited to improvement in ADL. Functional improvement during hospital stay according to 
the Barthel index has been associated with shorter LoS (297), functional recovery (regaining the same 
levels of functioning as those reported two weeks prior to hospital admission)(340), and lower 1-year 
mortality (344). Correspondingly, lack of function regain during hospitalization has been associated 
with greater risk for nursing home admission within 30 days following discharge (305) and higher 
mortality rate at 1, 3, 6, and 12 months (299,345). A related implication is that further research aiming 
to investigate independent associations with mortality in community-dwelling older men should 
control for frailty or sarcopenic status, or physical function. Likewise, studies examining 
independent associations with hospital outcome of acutely ill older adults should take into account 
physical function at admission or pre-admission. Future research might revise our found 
associations in samples of populations with very specific diseases, although geriatric research and 
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clinical practice tends not to focus on single diseases but rather on reflections of overall health 
status. 
As estimate for frailty and sarcopenia prevalence 
Findings from Chapter 2.1 indicate that sarcopenia (3 – 8%) and frailty (7%) are quite prevalent in 
apparently healthy older community-dwelling men. These estimates may even be underestimated, as 
non-participants are likely to have worse physical function. 
As target definer for interventions 
Chapter 2 illustrates how the SOF frailty index, FNIH criteria, and physical function assessments 
can be used as screening tools to identify community-dwelling older men at higher risk of mortality 
and therefore in need of intervention. Previously the SPPB test (0 – 12) has been used to target 
subjects for the Lifestyle Interventions and Independence for Elders study by excluding those with 
scores above nine (346). Recent studies have indicated physical function assessments can also help 
select subjects who would most likely benefit from intervention. However, this needs further 
research. While mobile subjects with poorer function at baseline (SPPB score < 8) have shown 
greater beneficial effects of exercise training (346), this has also been found for subjects with 
moderate frailty as opposed to severe frailty and/or disability (347). The contrast might indicate there 
is a window for level of physical function in which interventions are most beneficial. 
Similar as in ambulatory setting, assessment of physical function in acutely ill older in-patients at 
hospital admission can help target populations in need of hospital models of care (Chapter 3.1). 
Several methods have been established to help prevent functional decline of older hospitalized 
patients and to improve their hospital outcome. Most approaches start with assessment of older 
patients’ function and risks for functional loss to determine if they are eligible for the program. 
Gait speed and Grip strength can be used to evaluate a patient’s physical function during hospital 
stay and to identify those patients who are in need of comprehensive geriatric assessment or 
exercise training (more details on hospital models of care can be found in Chapter 4.3.3). 
As outcome measure in interventions 
Results from Chapter 2.3 support the use of physical function assessments to evaluate the 
effectiveness of geriatric interventions, as they demonstrate how decline in physical function has an 
impact on mortality. Given the observed time-dependent effect, future large randomized controlled 
trials with long follow-up of both physical function and mortality outcome are needed to further 
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validate physical function as outcome measure in interventions. Further research should examine 
how counteracting decline in physical function has an impact on health risks in older persons. 
4.3.2 PHYSICAL FUNCTION & ITS NUMEROUS OPERATIONAL DEFINITIONS 
On the one hand, there is a need for one standard assessment of physical function to be 
implemented across studies, to allow more accurate comparison of study populations. On the other 
hand, there is no single assessment that will be feasible in all settings, nor will it suit all purposes. 
When deciding how to assess physical function, consideration should be given to the intended 
purpose, clinimetric properties, and practical issues (109,110,124). 
The intended purpose will largely determine which assessment tools are appropriate to use. When 
the main goal is to classify persons at risk of adverse health outcomes, assessment tools with an 
ordinal or even dichotomous scoring system can be used (110). Likewise, classifying older persons as 
frail vs. non-frail or sarcopenic vs. non-sarcopenic is useful to estimate the prevalence of frailty and 
sarcopenia, respectively (110). However, purposes such as guiding clinical decision making or 
evaluating the impact of an intervention will benefit from assessments that address physical 
function, frailty and sarcopenia as a dynamic process (110). These latter assessments should enable 
early detection of small declines and hence foster prevention rather than treatment. When 
screening patients for inclusion/exclusion into a study, assessments that can identify a window 
within the functional spectrum might help target populations in which interventions are most 
beneficial. Finally, when the purpose is to understand the etiology behind frailty, it is important the 
instrument does not include disability or comorbidity (109).  
Clinimetric properties should also be taken into account when selecting a physical function 
assessment. Obviously predictive validity will be important when the primary purpose is to identify 
older persons at risk. Likewise responsiveness will be pivotal when the assessment is used to 
evaluate the impact of an intervention. Further attention needs to be paid to the feasibility of 
assessments and their floor- and ceiling effects, because assessments may not cover the whole 
functional spectrum within older persons.  
Finally, practical issues also need to be taken into consideration when selecting an assessment. 
Feasibility may be considered as one of these issues, as well as restraints related to time, costs, 
resources, and space.  
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All physical function (related) assessments examined in the Merelbeke study have supported their 
use as predictors of mortality. Their clinimetric properties have been described in Chapter 1.5.1. 
Nevertheless, they also come with some practical considerations. Both the SOF frailty index and 
the FNIH criteria come with the advantage that they do not further require the establishment of a 
reference population. This is not the case for some other well-recognised frailty and sarcopenia 
instruments, such as the Fried and EWGSOP criteria. Optimal cutoff points for most of our 
examined measures of physical function still need to be established. In our study population, 12.5 
seconds has shown to be a successful cutoff point to identify limited Timed Up and Go 
performance associated with mortality. Nevertheless, future research might truly focus on 
identifying cutoff points of physical function that can distinguish low levels of function associated 
with mortality and other adverse health risks, such as mobility limitation. Reported and timed 
physical function measurements and also the SOF frailty index do not require any special 
equipment, whilst inter-instrument variability can influence Grip strength and the FNIH criteria. 
On the other hand, environmental differences may influence reported physical function 
measurements including the SOF question on low energy-level. The FNIH criterion for low muscle 
mass is more expensive to assess, since DXA is not refunded for sarcopenia indications. 
In light of the reflections above the SPPB test, which was regretfully not assessed in the Merelbeke 
study, might be a suitable assessment tool in community-dwelling older persons for several 
purposes (risk prediction, evaluation of interventions, target selection), as it has predictive validity 
with regards to mortality (348), is responsive to change (348), and can identify subpopulations in 
whom interventions are most beneficial (346). Floor effects have been reported in 0 – 7% and ceiling 
effects in 2 – 16% (348). However, it was found that in older adults with impaired mobility and at 
least 1 ADL dependency (who already have increased mortality risk), SPPB cannot further 
distinguish mortality risk (284). 
4.3.3 PHYSICAL FUNCTION & ITS INTERVENTIONS  
Interventions in older adults  
Therapeutic approaches have been proposed to slow down or even inverse the loss of physical 
function in older adults. These targeted interventions are mainly focused on exercise, nutrition, and 
pharmacological agents.  
Exercise is believed to be the most effective intervention to improve physical function of older 
adults. In non-hospitalized older adults, most evidence has been gathered for progressive resistance 
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training by a Cochrane review of 121 randomized controlled trials (60). Progressive resistance 
training has a small but significant effect on improving physical (dis)ability, a small to moderate 
effect on decreasing some functional limitations, and a large effect on increasing strength. 
Regarding outcomes related to our research, progressive resistance training leads to a significant 
improvement of Timed Up and Go and Chair rising time, but not to any difference in disability 
according to the SF-36 Physical Function Index. A meta-analysis on supervised whole-body 
resistance training (for at least eight weeks) has found a robust association with increased lean body 
mass in adults ≥ 50 years, with volume of training (defined as number of sets per session) and age 
as important predictors of effectiveness. Higher volume interventions are associated with greater 
increases in muscle mass, while older persons experience less gain (349). In frail older adults, 
according to reviews, exercise interventions improve muscle strength and physical performance, 
but not always muscle mass (147,347). Systematic reviews of randomized controlled trials find 
multicomponent exercise interventions to be most effective for improvement of mobility, balance, 
and strength (350,351). Superior outcomes are obtained with multicomponent training interventions of 
long duration (≥ 5 months), performed three times per week, for 30 – 45 minutes per session (350). 
Limited evidence is currently available for nutritional interventions. A Cochrane review found no 
evidence of functional benefit with oral protein and energy supplementation in older people (352). 
Although some positive effects are reported in malnourished older patients (353). Moderate evidence 
was found for vitamin D supplements in older persons, which have a positive effect on lower limb 
muscle strength; especially in persons with 25(OH)-vitamin D levels below 30 nmol/L (354). Both in 
frail and in sarcopenic older persons, current recommendations include correcting vitamin D 
insufficiency and optimizing protein intake (355,356). Recommended daily intake of vitamin D for 
older adults is at least 800 to 1000 IU. Recommended average daily protein intake for healthy older 
people lies in the range of 1.0 to 1.2 g protein per kilogram of body weight to help maintain and 
regain lean body mass and function. Higher protein intake is advised for older persons who are 
exercising and otherwise active, and for those with acute or chronic diseases (except with severe 
kidney disease and no dialysis) (353). Further research still needs to establish recommendations 
regarding protein quality and timing of ingestion (353,357). Novel nutrition strategies, which are under 
development, include β-hydroxy β-methylbutyrate, omega-3 fatty acids, and ursolic acid (357,358).  
At the moment, there is no consistent evidence to combine exercise training with dietary 
supplementation (359). However, some trials have shown enhanced benefits, hence there might be 
potential for future interventions (359,360). Creatine for instance, has a positive effect on muscle mass 
and strength when combined with exercise training (357,359). 
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To date insufficient evidence has been found for recommending pharmacological treatment (355,361), 
perhaps with the exception of testosterone treatment. Testosterone replacement therapy in older 
men produces a moderate increase in muscle strength (362), but might also be associated with 
increased prostate and cardiovascular events (363–365). Testosterone supplements may be considered 
in men with repeated low serum testosterone and consistent signs and symptoms of androgen 
deficiency (366,367). Growth hormone administration, which is associated with adverse events related 
to fluid retention, arthralgia, carpal tunnel syndrome, and gynaecomastia, cannot be recommended 
in older people, except in conditions with growth hormone deficiency (361,368). Growth hormone 
secretagogues may increase absolute lean body mass and potentially improve physical function in 
frail older persons. However, only short-term studies have been performed and these reported 
frequent side effects such as increased appetite, insomnia, mild lower extremity oedema and muscle 
pain (369,370). A promising treatment may be with angiotensin-converting enzyme inhibitors, which 
are currently used in cardiovascular prevention, but also have some evidence for improved physical 
function (361,371). Compounds currently under development are myostatin antagonists such as 
bimagrumab, and nonsteroidal selective androgen receptor modulators (372,373). 
Hospital models of careRegarding the several programs developed for improving hospitalized care 
for older adults, the strongest evidence for reducing decline has been found for Acute Care for the 
Elderly (ACE) units (374). This model of care typically includes a specifically designed environment 
that is friendlier to older adults, patient-centred care, early discharge planning with follow-up, and 
review of medical care. ACE units use geriatric assessment and multidisciplinary teams to deliver 
acute medical care while targeting interventions to maintain function (374). A meta-analysis found 
older people admitted to acute geriatric units to have lower risk of functional decline at discharge 
and higher likelihood to live at home after discharge compared with older people admitted to 
conventional care units (344). In-patient comprehensive geriatric assessment can be delivered in such 
ACE unit or in a general ward setting by a mobile team. However, a meta-analysis revealed positive 
effects of comprehensive geriatric assessment on survival and living at home after twelve months, 
only when delivered in a designated ward and not by a mobile team (375). However, when 
comprehensive geriatric assessment performed by a mobile team was followed by transfer to 
geriatric wards or case-management, LoS has shown to decrease (pre vs. post) (376). Other 
approaches have focused on geriatric resource nurse models (374) (where primary nurses and unit-
based resource nurses are trained to become geriatric resource nurses), volunteer programs (377) 
(where trained volunteers carry out therapeutic activities, nutritional assistance, or physical activities 
with patients), transitional care models (378,379) (with comprehensive discharge planning, 
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coordination of services and agencies, and education of patients), and exercise programs. Exercise 
programs can improve physical function, with no increase of adverse events during acute 
hospitalization (380,381). Albeit hospitalized frail older adults do not seem to benefit from exercise to 
the same extent as do community-dwelling older adults (350). Multidisciplinary programs including 
an exercise component may also improve hospital outcomes, such as LoS and home discharge 
(380,381). 
4.3.4 PHYSICAL FUNCTION & THE OLDER INDIVIDUAL 
In this doctoral thesis, most effect measures were presented as HRs, ORs, and regression 
coefficients, which reflect relative risk. To assess the probability that an older individual at an initial 
age a will experience a certain health risk or death in the subsequent interval [a, t] (382) absolute risk 
models, however, are needed. A variety of metrics can be used to evaluate models of absolute risk. 
Widely used classes of criteria are calibration, discrimination, accuracy, and proportion of variation 
explained. Although we have not reported measures of calibration (or goodness-of-fit of the 
models), we have occasionally described the other criteria.  
For instance in Chapter 2.1, we have measured discrimination with the concordance statistic and 
accuracy with positive and negative predictive values. While our HRs indicate an association of 
frailty and sarcopenia with mortality, this does not necessarily imply that frailty and sarcopenia can 
discriminate between older persons likely to die within three or nine years and those who do not. 
Therefore, concordance statistics were computed to measure the discriminatory power of age and 
frailty or sarcopenia (AUCs > 0.67). The reported positive and negative predictive values reflect 
how accurately frailty and sarcopenia classify death within three and nine years. While men without 
weakness and low muscle mass as well as robust men are likely (> 85%) to stay a live within the 
next three years; men with weakness and low muscle mass as do frail men are likely to die within 
the next nine years (> 80%).  
In Chapter 3.1, our multivariate models could explain 28.5% and 32.9% of the variability of in-
hospital mortality and institutionalization risk, respectively. 
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4.3.5 PHYSICAL FUNCTION & ITS FUTURE 
Increasing popularity of the SPPB test may be anticipated, as it is currently being used as an 
outcome measure in several large-scale projects on interventions in frailty (383) and sarcopenia (384). 
Furthermore, there has been a growing interest in muscle quality. With age, fat in the muscle 
increases and influences the muscle’s metabolic and contractile function (myosteatosis). It could be 
expected that future definitions of sarcopenia will include fat-adjusted estimates of ALM. 
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4.4 METHODOLOGICAL CONSIDERATIONS  
4.4.1 MERELBEKE STUDY 
Representativeness & external validity 
The entire older male population of Merelbeke was considered for longitudinal assessment in the 
Merelbeke study. This population-based cohort study design added to the representativeness of the 
sample studied and external validity of the associations found. Representativeness was further 
supported by the wide eligibility criteria for inclusion (which were age between 70 and 85 years old 
and willingness to participate) and the stability of the cohort on follow-up. Follow-up on survival 
status until 2015 was 99% complete, only three subjects could last be contacted in 2010. Follow-up 
rates were 75% at the second visit and 59% at the fifth visit (76% when excluding the 68 subjects 
who deceased). Therefore, results from Chapter 2.3 might be influenced by selection bias, since 
only subjects who participated in both the second and fifth visit could be included in the analyses. 
Representativeness might be influenced by our initial participation rate of 47%. Although this rate 
is in accordance with other population-based studies (226), it is unfortunate that no clinical data are 
available for the men who declined to participate. It is not unlikely that these non-participating men 
had higher mortality rates than our participants (227), thereby introducing some selection bias. 
Having a representative study sample allowed for estimation of prevalence rates in older, 
community-dwelling Belgian men. In this respect our prevalence of SOF frailty and FNIH 
sarcopenia corresponded with those reported in other population-based studies in community-
dwelling older persons. Even more important, our mortality rate corresponded with that of Belgian 
older men (Figure 19). In 2014, cumulative mortality of Belgian men aged 71 – 86 years in 1997 
was 89.7%, which matches the 89.6% mortality rate of Merelbeke study participants. 
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Figure 19. (Cumulative) mortality rates between 1997 and 2014 of men aged 71 – 86 years in 
1997 in the Belgian population (7) and Merelbeke study population. 
Comparisons to other studies would have been facilitated if certain characteristics of our study 
population were known (e.g. Gait speed, SPPB score, and presence of CHS physical frailty). 
Accuracy & reliability 
Several factors contributed to the accuracy and reliability of our results. First, all assessments were 
performed by a fixed group of four dedicated study nurses from the second visit on. Second, rate 
of change in physical function (Chapter 2.3) was estimated from four measurements over a 3-year 
period. Third, few observations were censored in the Cox proportional hazards analyses, due to the 
small survival rate.  
Unfortunately, the study sample was relatively small and lack of power may have attributed to some 
of the unexpected non-significant findings.  
Internal validity 
Cohort studies, like the Merelbeke study, allow analyzing predictors. However, confounding 
variables are the main problem when analyzing cohort studies. Due to our relatively small sample, 
we could not adjust our analyses for many variables, thereby potentially omitting confounders.  
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An important confounder which was taken into account, albeit unintentionally, was gender. As the 
Merelbeke study population was composed solely of men. In Chapter 1.1, we discussed the 
difference between genders when it comes to life expectancy and mortality events, whilst in 
Chapter 1.2.4, we noticed a difference between genders in prevalence of frailty. Results might have 
been different if our study population comprised older women. Given the gender-neutral 
components of the SOF frailty index, not much difference is expected for related results from 
Chapter 2.1. Indeed, similar classification performance of the SOF index has been found in men 
and women (age-adjusted AUC for 9-year mortality was 0.72 in women of the SOF study (30), age-
adjusted AUC for 3-year mortality was 0.71 in men of the MrOS study (31)). In contrast, during 
development of the FNIH criteria different components and cutoff points were found to best 
predict mobility impairment and weakness in men and women. Whilst our analyses in men 
identified the combination of low Grip strength and low ALMBMI to best predict mortality, in 
women the combination of low Grip strength to BMI - ratio and low unadjusted ALM might work 
better (50,51). In addition, prevalence of low ALM varies more in women than men when different 
cutoff points are applied (148), which might influence the consistency of observed associations. The 
association of physical function measurements with long-term mortality (Chapter 2.2) has likewise 
been found in older women. A cohort study in older women with follow-up and mortality rate 
close to those of the Merelbeke study population found Timed Up and Go to be independently 
associated with mortality hazard. Their unadjusted HR per second increase of 1.10 (CI95 = 1.06 – 
1.14) is comparable with our age-adjusted HR per second increase of 1.10 (CI95 = 1.07 – 1.12) (324). 
Meta-analysis of associations of Grip strength with all-cause mortality found similar HR’s in men 
and women per 1 kg increase, however when the lowest quarter was compared with the best 
quarter, the overall HR was higher in men (HR = 1.75 (CI95 = 1.41 – 2.16) than women (HR = 
1.46 (CI95 = 1.29 – 1.66)) (120). Given that strength declines more rapidly in older men than in older 
women (over three years men lose almost twice as much absolute strength as women (385)), 3-year 
functional changes in women might be too confined to observe any association with mortality, 
independent from baseline function (Chapter 2.3). 
Our analyses were restricted to all-cause mortality, because cause of death could not be validated 
based on death certificates, but relied on communication with the treating general practitioner 
and/or proxy. Associations might strengthen or weaken if only subsamples with certain mortality 
cause are investigated. Different trajectories of functional decline have been observed in persons 
with sudden death, cancer death, death from organ failure (congestive heart failure or chronic lung 
disease), and death from frailty (defined as reporting a nursing home stay). People deceased with 
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frailty were more likely to have ADL disability throughout their final year with a substantial decline 
in function during the last 3 months of life (386). 
Regretfully, no comorbidity index was used to assess morbidity burden in the Merelbeke study 
population. Number of medications was counted from a list of medications provided by the 
participants. Only seven diseases were specified in the questionnaire used in the first wave and 
cancer was not one of them, while it and its treatment are major stressors which influence physical 
function. Whereas the Charlson index, a commonly used measure of morbidity (which assigns 
more weight to diagnoses such as malignant tumors), has strong evidence in relation to predictive 
validity for mortality, some suggest simple counts of diseases or medications (which was available 
to us) perform almost as well as complex measures in predicting most outcomes (387). Another 
measure of morbidity, which was developed to predict physical function (according to the SF-36 
Physical Function Index), namely the Functional Comorbidity Index, includes 18 items amongst 
which COPD, diabetes, and several cardiovascular diseases (388) (these latter were also available to 
us). In Chapter 2.1 associations of sarcopenia and frailty with mortality remained significant after 
adjustment for number of medications. In Chapter 2.2 the association of Timed Up and Go with 
mortality remained significant in a subsample of men with cardiovascular disease. The lack of 
significance in men with COPD or diabetes was most likely due to the small sample sizes (N = 28 
and N = 25, respectively). In Chapter 2.3 associations of baseline physical function with mortality 
mostly remained significant after adjustment for polypharmacy and other covariates.  
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4.4.2 CRIME STUDY 
Representativeness & external validity 
The CRIME study was a multicentre, observational study in which all older patients consecutively 
admitted to geriatric and internal medicine acute care wards were approached for participation. 
Representativeness was supported by the wide eligibility criteria for inclusion (which were age of at 
least 65 years and willingness to participate), the initial participation rate of 73%, and the stability of 
the cohort on follow-up (only 4% could not be followed until discharge due to transfer to another 
ward). Despite the multicentre design of our study, findings may not be generalizable towards all 
older patients admitted to an acute care ward, because the centres involved were exclusively Italian 
facilities and they were not randomly chosen.  
Accuracy 
Accuracy of our results was supported by using objective physical function data.  
In Chapter 3.2, bias may have been introduced by assigning a continuous value (equivalent to the 
worst percentile of performance) to those patients who were unable to perform Gait speed and 
Grip strength. Nevertheless, excluding those subjects who were unable to perform the tests led to 
similar mean changes. Although the reason why subjects were unable to perform physical 
performance measurements was not recorded, the main cause must be physical problems, since 
subjects with cognitive problems or inability to understand instructions were excluded.  
Internal validity 
A potential confounding factor, that was not recorded, was the main disease that led to hospital 
admission. Severity of admission reason is, however, partially captured in type of admission, 
because patients admitted from the emergency room often present with severe acute conditions, 
while patients admitted electively are less likely to present severe acute conditions. 
First assessment of physical performance was performed within 24 hours of admission, therefore 
some medical therapy still could have taken place before assessment, which could have affected 
patients’ physical performance.  
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SUMMARY 
The increasing life expectancy contributes to the ageing of the population, making Belgium an 
‘aged society’. With advancing age important physiological changes occur. The age-related loss of 
physiologic reserve and hence loss of resistance to stressors is characteristic for the condition called 
frailty, in which minimal stress can lead to function impairment. Sarcopenia, the age-related loss of 
muscle mass and function, is considered a key component in the development of physical frailty. 
While these ‘twin’ conditions are close to reaching consensus on their conceptual framework, the 
search towards a consensus operational definition for each is still ongoing. Lately, there has been a 
shift in focus towards the shared feature of physical frailty and sarcopenia, namely low physical 
function. Low levels of physical function include impairments (which can be measured with e.g. Grip 
strength), functional limitations according to physical performance measurements (e.g. Balance, Chair 
Rising, and Timed up and Go), and disabilities related to physical domains of health-related quality 
of life (e.g. SF-36 Physical Function Index) and ADL (e.g. RDRS-2 ADL).  
The general aim of this thesis is twofold. Firstly, we aim to evaluate the predictive value of physical 
function (related) assessments towards health risks in older adults; secondly we want to assess 
changes in physical function occurring over time. For both objectives we have used data from two 
studies: the first being a population-based cohort study in apparently healthy community-dwelling 
older Belgian men (Merelbeke study), the second a multicentre cohort study in acutely ill 
hospitalized older Italian patients (CRIME study). 
In Chapter 1 we present a general background starting with the ageing and aged population. This 
leads us to conceptual and operational definitions of physical frailty and sarcopenia and their shared 
feature of low levels of physical function. We subsequently report their epidemiology and some 
underpinning pathophysiological mechanisms, which include neuromuscular changes, low-grade 
inflammation, coagulation, and hormonal dysregulation. Furthermore we describe our above-
mentioned research objectives and study populations more in depth. This chapter ends with a 
description of our used methodology. 
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In Chapter 2 we report all our findings in community-dwelling older men. All three subchapters 
focus on predictive value towards long-term all-cause mortality, since the Merelbeke study has had 
an exceptionally long survival follow-up. While the first two subchapters involve physical function 
(related) assessments at a single time-point, the last subchapter includes changes in physical 
function over 3-year time not caused by any active intervention.  
In Chapter 2.1 we explore the association of the simple SOF index for physical frailty and the 
data-driven FNIH criteria for weakness and low muscle mass with subsequent 15-year mortality. 
Since both instruments do not rely on their parameters’ distribution in reference populations, their 
validation in populations, other than those in which they were developed, is important. Presence of 
physical frailty and sarcopenia could be identified in respectively 7 and 6% of 191 men who 
attended the study’s fifth wave. Remarkably, with only 1.6% overlap, the instruments have not 
selected the same men. Both physical frailty and weakness combined with low muscle mass have 
shown to be significantly associated with higher mortality hazard compared to robustness or 
normal Grip strength with normal muscle mass respectively, independently from age and number 
of medications.  
In Chapter 2.2 we evaluate and compare the association of four objective physical function 
measurements (Grip strength, Standing balance, Chair rising, and Timed Up and Go) and two 
disability instruments (RDRS-2 ADL and SF-36 Physical Function Index) with subsequent 15-year 
mortality. With the exception of Grip strength and SF-36 Physical Function Index, these 
measurements have not been validated before towards mortality hazard in studies with more than 
10-year follow-up. All six physical function measurements, assessed at baseline in 352 men, have 
shown to be significantly associated with mortality hazard. The highest standardized HRs have 
been observed with timed physical performance measurements, especially Timed Up and Go.  
In Chapter 2.3 we investigate the association of physical function changes with subsequent 15-year 
mortality. Functional changes have rarely been related to changes in clinical outcomes before. We 
have examined decline in physical function (SF-36 Physical Function Index, Grip strength, Chair 
rising, and Timed Up and Go) over four time-points within three years in 171 men who 
participated in both the second and fifth wave of the Merelbeke study. While decline in all physical 
function measurements could be significantly associated with higher mortality hazard, a significant 
time-attenuated effect for SF-36 Physical Function Index, Grip strength, and Chair rising has been 
observed after seven years. Interestingly, physical function at a single-time point also has remained 
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to be significantly associated in these multivariate models, indicating the robustness of single time-
point physical function measurements. 
In Chapter 3 we report all our findings in older Italian in-patients admitted to acute care. While the 
first subchapter focuses on the prediction of hospital outcomes, the second subchapter addresses 
changes in physical function from admission until discharge. In Chapter 3.1 we identify predictors 
of LoS, in-hospital mortality, and institutionalization in 1123 older in-patients. Contrary to most 
previous studies that relied on routinely collected data, we have data on patients’ functional status 
and physical performance. Indeed, our multivariate analyses have identified these multifaceted 
aspects as independent predictors of hospital outcome. Gait speed category could be significantly 
associated with LoS, Grip strength inability with in-hospital mortality, and ADL total dependency 
with both in-hospital mortality and institutionalization. In Chapter 3.2, we look into functional 
changes during hospital stay assessed through Grip strength and Gait speed in addition to ADL, 
whereas in-hospital changes have previously been established almost exclusively via ADL 
measurements. In 639 patients with an MMSE score of at least 18, we could not find a significant 
in-hospital change in ADL on average, while we have found an overall improvement in Grip 
strength and Gait speed, especially in patients with poor baseline performance, admission from the 
emergency room, and older age. 
Finally in Chapter 4, our main findings together with contributions to the existing literature are 
summarized and discussed. The apparently healthy European male population and long-term 
survival follow-up of our studies in Chapter 2 have added new contributions to the validation of 
physical function (related) assessments. The assessment of Grip strength and Gait speed in our 
studies of Chapter 3 has contributed to the feasibility of objective physical function measurements 
in hospital setting. Further along this chapter, we discuss the implications of our findings and some 
perspectives for future research related to physical function and its health risk indications, dynamic 
nature, numerous operational definitions, and use in interventions to define the target population 
and to evaluate effectiveness. Finally, we mention some methodological considerations related to 
the overall representativeness and external validity, accuracy and reliability, and internal validity of 
our findings. 
With this doctoral thesis, we contribute to the research on physical frailty and sarcopenia, more 
specifically the prognostic value and dynamic nature of physical function (related) assessments. 
Consensus on operational instruments should push research forward towards finding effective 
interventions to counteract low levels of physical function. 
SAMENVATTING 
 
 
207 
SAMENVATTING 
De toenemende levensverwachting draagt bij tot de vergrijzing van de bevolking, waardoor België 
een ‘oude samenleving’ kent. Met het verouderen treden belangrijke fysiologische veranderingen 
op: het leeftijdsgebonden verlies aan fysiologische reserve en het daarmee gepaard gaande verlies 
aan weerstand tegen stressfactoren is kenmerkend voor kwetsbaarheid, een aandoening waarbij reeds 
minimale stress kan leiden tot een functiebeperking. Sarcopenie, het leeftijdsgebonden verlies van 
spiermassa en -functie, wordt beschouwd als een belangrijk element betrokken bij de ontwikkeling 
van deze fysieke kwetsbaarheid. Hoewel het conceptuele kader van deze ‘tweeling’ condities 
nagenoeg vastligt, is de zoektocht naar een consensus operationele definitie voor elk nog gaande. 
Recentelijk wordt er meer aandacht geschonken aan het gemeenschappelijke kenmerk van fysieke 
kwetsbaarheid en sarcopenie, namelijk lage fysieke functie. Lage fysieke functie omvat verzwakkingen 
(onder meer gemeten met bijv. Handgrijpkracht), functionele beperkingen aantoonbaar op basis van 
fysieke prestatie metingen (bijv. Evenwicht, Chair rising en Timed Up and Go) en onbekwaamheden 
samenhangend met ofwel fysieke aspecten van gezondheidsgerelateerde levenskwaliteit (bijv. SF- 
36 Fysieke Functie Index) ofwel activiteiten van het dagelijks leven (bijv. RDRS-2 ADL). 
Het algemene doel van dit proefschrift is tweeledig. In de eerste plaats willen we van bovenstaande 
fysieke functie (gerelateerde) metingen de voorspellende waarde met betrekking tot 
gezondheidsrisico's bij ouderen evalueren. Ten tweede willen we veranderingen in fysieke functie 
na verloop van tijd evalueren. Voor beide doelstellingen hebben we gebruik gemaakt van gegevens 
uit twee studies: de eerste is een bevolkingsgebaseerde, cohort studie bij ogenschijnlijk gezonde, 
thuiswonende, oudere, Belgische mannen (de Merelbeke studie) en de tweede een multicentrische, 
cohort studie bij acuut zieke, gehospitaliseerde, oudere, Italiaanse patiënten (de CRIME studie). 
In Hoofdstuk 1 presenteren we een algemene achtergrond beginnend bij de vergrijsde en oudere 
bevolking. Dit leidt ons tot conceptuele en operationele definities van fysieke kwetsbaarheid en 
sarcopenie en hun gemeenschappelijk kenmerk namelijk lage fysieke functie. We rapporteren 
aansluitend hun epidemiologie en enkele onderbouwende pathofysiologische mechanismen, 
waaronder neuromusculaire veranderingen, laaggradige ontsteking, coagulatie, en hormonale 
ontregelingen. Verder beschrijven we onze bovengenoemde doelstellingen en studiepopulaties 
meer in de diepte. Dit hoofdstuk eindigt met een beschrijving van onze gebruikte methodologie. 
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In Hoofdstuk 2 rapporteren we al onze bevindingen bij thuiswonende, oudere mannen. Alle 
subhoofdstukken richten zich op de voorspellende waarde van fysieke functie (gerelateerde) 
metingen met betrekking tot lange termijn-sterfte van alle oorzaken, omdat de Merelbeke studie 
een uitzonderlijk lange overlevingsopvolging heeft gekend. Terwijl de eerste twee subhoofdstukken 
betrekking hebben tot fysieke functie (gerelateerde) metingen op één enkel tijdspunt, omvat het 
laatste subhoofdstuk veranderingen in fysieke functie over drie jaar tijd, die niet veroorzaakt 
werden door een actieve interventie.  
In Hoofdstuk 2.1 onderzoeken we de associatie van de eenvoudige SOF-index voor fysieke 
kwetsbaarheid en de door data aangedreven FNIH criteria voor zwakte en lage spiermassa met 
daaropvolgende 15-jaars mortaliteit. Omdat beide instrumenten hun parameters niet afhankelijk 
zijn van de verdeling in referentiepopulaties, is hun validatie in andere populaties dan die waarin ze 
werden ontwikkeld, belangrijk. Fysieke kwetsbaarheid en sarcopenie konden worden 
teruggevonden in respectievelijk 7 en 6% van 191 mannen die aanwezig waren op de vijfde visite 
van de studie. Opvallend is dat, met slechts 1.6% overlapping, de instrumenten niet dezelfde 
mannen hebben geselecteerd. Zowel fysieke kwetsbaarheid als zwakte in combinatie met lage 
spiermassa bleek significant geassocieerd te zijn met een hogere mortaliteitshazard in vergelijking 
met robuustheid of normale Handgrijpkracht en spiermassa, respectievelijk, onafhankelijk van de 
leeftijd en het aantal in te nemen geneesmiddelen.  
In Hoofdstuk 2.2 evalueren en vergelijken we de voorspellende waarde van vier objectieve fysieke 
functie metingen (Handgrijpkracht, Staand evenwicht, Chair rising en Timed Up and Go) en twee 
onbekwaamheidsinstrumenten (RDRS-2 ADL en SF-36 Fysieke Functie Index) voor 
daaropvolgende 15-jaars mortaliteit. Met uitzondering van Handgrijpkracht en SF-36 Fysieke 
Functie Index, zijn deze metingen nooit eerder gevalideerd met betrekking tot mortaliteit in studies 
met meer dan tien jaar opvolging. Alle zes fysieke functie metingen, beschouwd in het begin van de 
studie bij 352 mannen, hebben aangetoond significant geassocieerd te zijn met mortaliteitshazard. 
De hoogste gestandaardiseerde hazardratio's zijn waargenomen met tijdsgemeten fysieke prestaties 
metingen, in het bijzonder Timed Up and Go.  
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In Hoofdstuk 2.3 onderzoeken we de associatie van veranderingen in fysieke functie met 
daaropvolgende 15-jaars mortaliteit. Functionele veranderingen zijn voordien zelden gelinkt 
geweest aan veranderingen in klinische eindpunten. We hebben de achteruitgang in fysieke functie 
(gemeten aan de hand van SF-36 Fysieke Functie Index, Handgrijpkracht, Chair rising en Timed 
Up and Go) over vier tijdspunten binnen drie jaar onderzocht in 171 mannen, die hebben 
deelgenomen aan zowel de tweede als de vijfde visite van de Merelbeke studie. Terwijl 
achteruitgang in alle fysieke functie metingen significant kon worden geassocieerd met een hogere 
mortaliteitshazard, is er een significant afzwakkend effect met de tijd waargenomen voor de SF-36 
Fysieke Functie Index, Handgrijpkracht en Chair rising na zeven jaar. Interessant is dat fysieke 
functie gemeten op een enkel tijdspunt steeds significant geassocieerd is gebleven met mortaliteit in 
deze multivariate modellen met verandering in fysieke functie, wat duidt op de robuustheid van 
fysieke functie metingen op een enkel tijdspunt. 
In Hoofdstuk 3 rapporteren we onze bevindingen bij oudere, Italiaanse, gehospitaliseerde 
patiënten opgenomen op acute zorg. Terwijl het eerste subhoofdstuk zich richt op de voorspelling 
van ziekenhuisuitkomsten, behandelt het tweede subhoofdstuk veranderingen in fysieke functie 
gedurende de ziekenhuisopname, van opname tot ontslag. In Hoofdstuk 3.1 identificeren we 
voorspellende factoren voor de duur van ziekenhuisverblijf, sterfte in het ziekenhuis, en 
institutionalisering bij ontslag in 1123 oudere patiënten. In tegenstelling tot de meeste voorgaande 
studies die vertrouwden op routinematig verzamelde data, beschikken wij ook over gegevens zoals 
functionele status en fysieke prestatie. Onze multivariate analyses hebben bovendien deze 
veelzijdige aspecten als onafhankelijk voorspellende factoren van ziekenhuisuitkomst 
geïdentificeerd. Wandelsnelheid categorie kon worden geassocieerd met de duur van 
ziekenhuisverblijf, onvermogen om Handgrijpkracht uit te voeren met mortaliteit en ADL totale 
afhankelijkheid met zowel mortaliteit als institutionalisering bij ontslag. In Hoofdstuk 3.2 kijken 
we naar functionele veranderingen tijdens verblijf in het ziekenhuis, beoordeeld via 
Handgrijpkracht, Wandelsnelheid en ADL, terwijl voorheen deze functionele veranderingen vrijwel 
uitsluitend bestudeerd zijn geweest via ADL metingen. Bij 639 patiënten met een MMSE score van 
ten minste 18, hebben we geen significante verandering in gemiddelde ADL waargenomen, terwijl 
we wel een algemene verbetering van Handgrijpkracht en Wandelsnelheid hebben gedetecteerd, 
vooral bij patiënten met een lage fysieke functie bij opname, een opname via de spoeddienst en een 
oudere leeftijd. 
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Ten slotte, in Hoofdstuk 4 geven we een bespreking en samenvatting van onze belangrijkste 
bevindingen samen met onze bijdrage aan de bestaande literatuur. De ogenschijnlijk gezonde, 
Europese, mannelijke bevolking en de lange-termijn overlevingsopvolging van onze studies in 
Hoofdstuk 2 hebben nieuwe bijdragen aan de validering van fysieke functie (gerelateerde) metingen 
toegevoegd. De beoordeling van Handgrijpkracht en Wandelsnelheid in onze studies van 
Hoofdstuk 3 heeft bijgedragen aan de uitvoerbaarheid van objectieve fysieke functie metingen in 
ziekenhuiskader. Verderop in dit hoofdstuk bespreken we de implicaties van onze bevindingen en 
een aantal perspectieven voor toekomstig onderzoek die verband houden met fysieke functie en 
haar indicaties voor gezondheidsrisico’s, dynamische karakter, tal van operationele definities en 
gebruik in interventies om doelpopulaties af te bakenen en de doeltreffendheid te evalueren. Tot 
slot vermelden we een aantal methodologische overwegingen met betrekking tot de algemene 
representativiteit en externe validiteit, nauwkeurigheid en betrouwbaarheid, en interne validiteit van 
onze bevindingen. 
Met dit proefschrift hebben we een bijdrage geleverd aan het onderzoek naar fysieke kwetsbaarheid 
en sarcopenie, meer in het bijzonder de prognostische waarde en het dynamische karakter van 
fysieke functie (gerelateerde) metingen. Eensgezindheid over een operationeel instrument zou het 
onderzoek kunnen doen voortbewegen richting het zoeken naar effectieve interventies om lage 
fysieke functie tegen te gaan. 
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